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SUM M ARY
C ircadian rhythm s are k n ow n  to  b e  entrained to the 2 4  hour day through interactions  
b etw een  en d ogen ou s m ech an ism s and a num ber ex o g en o u s factors that in clu d e the ligh t-  
dark c y c le  and so c ia l in teraction . In ten siv e  care patients are th ought to be prone to  
disturbances in  their circadian rhythm s due to iso la tio n  from  environm ental ch an ges and  
sensory  deprivation as a result o f  sedation  and sleep  disturbance.
T h e m ain aim  o f  this thesis w as to d eterm ine w hether circadian rhythm s in  critica lly  ill  
patients are desynchron ised  from  the environm ent in com parison  w ith  th ose  observed  in  
healthy  in d iv id u a ls , u sin g  urinary aM T 6s excretion , p lasm a m ela ton in  and core  b od y  
tem perature as m arkers o f  the en d o g en o u s c lo ck . P atients in  the In ten siv e  Care U n it  
(IC U ) at th e R o y a l F ree  H o sp ita l, L o n d o n , w h o  w ere  sta b le , in o tro p e -free , n o t  
u n d ergo in g  h aem od iafiltra tion  and w ith  an IC U  stay  o f  m ore than three d ays w ere  
studied.
C osin or an a lysis o f  retrosp ective core b o d y  tem perature data taken from  nursing charts 
sh ow ed  that a statistica lly  sign ifican t rhythm  w ith  a period o f  24h  w as present in 49.5%  
o f  the patien t days studied . T h e p o sit io n  o f  acrophase sh o w ed  abnorm alities w ith in  
in d iv id u a ls  and b e tw een  in d iv id u a ls . P r o sp e c tiv e  core  b o d y  tem perature stu d ies  
confirm ed  the fin d in gs o f  abnorm al circadian rhythm icity but su ggested  that the rhythm s 
w ere in flu en ced  b y  fever  associated  w ith  in fection .
U rinary 6 -su lp h atoxym ela ton in  (aM T 6s) excretion  data detected  rhythm ic activ ity  and  
a llo w e d  fo r  the id en tif ica tio n  o f  fo u r  patterns o f  ex cre tio n  rate o v er  24h: norm al 
rhythm icity , p h ase sh ifted  rhythm s, abnorm al w ith  frequent flu ctu ation s and abnorm al 
but arrhythm ic. U rinary aM T 6s ex cretio n  rate m easured  on tw o  or three o cca sio n s at 
w e e k ly  in terva ls id e n tif ie d  ch a n g es a sso c ia ted  w ith  the n o rm alisa tion  o f  c ircad ian  
rhythm icity, nam ely  an increase in  the am plitude in som e patients and the d evelop m en t o f  
sign ifican t diurnal changes from  grossly  abnorm al patterns o f  urinary aM T 6s excretion  in  
others. T h is trend w as seen  in patients that w ere  im proving c lin ica lly , but cou ld  not be  
associa ted  w ith  d isea se  sever ity  as determ ined  by A P A C H E  II scorin g . Studies on  the  
circadian rhythm s o f  urine v o lu m e and creatin ine clearance su ggested  that renal function  
in the ab sen ce o f  acute renal fa ilure w as still im paired or p o ssib ly  in flu en ced  by treatm ent 
m edication  and cou ld  m od ify  urinary aM T 6s excretion .
M easurem ents o f  p lasm a m elatonin  id en tified  circadian rhythm icity in  7 out o f  9  patients 
o f  w h ich  5 w ere sign ifican t by cosin or an a lysis. T hese 5 patients had p lasm a m elatonin  
rhythm s that w ere  e ither norm al or p h ase  sh ifted . T he circadian  rhythm s o f  p lasm a  
cortiso l, p lasm a prolactin  and p lasm a T S H  in m ost IC U  patients w ere also abnorm al and  
sh ow ed  poor correlations w ith  plasm a m elatonin .
O verall th is th esis p rovid es ev id en ce  o f  abnorm al circadian rhythm icity  in  cr itica lly  ill 
patients and id en tifie s  th is group o f  patients as on e that m igh t b en e fit  from  lig h t or  
m elatonin  treatm ent to help  resynchronise rhythm s.
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F igure 5. N eural pathw ays b etw een  the retina and pineal gland o f  89
the rat, taken from  K lein  et al, 1991.
F igure 6. M echanism  o f  (X and (3-receptor stim ulation b y  N oradrenaline. 91
Figure 7. T he synthetic pathw ay o f  m elaton in  from  tryptophan 93
Figure 8. D iagram  to sh ow  the circadian variation in en zym es and 95
Figure 4. Diagram o f the human brain to show the position o f the 87
horm ones o f  the m elaton in  synthetic pathw ay reproduced  
from  K lein  e t a l, 1992. N A T  =  N -acety l transferase.
Figure 9. M etabolic pathw ay o f  m elaton in  97
Figure 10. B inned  phase sh ifts after m elaton in  adm inistration 98
to g iv e  a phase response curve for m elatonin. Each tim e  
point represents data from  6 individuals. D ata w ere  
averaged into approxim ately 2 -h  bins. A dapted from  
L ew y  et al, 1998.
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V ariation in average ligh t in tensity  at b ed sp a ce l o f  165
the R o ya l Free H osp ita l IC U  at four tim es o f  the year.
V ariation in average ligh t intensity  at b edspace 2  o f  167
the R o ya l Free H osp ita l IC U  at four tim es o f  the year.
V ariation in average ligh t in tensity  at b edspace 3 o f  the 166
R oyal Free H ospital IC U  at four tim es o f  the year.
Variation in average ligh t in tensity  at bedspace 4  o f  168
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F igure 25 .
V ariation in  average ligh t intensity  at bedspace 5 o f  169
the R oya l Free H osp ita l IC U  at four tim es o f  the year.
V ariation in  average ligh t intensity  at bedspace 6 o f  170
the R o ya l Free H osp ita l IC U  at four tim es o f  the year.
V ariation in  average ligh t in tensity at bedspace 7  o f  the 171
R oyal Free H osp ita l IC U  at four tim es o f  the year.
V ariation in  average ligh t in tensity at bedspace 8 o f  the 172
R oyal Free H ospital IC U  at four tim es o f  the year.
V ariation in  average ligh t in tensity at bedspace 9  o f  the 173
R oyal Free H ospital IC U  at four tim es o f  the year.
V ariation in  average ligh t in tensity at bedspace 10 o f  the 174  
R oyal Free H ospital IC U  at four tim es o f  the year.
V ariation in average ligh t in tensity at beds w ith  east 175
facing  w in d o w s, south facin g  w in d ow s and no w in d ow s  
in winter.
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Figure 29.
Figure 30.
facin g  w in d o w s, south facin g  w in d ow s and no w in d ow s  
in spring.
V ariation in  average ligh t in tensity  at beds w ith  east 177
facin g  w in d ow s, south fac in g  w in d ow s and no w in d ow s  
in sum m er.
V ariation in average ligh t in tensity at beds w ith  east 178
facin g  w in d o w s, south fac in g  w in d ow s and no w in d ow s  
in autumn.
A COMPARISON OF HOURLY PLASMA AND 185
SALIVARY MELATONIN, URINARY aMT6s 
AND CORE BODY TEMPERATURE IN 
HEALTHY VOLUNTEERS.
Graphs to sh ow  a. the variation in hourly ligh t 188
intensity , urinary aM T 6s and plasm a m elatonin  
concentration  a n d  b. hourly core body temperature
and plasm a m elaton in  concentration over 2 4  hours for  
subject C l .
Graphs to sh ow  the variation in a. hourly ligh t in tensity , 189  
urinary aM T 6s excretion  rate, p lasm a and salivary
Variation in average light intensity at beds with east 176
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Figure 31.
Figure 32.
Figure 33.
m elaton in  concentration  and b. hourly core b ody  
tem perature and p lasm a m elatonin  concentration over  
2 4  hours for subject C 2.
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 190  
urinary aM T 6s excretion  rate, p lasm a and salivary  
m elatonin  and b. hourly  core body temperature and  
plasm a m elaton in  concentration  over 2 4  hours for  
sQbject C 3.
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 191 
urinary aM T 6s excretion  rate, plasm a and salivary  
m elaton in  concentration  and b. hourly core body  
temperature and p lasm a m elatonin  concentration  
over 2 4  hours for subject C4.
Graphs to sh o w  a. the variation in hourly ligh t in tensity , 192  
urinary aM T 6s excretion  rate, plasm a and salivary  
m elaton in  concentration and b. hourly core body  
tem perature and p lasm a m elatonin  concentration over  
2 4  hours for subject C5.
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Figure 35.
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Figure 37.
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 193  
urinary aM T 6s excretion  rate, p lasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and plasm a m elatonin  concentration over  
2 4  hours for subject C 6.
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 194  
urinary aM T 6s excretion  rate, plasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and p lasm a m elatonin  over 2 4  hours for  
subject C 7.
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 195  
urinary aM T 6s excretion  rate, p lasm a and salivary  
m elaton in  concentration  and b. hourly core b ody  
tem perature and p lasm a m elatonin  concentration over  
2 4  hours for subject C8.
Graphs to sh ow  a. the variation in  hourly ligh t in tensity, 196  
urinary aM T 6s excretion  rate, p lasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and p lasm a m elatonin  concentration over
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Figure 39.
F igure 40 .
F igure 41.
Graphs to sh ow  a. the variation in  hourly ligh t in tensity , 197  
urinary aM T 6s excretion  rate, plasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and p lasm a m elaton in  concentration over  
2 4  hours for subject CIO.
Graphs to sh ow  a. the variation in ligh t in tensity , urinary 198 
aM T 6s excretion  rate, p lasm a and salivary m elaton in  
concentration and b. hourly core body tem perature and 
plasm a m elaton in  concentration  over 2 4  hours for  
subject C l l .
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 199  
urinary aM T 6s excretion  rate, p lasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and p lasm a m elatonin  concentration over  
2 4  hours for subject C l 2.
Graphs to sh ow  a. the variation in  hourly ligh t in tensity , 2 0 0  
urinary aM T 6s excretion  rate, plasm a and salivary  
m elaton in  concentration  and b. hourly core body  
tem perature and p lasm a m elatonin  concentration over
24 hours for subject C9.
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Figure 42.
F igure 43 .
Figure 44 .
F igure 45 .
Graphs to sh ow  a. the variation in hourly ligh t in tensity , 201  
urinary aM T 6s excretion  rate, plasm a and salivary  
m elatonin  concentration  and b. hourly core body  
tem perature and plasm a m elatonin  concentration over  
2 4  hours for subject C l 4.
Graph to sh o w  the m ean  variation in hourly m ean  2 1 0
plasm a m elaton in  concentration, m ean salivary  
m elatonin  concentration  and m ean urinary aM T6s 
excretion  rate over 2 4  hours in  healthy volunteers.
Graph to sh ow  the variation in  hourly m ean p lasm a 211
m elaton in  concentration  and m ean core body  
tem perature over 2 4  hours in  healthy volunteers.
Scatter diagram  to sh ow  the correlation and 2 1 2
regression  line b etw een  m ean plasm a m elatonin  
concentration and m ean salivary m elatonin  
concentration at each  tim e poin t (n =  2 5 ) in healthy  
volunteers (n  =  13).
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Figure 48 .
F igure 49.
Figure 50.
line b etw een  m ean plasm a m elatonin  concentration  
and m ean  urinary aM T 6s excretion  rate at each  tim e  
point (n =  2 5 ) in healthy volunteers (n =  14)
Scatter diagram  to sh ow  the correlation and regression  2 1 4
line b etw een  m ean urinaiy aM T 6s excretion  rate and 
m ean salivary m elaton in  concentration at each tim e  
point (n =  2 5 ) in healthy volunteers (n =  13)
Scatter diagram  to sh ow  the correlation and regression  215
lin e  b etw een  m ean core body temperature and m ean  
plasm a m elaton in  concentration  at each  tim e poin t in  
healthy volunteers.
Scatter diagram to show the correlation and regression 213
Scatter diagram  to sh ow  the correlation and regression  2 1 6
line b etw een  m ean core body tem perature and m ean  
salivary m elatonin  concentration at each  tim e point in  
healthy volunteers.
Scatter diagram  to sh ow  the correlation and regression  217
line b etw een  m ean core body tem perature and m ean
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urinary aM T 6s excretion  rate at each  tim e poin t (n = 25)  
in healthy volunteers (n = 14).
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C om parison o f  the m ean peak  on set tim es, o ffse t tim es 219  
and p eak  duration b etw een  p lasm a m elatonin  (P), 
salivary m elaton in  (S ), urinary aM T 6s (U ) and the 
trough core body tem perature (C ), in  healthy volunteers  
(n=14)
Correlation and regression  b etw een  the p lasm a 221
m elaton in  am plitude and salivary m elatonin  am plitude  
in healthy volunteers (n = 6)
Correlation and regression  b etw een  plasm a m elatonin  2 2 2  
am plitude and urinary aM T 6s am plitude in  healthy  
volunteers (n = 13)
Correlation and regression  lin e  betw een  p lasm a 223
m elaton in  m esor and urinary aM T 6s m esor for  
healthy volunteers (n= 13).
C orrelation and regression  line betw een  plasm a 2 2 4
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Figure 58.
m elaton in  (j) and urinary aM T 6s (j) for healthy  
volunteers (n = 13).
C om parison o f  am plitude, m esor and (j) for p lasm a 225
m elatonin-P , salivary m elaton in -S  (pg/m l), urinary 
aM T 6s-U  (jlg/hr) and C B T -C  (°c) in  healthy subjects
(n=6). )
K S
Graphs to illustrate the change in m esor (M ), 2 3 2
am plitude (A ), acrophase tim e (0 ) and percentage
rhythm  (% R) w ith  increasing co llection  tim e (a. lh ,  
b. 2h , c .3h , d. 4h ) for subject C4.
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Graph to sh o w  the variation in retrospective core body 2 5 2
tem perature o f  subject T1 over 6 days com pared to the 
m ean C B T  from  the control group w ith  b. cosin or  
param eters o f  best fit and c. a sum m ary o f  pertinent
N
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Figure 59.
Figure 60.
Figure 61.
F igure 62.
tem perature o f  subject T 2 over 8 days com pared to the 
m ean C B T  from  the control group w ith  b. cosin or  
parameters o f  b est fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh o w  the variation in retrospective core b ody 2 5 4
tem perature o f  subject T 3 over 5 days com pared to the 
m ean C B T  from  the control group w ith  b. cosin or  
parameters o f  best fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh ow  the variation in retrospective core b ody 255
tem perature o f  subject T 4  over 9 days com pared to the 
m ean C B T  from  the control group w ith  b. cosin or  
parameters o f  b est fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh ow  the variation in retrospective core body 2 5 6
tem perature o f  subject T5 over 15 days com pared to 
the m ean C B T  from  the control group w ith  b. cosin or  
parameters o f  b est fit and c. a sum m ary o f  pertinent
r
interventions.
Graph to show the variation in retrospective core body 253
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F igure 65.
Figure 66.
Graph to sh o w  the variation in  retrospective core body  
tem perature o f  subject T 6  over 5 days com pared to  
the m ean C B T  from  the control group w ith  b. cosinor  
param eters o f  b est fit  and c. a sum m ary o f  pertinent 
interventions.
Graph to sh ow  the variation in retrospective core b od y  
tem perature o f  subject T 7 over 7 days com pared to  
the m ean C B T  from  the control group w ith  b. cosin or  
param eters o f  b est fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh o w  the variation in retrospective core body  
tem perature o f  subject T 8 over 8 days com pared to 
the m ean C B T  from  the control group w ith b. cosinor  
parameters o f  b est fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh o w  the variation in  retrospective core body  
temperature o f  subject T 9  over 9  days com pared to 
the m ean C B T  from  the control group w ith  b. cosinor  
param eters o f  best fit and c. a sum m ary o f  pertinent
interventions.
Figure 67.
F igure 68.
F igure 69.
Figure 70 .
Graph to sh o w  the variation in retrospective core body 261  
tem perature o f  subject T 1 0  over 7 days com pared to 
the m ean C B T  from  the control group w ith  b. cosinor  
param eters o f  best fit and c. a sum m aiy  o f  pertinent 
interventions.
Graph to sh o w  the variation in retrospective core body 2 6 2
tem perature o f  subject T i l  over 9  days com pared to 
the m ean C B T  from  the control group w ith b. cosin or  
param eters o f  best fit and c. a sum m ary o f  pertinent 
interventions.
Graph to sh o w  the variation in  retrospective core b ody 263
tem perature o f  subject T 12  over 9 days com pared to 
the m ean C B T  from  the control group w ith  b. cosin or  
param eters o f  best fit and c. a sum m ary o f  pertinent 
interventions.
Graph to com pare m esor values for control subject 26 6
core body tem perature w ith m ean m esor values for  
IC U  patient core body temperature.
interventions.
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F igure 71 . Graph to com pare m ean am plitude o f  core body 2 6 7
tem perature rhythm s from  IC U  patients w ith  am plitude  
o f  control subjects.
Figure 72a.
Figure 72b .
Figure 73.
Graphs to sh ow  the d aily  p osition  o f  acrophase tim e o f  268
core body tem perature rhythm s in IC U  patients on
days w h en  co sin o r  analysis sh ow ed  a statistically
sign ifican t 2 4  hour rhythm . D ays w ithout a
sign ifican t rhythm  have been  om itted, w ith  days on
either sid e , w ith  sign ifican t rhythm s, jo in ed  by a
dashed line.
Graphs to sh ow  the daily  p osition  o f  acrophase tim e o f  269
core body tem perature rhythm s in IC U  patients on
days w hen  cosin or  analysis sh ow ed  a statistically
sign ifican t 2 4  hour rhythm . D ays w ithout a
sign ifican t rhythm  have been  om itted, w ith days on
either side, w ith  sign ifican t rhythm s, jo in ed  by a
dashed line.
Graph to sh o w  the variation in urinary aM T 6s excretion  271  
rate and ligh t in tensity  over 2 4  hours for subject R1 at 
bedspace 7.
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Figure 74.
Figure 75.
Figure 76 .
Figure 77 .
F igure 78.
Figure 79.
Graph to sh o w  the variation in urinary aM T 6s excretion  2 7 2  
rate and ligh t intensity  over 2 4  hours for subject R 2 at 
bedspace 3.
Graph to sh o w  the variation in  urinary aM T 6s excretion  273  
rate and ligh t intensity  over 2 4  hours for subject R 3 at 
bedspace 1.
Graph to sh o w  the variation in urinary aM T 6s excretion  2 7 4  
rate and ligh t intensity  over 2 4  hours for subject R 4  at 
bedspace 2.
Graph to sh o w  the variation in urinary aM T 6s excretion  275  
rate and ligh t intensity  over 2 4  hours for subject R 5 at 
bedspace 9.
Graph to sh ow  the variation in urinary aM T 6s excretion  27 6  
rate and ligh t intensity  over 2 4  hours for subject R 6 at 
bedspace 4.
Graph to sh ow  the variation in urinary aM T 6s excretion  277  
rate and ligh t in tensity  over 2 4  hours for subject R 7 at
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Figure 80.
Figure 81.
Figure 82.
Figure 83.
F igure 84.
Figure 85.
Graph to sh o w  the variation in urinary aM T 6s excretion  278  
rate and ligh t intensity  over 2 4  hours for subject R 8 at 
bedspace 9.
Graph to sh ow  the variation in  urinary aM T 6s excretion  279  
rate and ligh t in tensity  over 2 4  hours for subject R 9 at 
bedspace 7.
Graph to sh ow  the variation in  urinary aM T 6s excretion  2 8 0  
rate and average ligh t in tensity  over 2 4  hours for subject 
R 20  at bedspace 10.
Graph to sh ow  the variation in urinary aM T 6s excretion  281  
rate and ligh t in tensity  over 2 4  hours for subject R 21 at 
bedspace 4.
Graph to sh o w  the variation in urinary aM T 6s excretion  28 2  
rate and light intensity  over 2 4  hours for subject R 22  at 
bedspace 2.
P
Graph to sh ow  the variation in urinary aM T 6s excretion  286  
rate, core body tem perature and ligh t in tensity  over 2 4
bedspace 6.
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Figure 86.
Figure 87.
F igure 88.
Figure 89.
F igure 90.
Graph to sh o w  the variation in  urinary aM T 6s excretion  28 7
rate, core b od y  tem perature and light in tensity over 2 4  
hours for subject R 1 1 at b edspace 6.
Graph to sh o w  the variation in  urinary aM T 6s excretion  288
rate, core b od y  tem perature and light intensity  over  2 4  
hours for subject R 1 2  at bedspace 5.
Graph to sh ow  the variation in  urinary aM T 6s 2 8 9
excretion  rate, core b od y  tem perature and ligh t  
in tensity  over 2 4  hours for subject R 13 at 
bedspace 10.
Graph to sh ow  the variation in  urinary aM T 6s 29 0
excretion  rate, core b ody tem perature and ligh t 
in tensity  over 2 4  hours for subject R 14  at 
bedspace 3.
Graph to sh o w  the variation in  urinary aM T 6s 291
E xcretion  rate, core body tem perature and ligh t  
intensity  over 2 4  hours for subject R 15 at 
bedspace 2.
hours for subject RIO at bedspace 4.
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Figure 91.
Figure 92 .
F igure 93 .
F igure 94.
Figure 95.
excretion  rate, core body tem perature and ligh t  
in tensity over 2 4  hours for subject R 16  at 
bedspace 5.
Graph to sh o w  the variation in urinary aM T 6s 293
excretion  rate, core body tem perature and ligh t 
intensity  over 2 4  hours for subject R 17 at 
b edspace 1.
Graph to sh o w  the variation in urinary aM T 6s 2 9 4
excretion  rate, core body tem perature and ligh t  
in tensity  over 2 4  hours for subject R 18 at 
b edspace 8.
Graph to sh ow  the variation in  urinary aM T 6s 295
excretion  rate, core body tem perature and ligh t  
in tensity  over 2 4  hours for subject R 19  at 
b edspace 5.
Graph to sh ow  the variation in urinary aM T 6s 296
excretion  rate, core b ody tem perature and ligh t
Graph to show the variation in urinary aMT6s 292
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in tensity  over 2 4  hours for subject R 23 at 
b edspace 4.
Figure 96.
Figure 97 .
F igure 98 .
F igure 99 .
F igure 100.
F igure 101.
F igure 102.
Graphs to sh ow  urinary aM T 6s excretion  rates on 301
a. w eek  one and b. w eek  2  for subject R l .
Graphs to sh ow  urinary aM T 6s excretion  rates on 3 0 2
a. w eek  on e and b. w eek  2  for subject R 6.
Graphs to sh ow  urinary aM T 6s excretion  rates 303
on a. w e e k  one and b. w e e k  2  for subject R8.
Graphs to sh ow  urinary aM T 6s excretion  rates 3 0 4
on a. w e e k  one and b. w eek  2  for subject R l  1.
Graphs to sh ow  urinary aM T 6s excretion  rates 305
on a. w e e k  one and b. w eek  tw o for subject R 12
Graphs to sh ow  urinary aM T 6s excretion rates 3 0 6
on a. w e e k  on e b. w e e k  tw o  and c. w eek  four for  
subject R 14
Graphs to sh ow  urinary aM T 6s excretion  rates 307
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on a. w eek one, b. w eek two and c. w eek four 
fo r subject R 1 5 .
F ig u re  103.
F ig ure 104.
F ig ure 105.
F ig u re 106.
Fig u re 107.
Fig u re 108.
G raphs to show urinary aM T6s excretion rates 308
on a. w eek one and b. w eek two fo r subject R 18.
G raphs to show urinary aM T 6s excretion rates 309
on a. w eek one and b. w eek two fo r subject R 19.
G raphs to show  u rin a iy  aM T6s excretion rates 310
on a. w eek one and b. w eek two fo r subject R 2 0
G raph to show  arterial plasm a m elatonin concentration 314  
com pared w ith venous plasm a m elatonin concentration  
fo r sam ples taken sim ultaneously from  IC U  patients (n  =  5).
G raphs to show the variation in  a. urin ary aM T6s 315
excretion rate and plasm a m elatonin concentr ation 
and b. plasm a m elatonin concentration and core body 
tem perature over 24 hours fo r subject R 24.
G raph to show  the variation in  a. urinary aM T6s 316
excretion rate and plasm a m elatonin concentration
4 2
A
and b. plasm a m elatonin concentration and core body  
temperature over 24  hours fo r subject R 25.
F ig u re  109.
F ig ure 110.
F ig ure 111.
Fig ure 112.
G raphs to show  the variation in  a. urinary aM T6s 317
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body  
tem perature over 2 4  hours fo r subject R 26.
G raphs to show the variation in  a. urinary aM T 6s 318
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
tem perature over 24  hours fo r subject R 27.
G raphs to show  the variation in  a. urinary aM T 6s 319
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
temperature over 24  hours fo r subject R 28.
G raphs to show  the variation in  a. urinary aM T6s 320
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
tem perature over 24  hours fo r subject R 29.
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F ig u re  113.
F ig ure 114.
Fig u re 115.
Fig ure 116.
Fig u re 117.
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
temperature over 24  hours fo r subject R 30.
G raphs to show the variation in  a. u rinary aM T6s 322
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
tem perature over 24  hours fo r subject R 31 .
G raphs to show the variation in  a. urinary aM T6s 323
excretion rate and plasm a m elatonin concentration  
and b. plasm a m elatonin concentration and core body 
temperature over 24  hours fo r subject R 32.
G raph to show  the age range and means o f the IC U  329
patient group com pared to those o f the in-house  
laboratory age range and the healthy volunteer age range.
G raph to com pare the total plasm a m elatonin produced 330  
over 2 4  hours (ng/m l.24h ) in  IC U  patients and healthy 
controls.
Graphs to show the varia tio n  in  a. u rin a ry  a M T 6 s  321
4 4
(ng/m l.24h ) in  IC U  patients and healthy controls w ith  
the laboratory m ean (± S D )
F ig u re  118. G raph  to com pare the to ta l u rinary  a M T 6 s  excreted  331
F ig ure 119.
CHAPTER 6
Fig ure 120.
Fig u re 121.
Fig u re 122.
G raph to show  the num ber o f patients w ith rhythm  332
abnorm alities based on w hether or not they w ere 
treated at bed areas w ith or w ithout w indow s.
INVESTIGATION OF CORTISOL, PROLACTIN 340
AND THYROID STIMULATING HORMONE 
CIRCADIAN RHYTHMICITY IN CRITICALLY 
ILL PATIENTS
G raph to show  the m ean variation (± S E M ) over 24  hours 344  
o f plasm a co rtiso l concentration in  healthy control 
subjects (n = 14 ).
G raph to show  the m ean variation (± S E M ) over 24 hours 345  
o f plasm a prolactin  concentration in  healthy control 
subjects (n = 14 ).
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C H A P T E R  1. IN T R O D U C T IO N
1.1. Natural Rhythmicity
A ncient civilisations were knowledgeable about the daily and seasonal changes in solar 
days, lunar nights, ambient temperature and tidal patterns and adjusted their lifestyles 
accordingly. Today we know  that these changes stem from  the rotation o f the earth 
about its own axis and around the sun, and not only man, but m ost eukaryotic 
organism s have adapted to this, both behaviourally and physiologically.
T he 24-hour solar day is the most sign ificant cy clica l change influencing the m ajority o f 
organism s. M any species have developed prom inent daily or circadian (circa: about, 
diem: a day) rhythm s in  response to this, in  terms o f their behaviour, physiology, 
biochem istry and gene expression. The term ‘circa d ia n ’ is strictly used to describe 
rhythm s that are generated w ithin the organism . F o r example, in  unicellular' algae, 
photosynthesis proceeds at a m axim um  rate at noon each day (Sweeney, 1983). 
Hum ans on the other hand have a d aily  sleep-wake cycle, and physiological changes 
such as core body temperature (C B T ), blood pressure, urine volum e and solute 
excretion (M oore-Ede et al, 1983), that are at a m axim um  during the day.
1.2. Generation and entrainment of circadian rhythms
The control o f circadian rhythms is brought about through interactions between internal 
or endogenous m echanism s and a num ber o f external or exogenous factors.
1.2.1. Endogenous M echanism s
1.2.1.1. E a rly  Studies
O rganism s that express circadian rhythm s have been shown to possess internal tim ing 
system s that act as internal “clo cks” . These can m aintain circadian rhythm icity in  the 
absence o f environm ental time cues.
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D e M airan first demonstrated this using a heliotropic plant, w hich characteristically 
raises it’ s leaves during the day and low ers them at night (M cFadden, 1988). H e found  
that in total continuous darkness, the plant continued to raise its leaves in  the day and 
low er them at night, suggesting that the rhythm o f leaf-raising is  generated internally or 
endogenously. Further studies by D e Candolle showed that in  total darkness the 
heliotrope no longer raised it s  leaves with a period o f 24 hours, but developed rhythm s 
that were independent o f solar time.
In  1939, w ild  m ice kept in conditions o f constant light were show n to maintain an 
activity-rest cycle. T h is led Johnson to postulate that there is  also a 'self-w inding and 
self-regulating physiological clock' o r endogenous regulator in mammals, w hich 
m aintains an internal rhythm when external cues are absent (Johnson, 1939).
A sch o ff and W ever were the first to observe the endogenous nature o f circadian  
rhythm s in  man (A schoff, 1967, W ever 1979), by placing human subjects in  
underground bunkers fo r 3 to 4  weeks, free from  all possible time cues such as natural 
daylight, temperature, sound and magnetic field  changes, radios and clocks. They  
m onitored core body temperature, rest-activity patterns, urinary electrolytes and urine 
volum e. The subjects continued to display circadian rhythm icity in  a ll physiological and 
biochem ical cycles, but with a period closer to 25 hours, thereby losing 1 hour per day 
(free-running) with respect to clo ck time. S im ilar studies were perform ed by Siffre. 
(S ifffe, 1964) in  caves. The deduction from  these studies was that endogenous 
circadian rhythm s exist in  man, they have a period o f approxim ately 25 hours and are 
re-set or entrained to a 24-h our rhythm  by environm ental factors such as the light-dark  
cycle, social cues, im posed behaviour and changes in ambient temperature. W e now  
know  that the average period in  hum ans is  shorter than described in  these original 
observations (Cam pbell et al, 1993; M iddleton et al, 1996; C ze isle r et al, 1999), and that 
the light-dark cycle  is by fa r the most im portant time cue.
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1.2.1.2. The Suprachiasm atic N u clei
1.2.1.2.1. Identification of the first mammalian pacemaker
U sing lesion studies on rats, R ich ter pinpointed the ventral hypothalam us as the area o f 
the brain, w hich contains a circadian pacem aker (Richter, 1965). Later, M oore and Lenn  
used lesion studies and a technique whereby H  amino acids were injected into the eye 
o f rats, to identify a novel bilateral projection that runs from  the retina to the 
suprachiasm atic nuclei (S C N ), the retinohypothalam ic tract (R H T ) (M oore and Lenn, 
1972). T h is led to further lesion studies on the S C N  to verify that this region was 
involved in  circadian rhythm control. The first o f these showed that ablation o f the S C N  
causes a loss o f circadian rhythm s o f adrenal corticosterone in  rodents (M oore and 
Eichler, 1972). Cessation o f circadian rhythm s has also been demonstrated in many 
other studies (M oore and K lein, 1974; Raism an and Brow n-Grant, 1977; Reppert et al, 
1981). E arly  post-natal ablation o f the S C N  has been shown to com pletely prevent 
circadian rhythms from  developing (M osko and M oore, 1978).
In  addition to the lesion study evidence, Inouye and Kawam ura electrophysiologically  
recorded the m ulti-unit activity from  the rat S C N  and found that it demonstrated 
circadian rhythm icity, with high activity during the day and low  activity at night. T h is  
phenom enon was observed even when the S C N  was isolated from  surrounding brain  
structures (Inouye and Kaw am ura, 1979) and provided proof that the S C N  can generate 
a rhythm  without neural input o r a light-dark cycle to sustain circadian rhythm icity. 
Schwartz et al demonstrated circadian rhythm icity in  metabolism using a deoxyglucose 
method and found that m etabolism  o f glucose by the S C N  was high during the day, low  
at night and free ran in  conditions o f continuous darkness (Schw artz et al, 1977). In  
addition to this, R usak showed that electrical stim ulation o f the S C N  in hamsters 
induced changes in  period length and phase shifts in free running circadian rhythms 
(Rusak, 1977). These studies provided convincing evidence that the S C N  was in fact a 
b iological clo ck  that generates an endogenous circadian rhythm in mammals.
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1.2.1.2.2. SCN Structure
In  mammals, the S C N  is located in  the anterior hypothalamus o f the brain, dorsal to the 
optic chiasm  and lateral to the third ventricle (M oore, 1983). Photom icrographs o f 
sections through the rat S C N  have shown that the nuclei are made up o f two compact 
ce ll m asses consisting o f neurons. The cell m asses have three further subdivisions  
based on neuron size, quantity o f cytoplasm  and presence o f retinal afferent projections; 
the rostral and caudal sections. The rostral section has sm all neurons, low  amounts o f 
cytoplasm  and no retinal afferents. The caudal section is  made up o f two further parts. 
The first is the dorsom edial part, w hich is  sim ilar to the rostral section and the 
ventrolateral section, w hich has large neurons, m ore cytoplasm  and m ore organelles. It  
appears that retinal afferents are confined alm ost exclusively to this region (M oore, 
1983).
1.2.1.2.3. SCN Innervation
The S C N  has been shown to be innervated via  a num ber o f pathways, w hich involve the 
retina, retinohypothalam ic tract (R H T ), geniculohypothalam ic tract (G H T ), pretectal 
hypothalam ic tract (P H T ), raphe nuclei, cortex, basal forebrain, brainstem, 
paraventricular thalam ic nucleus and other hypothalam ic areas, as sum m arised in  Fig ure  
1.
1.2.1.2.3.1. The Retina
In  mammalian species, light is  detected by the retina, w hich is  made up o f rods and 
cones. Scientific evidence suggest that the cones are the photoreceptors that transduce 
inform ation about the light-dark cycle into a neural signal (Foster et al, 1991; M oore et 
al, 1995), however a coneless rodless m ouse also show s circadian responses to light 
(Foster et al, 1999) and novel circadian photoreceptors have been proposed. In  rats, a 
specific subgroup o f retinal ganglion cells (type III),  that measure 12.5pm  in diameter 
and are distributed throughout the retina, have been identified as the ganglion cells that 
project into the circadian system. A s yet the retinal ganglion cells in primates have not
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Figure 1. D iagram m atic representation o f the innervation pathways o f the S C N  by the retina 
via  retinal ganglion c e lls  (R G C ) that m ake up the retinohypothalam ic tract (R H T ), the 
Intergeniculate Leaflet (IG L ) via  the geniculohypothalam ic tract (G H T ), the m edial pretectal 
area (M P A ) v ia  the pretectal hypothalam ic tract (P H T ), raphe n u clei, p araven tricu lar 
thalam ic nucleus (P V T N ) and hypothalam us (H T )
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been identified (M oore, 1998). The retinal hypothalam ic projections terminate on two 
structures, w hich are the S C N  and the Intergeniculate Leaflet (IG L ) located in the lateral 
geniculate com plex.
Although the retinal origin o f the R H T  in  primates has not been identified (M oore
1998), some evidence is  beginning to show lin k s between the primate and rodent 
system s. Prim ates have been shown to have some retinal ganglion cells that contain 
substance-P, the prim ary termination o f the retinal projections being on the ventral and 
lateral regions o f the S C N  (M oore and Speh, 1994). Substance-P is also found in  the 
rodent system. The m ain transmitter o f retinal ganglion cells however is  glutamate 
(Castel et al, 1993).
1.2.1.2.3.2. The Retinal Hypothalamic Tract (RHT)
Th e R H T  is  the pathway that lin ks the retina directly to the S C N  and indirectly via the 
IG L . M o o re’ s early autoradiographic tracing studies showed that the R H T  exists in  a 
w ide variety o f species (M oore 1973). Studies have shown that the pathway is essential 
fo r entrainment, as lesions introduced in the R H T  cause loss o f entrainment (Johnson et 
al, 1988). Inouye and Kaw am ura have also demonstrated that the S C N  can be entrained 
so lely by the R H T  (Inouye and Kawamura, 1982). The R H T  is therefore essential fo r 
entrainment o f circadian rhythms.
1.2.1.2.3.3. The Geniculohypothalamic Tract (GHT)
Several groups demonstrated that the lateral geniculate com plex and in  particular the 
IG L  also has neuronal projections that terminate in  the SC N , in rats (Sw anson et al, 
1974; R ibak and Peters, 1975). The IG L  contains neuropeptide-Y producing neurons, 
w hich project into the ventral and lateral S C N  and also G A B A  producing neurons. In  
primates, the lateral geniculate com plex consists o f a dorsal lateral geniculate nucleus 
and a pregeniculate nucleus, the latter being equivalent to the IG L  and containing 
neuropeptide Y  producing neurons.
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1.2.1.2.3.4. Other Pathways of SCN Innervation
A  direct projection from  the olivary tract nucleus and the m edial pretectal area, w hich  
terminates predom inantly in  the S C N , has been identified in  the rat (M ikklesen  and 
Vrang, 1994). In  1998, M oga and M oore identified a further projection that extends 
from  the m idbrain raphe nuclei that contain serotonin, w hich has a dense pattern that 
overlays the input by the retina, P H T  and IG L  (M oga and M oore, 1998). The S C N  also 
has projections that originate from  other structures, including the paraventricular 
thalam ic nucleus and areas o f the hypothalam us and cortex (M oga and M oore, 1998).
1.2.1.3. The M ultiple O scillator Theory
Several studies show that circadian rhythm s are probably not controlled by a single  
pacem aker or oscillator but by several oscillators.
A sch o ff described a subject studied in  a tim e-free environment who developed a sleep- 
wake cycle and urinary calcium  excretion cycle with a period o f 32.6 hours but a core 
body temperature, water and potassium  excretion cycles with periods o f 24.7 hours - 
internal desynchronisation (A schoff, 1965). Further w ork has confirm ed this original 
observation (W ever, 1979) and has shown that this phenomenon is m ore profound over 
longer periods o f temporal isolation i.e. longer than 2 months (C ze isle r et al, 1980). 
These results suggest that at least two different oscillators exist.
Further evidence that there m ay be m ore biological clocks have com e from  animal 
studies. F u lle r demonstrated that lesions induced in the S C N  o f squ irrel m onkeys 
resulted in  a loss o f the circadian rhythm  fo r drinking behaviour although the circadian  
rhythm  fo r core body temperature persisted (F u lle r et al, 1981). S im ilar studies by 
Reppert et al, demonstrated that the cortisol rhythm  persisted after S C N  lesion (Reppert 
et al, 1981). M ost o f this is  controversial, but recent data show that the dorsom edial 
S C N  and ventrolateral S C N  show different responses (Sum ova and Ulnerova, in press). 
Furtherm ore, W elsh  et al have reported that individual rat S C N  neurons cultured on
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glass m ultielectrode plates produce spontaneous action potentials with prom inent near 
24h circadian rhythms (W elsh et al, 1995), w h ich suggests that the S C N  could po ssibly  
contain more oscillators.
It is  therefore generally acknowledged that there m ust be m ore than one pacemaker 
controlling circadian rhythms, but the master pacem aker resides in  the SCN . Although  
temporal isolation causes desynchronisation o f rhythms, the effect is  not immediate. 
Rhythm s rem ain synchronised with the same period fo r several days before internal 
desynchronisation occurs, from  w hich we m ay deduce that the pacemakers are initially  
coupled.
M oore-Ede has proposed that the m ultiple oscillator system is presided over by two 
coupled prim ary oscillators X  and Y. X  drives the rhythm s fo r core body temperature 
urinary water and potassium  excretion, w hilst Y  drives the sleep-wake cycle, plasm a 
growth horm one concentration and urinary calcium  excretion. M oore-Ede also  
proposed that these two pacem akers control a num ber o f secondary oscillators located 
in  other tissues (M oore-Ede, 1983).
1.2.1.4. N o n -S C N  O scillators
It has been shown that species other than mammals possess one o r m ore circadian  
oscillators located in  the retina (Takahashi and M enaker, 1982; Jan iket al 1990) and the 
hypothalam us (W elsh et al, 1995). O nly recently has a second oscillator been identified  
in  the retina o f mammals.
U sin g  the hibernating golden hamster, T o sin i and M enaker were able to culture neural
retinal tissue at a constant low  temperature o f 27°c, perfuse them with a medium  w hich  
was collected at 3-hourly intervals and assay the medium  fo r m elatonin by 
radioim m unoassay (T o sin i and M enaker, 1996). They found that the retinas in vitro
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were rhythm ic and synthesised m elatonin during the dark phase o f a light-dark cycle 
w ith a period o f 24 hours. The rhythm s o f melatonin synthesis could be phase delayed 
and advanced by light and could also free run, persisting fo r 5 to 6 cycles in constant 
darkness. T o sin i and M enaker have also used this technique in  healthy m ice and in  rd 
mutations to show that there is  a loss o f melatonin rhythm icity with age that is  
associated w ith the characteristic progressive loss o f rod and cone cells with age in such  
mutants (T o sin i and M enaker, 1998)
E a rlie r w ork by R alph and M enaker showed that the period o f the oscillator in  the S C N  
o f a mutant hamster know n as the tau mutant had a short circadian period o f 20 hours 
(R alph and M enaker, 1988). C ro ss breeding experim ents showed clearly that 
periodicity or tau was inherited. Retinal tissue from  tau mutant hamsters also had 
periods that averaged 20 hours dem onstrating that the gene also m odifies the period o f 
oscillation o f the retinal clock. The retinal oscillator may control the d aily shedding and 
renew al o f rod outer segment discs and m elatonin (review  von Schantz, 1998).
1.2.1.5. G enetic and M o lecu lar Control
I.2.I.5.I. frq, p e r  and tim genes
G enetic studies and m olecular biology techniques have been em ployed to determine the 
underlying m echanism  by w hich circadian rhythm s are controlled. F irst clues came 
from  studies on the fru it fly  Drosophila melanogaster and the bread m ould 
Neurospora crassa, in  w hich several genes involved in the circadian m echanism  have 
been isolated.
In  Neurospora, the frequency gene (frq) was identified, mutations o f w hich cause either 
alterations in  period length fo r fungi sporulation or arrhythm icity (D unlap, 1993). frq  is  
transcribed by frq  m R N A  to produce the protein FR Q . It has been shown that both frq 
m R N A  and F R Q  protein have a circadian rhythm  in  terms o f the quantity present, with
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the amount o f frq  m R N A  peaking at noon (Aronson, 1994 and Dunlap, 1996). The 
rhythm ic change in  frq  is believed to be essential fo r the overt rhythm o f sporulation.
Ligh t has been show n to have an effect on the regulation o f frq . Crosthw aite et al 
showed that b rie f white light causes a transient but substantial increase in  the quantity o f 
frq  m R N A  at a ll phases o f the circadian cycle (Crosthwaite, 1995). The effect o f b rief 
exposure to bright light depends on the time o f day at w hich the light dose is given. 
Ligh t given in the late afternoon, when transcription is decreasing, delays the decrease 
and thus the circadian cycle, causing a delay in  conidiation. Light given at night causes 
the cycle to advance. Linden et al have also looked at the response o f Neurospora to 
light and have isolated mutant strains that do not respond to light (Linden and M acino
1995). These are the white co llar strains, W C -1  and W C -2 , w hich lack a characteristic 
carotenoid pigm ent at the fringes o f the fungal colonies. Both genes have been cloned  
and have been shown to be transcriptional factors involved in phototransduction 
(Crosthwaite, 1996). W C -2  in  particular has been shown to be a clo ck  component 
necessary fo r the expression o f frq. The wc-1 gene does not seem to encode a clo ck  
component, but the protein W C -1 does seem to be an essential element fo r responses to 
light (Crosthw aite et al, 1997).
Tw o genetic lo ci have been identified in Drosophila, the period gene (per) and the 
tim eless gene (tim) (H ardin et al, 1990 and Seghal et al, 1994). M utations o f the per 
gene have been shown to cause changes in  period length and mutant strains o f both per 
and tim have shown arrhythm icity. per  and tim have demonstrated circadian oscillations 
in  gene transcription w ith a peak at night. H ow ever the production o f the proteins, P E R  
and T IM , do not cycle in  the same way. T IM  is  thought to be an essential protein fo r 
the stability o f P E R  (P rice et al, 1995). P E R  and T IM  appear to interact via a P A S  
dom ain in  P E R  to form  a 1:1 heterodim eric com plex. P A S  domains, w hich are protein 
dim erisation dom ains identified in P E R  as two direct repeats (P A S -A  and P A S -B ), have
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also been identified in Neurospora and are believed to be a characteristic feature o f 
clo ck  proteins. In  addition to the Drosophila P E R  protein, P A S  dom ain contains 
transcription factors that include the human aryl hydrocarbon receptor nuclear 
translocator protein - A R N T  and the Drosophila single-m inded protein - S IM . It has 
also been reported that two further clo ck  genes have been identified in  D rosophila, eye 
and Jrk. M utations o f both o f these prevent the expression o f per  and tim. They arc 
therefore thought to be involved in  activating per  and tim. H ardin et al have also shown 
that a sm all enhancer region o f the per  prom oter containing an E  box could promote per 
transcription (H ardin et al, 1997). L ig h t is  thought to have an opposite effect to that o f 
frq  because the oscillations o f per  and tim peak at night. It has been shown that T IM  is  
light sensitive and only accum ulates in the dark (H unter-Ensor, 1996 and M yers et al
1996). Therefore, constant darkness causes delays w hilst light advances the circadian  
rhythm  (Zeng et al 1996).
U sin g research evidence, a m odel has been proposed fo r a core circadian oscillator. It  
incorporates an autoregulatory transcriptional feedback loop, whereby the circadian  
clo ck  genes are activated by binding to paired transcriptional activators and are 
rhythm ically expressed, giving rise, after a short lag, to cyclin g  levels o f clo ck R N A s  
and proteins. The proteins then feedback to depress the levels o f their own transcripts. 
Fig ures 2a and b show the proposed m odels fo r the circadian clo cks in  Neurospora and 
Drosophila that incorporate all the clo ck  elements thought to be involved in  circadian  
regulation. In  Neurospora, F R Q  acts in  some w ay to feedback and depress the level o f 
frq  transcript (Figure 2a). Autoregulation in  Drosophila is thought to be brought about 
by the P E R -T IM  com plex accum ulating to a critical concentration and then entering the 
nucleus, where it feeds back to turn o ff per  and tim expression (Fig ure 2b).
1.2.1.5.2. Clock gene
G enetic proof that the m am m alian S C N  contains a biological clo ck  came from  R alph et 
al, who isolated a spontaneous, sem i-dom inant mutation, tau, in Syrian hamsters, that
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Fig ure 2. P ossible autoregulatory feedback loop m odels fo r a) the m olecular cycle  
w ithin the circad ian system  o f Neurospora crassa, b) the m olecular cy cle  w ithin the 
circad ian  system  o f Drosophila melanogaster and c ) the m o lecu lar cy cle  w ithin  
m am m alian species. Adapted from  D unlap J, 1998.
caused a reduction in  the circadian period from  24 hours to 20  hours (Ralph, et al 
1990). Further studies showed that transplantation o f the tau S C N  into a norm al 
hamster, caused the recipient to take on the periodicity o f the donor.
T o  isolate genes involved in  circadian rhythms, Takahashi’s group subjected m ice to N - 
ethyl-N -nitrosurea to induce m utagenesis and screened the second generation progeny 
fo r dom inant clo ck  mutations. In  1994, they reported that they had identified the Clock 
locus (Vitatem a et al, 1994), the mutation being mapped to the m idpoint o f m ouse 
chrom osom e 5. The gene m anifests itself in  hom ozygous Clock m ice kept in constant 
darkness, as an initial lengthening o f the rhythm  period (27-28  ho urs) leading to 
arrhythm icity after about two weeks. H ow ever a 6-hour light pulse has been show n to 
re-establish the long periodicity.
It is thought that either the Clock gene regulates circadian period or Clock encodes a 
protein that strengthens the coupling between m ultiple circadian clo cks in  the S C N  
(Shen et al, 1997). In  1997, the results o f a series o f sequencing studies by K in g  et al, 
revealed a sequence in  the Clock gene that was very sim ilar to the P A S  dom ain seen in  
Drosophila (K in g  et al, 1997). C lo n in g  o f the gene showed that it encodes a novel 
m em ber o f the basic helix loop helix (b H L H )-P A S  fam ily o f transcription factors. The 
carboxyl term inus contains a glutamine rich  region (Q -rich), w hich m ay be involved in  
the activation o f transcription. Clock m R N A  is highly expressed in the S C N  but also in  
the retina, indicating that a clo ck  m ay also be present in the retina. T h is has been 
demonstrated (T o sin i and M enaker, 1996).
M ore recently, three per  autologs have been identified (peri, per2 and per3), w hich can 
be transcribed to produce proteins, transcription peaking at night (D unlap, 1998). 
A ctivation o f transcription o f perl,per2  andper3 is thought to be by the C lo c k  protein.
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A  tw o-hybrid screen came up with possible partners fo r the clo ck  gene. B M A L 1  was 
one and it is thought that c lo c k -B M A L l heterodimers activate transcription from  the E - 
box element (G ekakis et al, 1998).
A t present it is not certain whether the Clock locus is  the clo ck  gene although it is  
involved in  regulation o f circadian rhythm icity. The m echanism  fo r how the gene 
functions also needs to be elucidated, but a possible m echanism  has been proposed by 
Jay D unlap as shown in  Fig ure 2c (D unlap, 1998).
It  is  interesting that the same or sim ilar m echanism s are present from  fun g i through to 
hum ans.
1.2.2. Exogenous C ontrol M echanism s
The free-running period o f circadian rhythm icity is  a feature o f the endogenous 
pacem aker. There therefore needs to be a m echanism  by w hich the internal ‘c lo c k ’ is  
reset to a 24-hour rhythm  either by lengthening the period, as in  mice, or shortening the 
period, as in  humans. T h is is  achieved through entrainment o f the endogenous rhythm  
by a num ber o f time cues or zeitgebers (from  the Germ an zeit fo r time and geber 
m eaning to give). Such time cues can be environmental, such as the light-dark cycle, 
ambient temperature o r relative hum idity, behavioural such as the sleep-w ake cycle or 
feeding times or as a result o f so cial interaction. O f these, it appears that the light-dark  
cycle  is the m ost im portant entraining time cue in most species.
1.2.2.1. Photic Entrainm ent
1.2.2.1.1. Entrainment in animals
Ligh t entrains the circadian pacem aker by phase shifting m echanism s (D eCoursey, 
1960; Pittendrigh, 1960). Studies have shown that light pulses fallin g  on an animal 
early in  the subjective night cause a phase delay in  the circadian system  (a transient 
lengthening o f the cycle), whereas light pulses adm inistered late in the subjective night
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cause phase advances (transient shortening o f the cycle). B right light pulses during the 
subjective day were shown to have no effect.
In  1982, Pohl found a difference between diurnal and nocturnal species in  their 
response to light during subjective day (Pohl, 1982). Nocturnal species o f rodent are 
insensitive to light pulses during the subjective day, but diurnal rodents produce a phase 
response curve with a constant negative slope during subjective day, indicating a 
sensitivity o f these species to light during the day.
1.2.2.1.2. Entrainment in humans
F o r m any years it was thought that lig ht does not play a m ajor role in  human pacem aker 
entrainment and that social interaction was the m ajor time cue. Recent studies have 
shown this not to be the case.
C ze isle r was the first to show that light o f 150 lux could entrain circadian rhythm s o f 
human subjects when all other artificial light sources were eliminated (C ze isle r et al, 
1981). T h is was follow ed by a dem onstration that when the sleep-wake cycle is kept 
constant, bright light exposure in the evening rapidly shifts the phase o f the endogenous 
com ponent o f the core body temperature and cortisol rhythms. T h is indicated that the 
b iological effect on the pacem aker was direct rather than indirect via the sleep-wake 
cycle (Czeisler, 1986). Later, “three-cycle lig h t” studies showed that bright light can 
produce strong “type 0 ” resetting o f the human circadian pacemaker. Phase delays in  
core body temperature were obtained when light exposure was 1 to 3 hours before the 
core body temperature m inim um . Phase advances were obtained when light was pulsed  
1 to 4  hours after the core body temperature m inim um . Furtherm ore, a phase shift o f up 
to 12 hours could be induced if  the light pulses were given near the core body 
temperature m inim um . Recently, C ze isle r’s group has demonstrated that bright light o f 
9,000 lux induces phase shifts in  human subjects during the subjective day, without 
changes in  amplitude (Jewett et al, 1997). In  addition to phase shifting, light given as
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one or two pulses at the core body temperature m inim um  has been show n to reduce the 
amplitude o f the circadian oscillator (Jewett et al, 1991).
1.2.2.1.3. Phase response curve for light
A  single and m ultiple pulse P R C  fo r light has been determined and can be used as an 
aid in  determ ining the tim ing o f exposure to bright light in  order to obtain phase 
advances or phase delays as show n in  figure 3 (M in o rs et al, 1991). Again, the phase 
advance period is  at the end o f the subjective night and the phase delay portion at the 
end o f the subjective day.
1.2.2.1.4. The Genetics of Photic entrainment
A  num ber o f groups have investigated the role o f im m ediate-early genes in  the process 
o f light-induced phase shifts. R ea et al found that during the subjective night, b rief light 
exposure results in  the increased expression o f the c-fos gene corresponding to an 
increase in  FO S  protein im m unoreactivity in  the rat S C N  (Rea et al, 1989). The F o s- 
im m unoreactive cells (F o s-ir) are located in  a discrete population o f cells in the SCN , 
innervated by the R H T . fos  expression has been shown to be stimulated only when 
light exposure is at circadian times that cause phase shifts (K om hauser et al, 1990). In  
addition, distinct patterns o f fos  expression occur after light exposure at different 
circadian times, suggesting that different ce ll populations may be involved in  phase 
advancing and phase delaying effects o f light (Rea, 1992). The fos-gene may therefore 
play a role in  the process o f phase shifting by light.
1.2.2.2. N on-Photic Entrainm ent
Although the light-dark cycle and to some degree ambient temperature are considered as 
the most important time cues fo r animals, other non-photic stim uli have been show n to 
play a role in  entraining circadian rhythms.
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Fig ure 3.
T im e  o f  l ight  (hr) r e la t iv e  to T min
The phase response curve o f core body tem perature to single light pulses 
in hum ans. R eproduced from  M in o rs et al, 1991. N egative phase shifts  
indicate phase delays.
82
Early studies in animals demonstrated possible entrainment by social factors. Halberg 
et al showed that free tunning blind mice could be entrained by sighted mice that were 
already entrained to the light-dark cycle (Halberg et al, 1954). Furthermore, a study by 
Menaker and Eskin suggested that the free running activity of sparrows can be entrained 
via auditory pathways, using tape-recorded bird song. The free running activity 
resumed when the bird song stimulus was removed (Menaker and Eskin, 1966). In this 
study though, only three out of ten birds satisfied the criteria for entrainment.
Hastings et al found that handling Syrian hamsters, whilst giving subcutaneous injections 
at particular circadian times (CT), CT8 and CT10, before the activity onset at CT12, 
acted as a potent zeitgeber and induced non-photic shifts o f the rhythm activity (Hastings 
et al, 1992). In trying to elucidate a mechanism for this using the rhythmic expression o f  
the c-fos-ir gene in the SCN as a marker, Hastings group found that c-fos-ir was not 
expressed after handling, indicating that FOS is not essential for non-photic 
synchronisation. (Mead et al, 1992).
In humans, social interaction was thought to be the predominant entraining factor, via 
psychosocial activities such as going to work or school, mealtimes, exercise and 
recreational activities. This was largely due to the early isolation studies o f Aschoff et al, 
who, in a small group o f subjects, showed that circadian rhythms free ran in the absence 
o f a light-dark cycle, but with independent periods (Aschoff et al, 1971). Wever also 
showed that acoustic signals instructing subjects to perform tasks could synchronise 
rhythms (Wever, 1979). These studies were however carried out in low intensity light 
conditions (300 lux), levels, which are now known to affect rhythmicity. Middleton et al 
showed free running rhythms in groups o f six subjects maintained in continuous dim light 
(< 8 lux) but with knowledge o f clock time (Middleton et al, 1996; Middleton et al,
1997), illustrating that knowledge o f clock time is not sufficient to entrain circadian 
rhythms.
1.2.2.2.1. Social Interaction
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Since Czeisler showed that light does entrain the human circadian system (Czeisler et al, 
1981), more recent studies have demonstrated that social cues play a minimal role in 
entraining the human pacemaker. Honma et al took subjects and imposed a three-day 
schedule of being awake from 08:00h to 24:00h with three meals and social contact 
twice a day from 09:00h to 12:00h and 14:00h to 17:00h. They then induced an 8-hour 
phase shift in the social schedule to 01:00h to 04:00h and 06:00h to 09:00h. Some 
subjects were then exposed to a 3-hour bright light pulse each day. These subjects 
became re-entrained to the new schedule faster in terms of core body temperature and 
plasma melatonin rhythms than those who had no light pulses and just room light (300 - 
800 lux) (Honma et al, 1995), showing that light had more influence on entrainment. 
All subjects here became synchronised by day 8.
Duffy et al inverted the rest, sedentary activity and social schedules of another group of 
male subjects and exposed some of these subjects to a 5-hour pulse of bright light. The 
timings of these pulses were such that they would either cause a phase delay or a phase 
advance in the subjects. Social contact for all subjects was scheduled during the ‘wake’ 
period. Core body temperature rhythms of the subjects exposed to the social contact 
alone did not adjust to the inverted schedule, even after 10 days, compared to the ‘light- 
treated group’, which showed a significant phase shift in core body temperature and had 
adapted to the new time schedule (Duffy et al, 1996). This indicated that the social cues 
were too weak to re-entrain the endogenous rhythm of the subjects.
I.2.2.2.2. Sleep-Wake Cycle
The sleep wake cycle has a circadian rhythm and in humans it is analogous to the rest - 
activity cycle of animals. Under normal conditions, sleep takes place during subjective 
night and has been shown by electroencephalography (EEG) to be made up of five 
distinct stages. Stages I to IV are non-rapid eye movement (NREM) stages, which are 
associated with progressively deeper sleep. Stages DI and IV make up slow wave sleep
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During stage V, rapid eye movement (REM) sleep takes place.
The sleep-wake cycle has been shown to entrain the circadian rhythms of core body 
temperature and of urinary cortisol, catecholamines and sodium, when subjects are kept 
in constant darkness (Aschoff et al, 1971).
The propensity to sleep is at it’s lowest between 20:00h and 22:00h when core body 
temperature is at it’s peak. However after this period there is a rapid increase in the 
ability to fall asleep (Dijk and Czeisler, 1994). The sleep-wake cycle is however 
influenced heavily by social cues and often overrides the circadian sleep propensity 
rhythm (Sack et al, 1992).
1.2.2.2.3. Mealtimes
Many rhythmic variables are known to be synchronised to periodic food availability 
(Boulos and Terman,1980). In 1981, Stephan showed that rats possess a circadian 
pacemaker that is entrained by the periodic ability to get food, called the food entrainable 
oscillator, which is separate from the SCN (Stephan, 1986). Evidence for this comes 
from lesion studies on the rat SCN, which demonstrate that the activity of rats can still 
be entrained to a range of periodic feeding regimens (Stephan, 1981). To date there is 
no evidence to show that mealtimes entrain human subjects.
1.3. The Pineal Gland
1.3.1. Structure and Function
The classical name for the pineal gland, given by Galen in around 130-200 AD is 
corpus pine ale, on observing that in humans, it is shaped like a pine tree cone (Kappers, 
1983). However, the pineal gland varies in size, shape and location within and between 
different mammalian species. Pineal volume increases as body weight increases across 
species. For example, the mean weight of the adult pineal gland in rats varies from
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0.9mg in Long-Evans rats to 1.56mg in Sprague Dawley rats (Arendt, 1995). By 
comparison, the adult human pineal gland weighs between 100 to 150mg.
The mammalian pineal organ arises in the embryo as an evagination of the diencephalic 
roof and in most species, is linked to the habenular commissure by a stalk-like structure 
(Wurtman et al, 1968). In some species, the pineal remains incorporated within the 
diencephalic roof e.g. hedgehog and dormouse. Pineal organs develop as two organs, 
although in many species they exist as a single midline structure. A means of 
classifying the arrangement of the pineal in different species has been developed by 
Vollrath (Vollrath, 1981). The pineal gland is often associated with the third ventricle, 
lying in the subarachnoid space and is therefore bathed in subarachnoid fluid. Figure 4 
shows the position of the pineal gland in the human brain.
In many species such as fish and amphibians, the pineal gland responds to 
photostimulation whereas in mammals the organ is purely secretory and is part of the 
endocrine system. In birds, the pineal gland serves both photoreceptor and secretory 
functions. The structure of the pineal consists of pinealocytes which have evolved from 
the photoreceptor and glial cells found in lower vertebrates (Reiter, 1981). In all species 
studied, the pineal gland acts as a transducer, converting information received from the 
SCN about the light-dark cycle to changes in body physiology. In mammals this is 
achieved through the production of the hormone melatonin.
1.3.2. Innervation of the Pineal Gland
In mammals, the pineal is innervated mainly by post-ganglionic adrenergic sympathetic 
fibres arising from the superior cervical ganglion, although it also receives input from 
parasympathetic, peptidergic and commissural fibres.
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Figure 4. Diagram of the human brain to show the position of the pineal gland.
87
Melatonin or 5-methoxy-N-acetyltryptamine is one of a number of indoleamines 
synthesised by the pineal gland. It was first isolated from bovine pineal glands by the 
dermatologist Lemer, who gave the hormone its name due to its ability to cause 
contraction of melanophores, the pigment-producing cells in frog and fish skin (Lemer, 
1958).
1.3.3.1. Neural Regulation of Melatonin Synthesis
1.3.3.1.1. Circadian Pacemaker Control
The SCN exerts its pacemaker effects on the pineal gland via the paraventricular nuclei 
(PVN), the superior cervical ganglion (SCG) the intermediolateral cell column (ICC) in 
the upper thoracic spinal cord and post-ganglionic sympathetic fibres, which terminate 
on the parenchymal cells of the pineal as shown in figure 5 (Klein et al, 1991). Lesions 
of the SCN result in the abolition of the melatonin rhythm and lesions of any part of the 
pathway from the SCN to the pineal gland also abolish the melatonin rhythm (Moore- 
Ede et al, 1983).
1.3.3.1.2. Adrenergic Control
Post-ganglionic sympathetic fibres terminating in the pineal gland predominantly 
control melatonin synthesis, through the release of noradrenaline (NAD) (Snyder and 
Axelrod, 1965) and to a lesser degree, serotonin, from the nerve endings, as 
demonstrated by studies on rats (Klein et al, 1992). Pineal levels of NAD have been 
shown to be higher at night than during the day in rats (Reiter, 1991). The current 
proposed mechanism of action is that NAD stimulates catecholamine receptor subtypes 
(al and pi), that are located in the pinealocyte membranes. NAD binds to the pi 
receptors thus activating adenylate cyclase (AC) via a guanine-nucleotide binding 
protein. Activation of AC causes a large increase in cyclic AMP production, which acts 
to stimulate the production of N-acetyltransferase (NAT) in the melatonin synthetic 
pathway (Sugden, 1989). NAD also stimulates a l receptors, which has several effects.
1.3 .3 . T h e  P ineal G land  and M e la to n in
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It causes a rapid increase in intracellular calcium and a stimulation of  
phosphatidylinositol turnover to form diacylglycerol (DAG). The DAG and calcium 
ions activate a protein kinase C (PKC), which is calcium and phospholipid dependent. 
PKC acts by potentiating the p-adrenergic stimulation of cyclic AMP production (Klein 
eta l, 1983). This mechanism is summarised in figure 6 (Sugden, 1991). a2 receptors 
that stimulate NAT synthesis have also been identified in the pineal gland (Klein et al, 
1992).
1.3.3.1.3. Melatonin Receptors
125In vitro autoradiographic methods using I-labelled melatonin have shown that high 
affinity melatonin receptors are located in the SCN of a variety o f mammalian species 
including rodents and primates (Vanacek, 1988; Weaver et al, 1989). Retinal receptors 
for melatonin have also been isolated in the chicken and rat (Dubocovich and Takahashi, 
1987; Dubocovich, 1985). Reppert et al also used these techniques on human subjects 
and found that melatonin receptors are present in the human SCN (Reppert et al, 1988). 
The retinal and brain melatonin receptors have been shown to have different 
characteristics based upon their ability to bind 2-[125I] iodomelatonin and were classified 
as ML-1 (retinal) and ML-2 (brain) (Dubocovich, 1988). Reppert et al have cloned two 
high-affinity G protein-coupled receptors for mammalian melatonin, M ella and M ellb
(Reppert et al, 1996). M ella is expressed in sites that bind 2-[ I] iodomelatonin such 
as the SCN and M ellb is expressed in the retina and brain. These receptors have recently 
been reclassified with an official nomenclature approved by the International Union of  
Pharmacology. M ella is now known as mt, (lower case because it has not been fully 
pharmacologically characterised) and M ellb is now MT2 (uppercase because it has been 
pharmacologically characterised) (Al-Ghoul et al, 1998). A  novel G protein-coupled 
receptor has also been identified in human pituitary - H9, which is believed to be related 
to the melatonin receptor family (45% of amino acids in H9 are common in mtj and 
MT2) although it does not bind melatonin (Reppert et al, 1996). The human H9 gene
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Figure 6. Mechanism of a  and (3-receptor stimulation by Noradrenaline.
a l  =  a lpha-adrenerg ic receptor 
P 1 =  beta-adrenerg ic receptor 
V IP  =  vasoactive in testinal peptide  
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91
has now been mapped to chromosome Xq28 (Gubitz and Reppeit, 1999). The 
identification of binding sites for melatonin in the SCN and retina is evidence that 
melatonin may play an important role in the entrainment mechanism.
1.3.3.2. Melatonin Synthesis
The chief site for melatonin synthesis in mammals is the pineal gland, although smaller 
fractions were thought to be synthesised by the retina, the gut, the Harderian gland and 
blood platelets (Wurtman et al, 1963; Pang et al, 1977; Launay et al, 1982). However, 
mRNA for N-acetyl transferase is only found in the pineal gland and retina, with tiny 
amounts found in a few other locations such as the pituitary gland (Coon et al, 1995) 
and so major synthetic sites other that the pineal and retina seem doubtful.
The pathway for the production of melatonin, via serotonin, as determined by Axelrod et 
al, is shown in figure 7 and begins with the uptake o f dietary tryptophan from the 
circulation into the pineal, possibly via an active transport mechanism against a 
concentration gradient (Axelrod, 1974). Within the pineal gland, tryptophan is 
converted to 5-hydroxytryptophan by the mitochondrial enzyme, tryptophan 5- 
hydroxylase, which is present at high levels. This conversion is a rate-limiting step in 
the formation of serotonin, the rate being determined by the availability of tryptophan.
The cytoplasmic enzyme, aromatic amino acid decarboxylase is highly active in the 
pineal and converts 5 -hydroxytryptophan to serotonin (5-hydroxytryptamine). 
Serotonin is then converted to N-acetylserotonin by N-acetyltransferase (NAT), an 
enzyme present in the cytoplasm of the pineal and in the retina. NAT has a veiy high 
activity. In the rat, the activity of the enzyme increases by 70 to 100-fold at night. As a 
result, NAT is considered to be the main rate-limiting step in the synthesis of melatonin 
(Klein and Weller, 1970). N-acetylserotonin is converted by hydroxyindole-O- 
methyltransferase (HIOMT) to N-acetyl-5-methoxytryptamine (melatonin) by O-
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Figure 7. The synthetic pathway of melatonin from tryptophan
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methylation. HIOMT also has rhythmic activity in the pineal, being higher at night due 
to an increase in enzyme protein.
The circadian activity o f the enzymes brings about circadian rhythmicity in the 
concentrations o f both serotonin and melatonin as shown in figure 8. Melatonin 
production in most vertebrates, including humans, is therefore high during the subjective 
night and low during the subjective day. Reiter showed that although melatonin is 
secreted at night, this secretion is species specific and he has described three provisional 
patterns o f melatonin secretion. In type A, melatonin levels are high only in the latter 
half o f the dark period. The type B pattern has a gradual rise and fall in melatonin 
secretion with the peak occurring near the mid-dark period, whilst type C shows a rapid 
increase in secretion to a maximum which is maintained until the light period, when 
there is a rapid decline. In all cases, melatonin secretion is extended when the dark 
phase is prolonged (Reiter, 1987).
1.3.3.3. Melatonin Metabolism
In all mammals, melatonin is metabolised primarily by the liver, where it undergoes 6- 
hydroxylation to form 6-hydroxymelatonin (Lane and Moss, 1985). This is followed 
by conjugation to either a sulphate group or a glucuronide group to form 6- 
hydroxymelatonin sulphate (also known as 6-sulphatoxymelatonin) or 6- 
hydroxymelatonin glucuronide respectively. Different species however have been 
shown to form these two conjugates to vaiying degrees. For example, in humans and 
rats, 6-sulphatoxymelatonin is the major metabolite.
The route o f melatonin administration also appears to affect the metabolic route taken. 
Sheep metabolise acute oral doses o f melatonin to produce 6-sulphatoxymelatonin as a 
minor metabolite, but when given intravenously, it is a major metabolite. Melatonin is 
also metabolised in this way by the kidneys. Minor metabolic routes are via the brain
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where melatonin is metabolised to produce the minor metabolites N-gamma-acetyl-N-2- 
fomiyl-5-methoxykynurenamine and N-gamma-acetyl-5-methoxykynurenamine, which 
may be physiologically active. Melatonin can also undergo cyclisation of the side chain 
on the 3 position to form cyclic 2-hydroxymelatonin or it can be demethylated to form 
N-acetylserotonin, which can then be hydroxylated and conjugated in the same way as 
melatonin. The metabolic pathway is shown in figure 9.
1.3.3.4. Melatonin and Light
Melatonin synthesis by the mammalian pineal gland is rhythmic, the rhythm being 
generated by the SCN. Light influences the rhythmicity o f melatonin production by 
entraining the rhythm to a 24 hour cycle, suppressing its production and inducing phase 
shifts in the rhythm.
1.3.3.4.1. Entrainment
The light-dark cycle brings about entrainment of the melatonin rhythm by the 
mechanism described earlier whereby light, detected by photoreceptors in the retina, is 
transmitted as an action potential predominantly along the RHT, terminating on the 
SCN. The SCN then relays this signal to the pineal gland, which leads to melatonin 
synthesis. In most mammalian species including man, melatonin is secreted in very low 
concentrations during the day but high concentrations at night
The entraining effects have been shown by human studies where the light-dark cycle has 
been inverted and the urinary melatonin rhythm subsequently was shown to adapt to the 
new photoperiod over several days (Lynch et al, 1978).
1.3.3.4.2. Suppression
Klein and Weller first showed that light induces a rapid suppression of serotonin N- 
acetyltransferase and therefore suppresses melatonin production in rats (Klein and 
Weller, 1972). In addition, sudden brief light exposure for one minute during the night
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has been shown to suppress raised NAT and melatonin levels in laboratory animals 
(Ulnerova and Vanecek, 1985; Reiter, 1985).
Early studies in human subjects suggested that light with an intensity of 100 to 800 lux 
could not suppress melatonin or that humans were resistant to these levels of light 
(Arendt, 1978; Brainard et al, 1988). However, Lewy et al showed that 2 hours of 
exposure to bright light with a higher intensity of 2500 lux, given at night, induced a 
marked decrease in plasma melatonin concentration in healthy human volunteers. 
Exposure to light with an intensity of 500 lux caused no such reaction (Lewy et al, 
1980). These results demonstrated that human melatonin production could also be 
suppressed by light o f a high intensity. More recently it has been demonstrated that 
light o f lower intensity in the range o f 100 to 650 lux can suppress human melatonin 
levels, provided that the exposure conditions to the light are carefully controlled 
(Bojkowski et al, 1987, Brainard, 1997). However the degree o f suppression is intensity 
dependent, a more profound suppression being induced at higher intensities compared 
to low intensities.
In addition to light intensity, many other factors affect the suppression of melatonin 
production. Studies have shown that the spectral properties of the light source are 
important for melatonin suppression (Brainard et al, 1984). In both rodents and 
humans, light with a wavelength in the green band (475-525nm) is the most effective at 
suppressing melatonin production (Brainard et al 1988) and this corresponds closely to 
the spectral sensitivity of rod cells. Light in the ultraviolet range (at around 360nm) and 
extremely low frequency wavelengths such as those generated by electric currents have 
also been shown to suppress melatonin production (Brainard et al, 1986, Wilson et al, 
1988). Recently Thapan, Skene and Arendt have reported in preliminary data using 
whole retinal illuminance and monochromatic light, that light in the blue range is most
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effective (Unpublished data presented at the European Pineal Society, Tours, France,
1999).
Reiter has documented that there are differences between species in terms of their 
sensitivities to light treatment. For example, laboratory rats only require a light intensity 
of 0.2 lux to suppress pineal NAT whereas levels as low as 300 lux suppress melatonin 
levels in man (Reiter, 1985). Some studies have also shown that individuals within a 
species vary in their sensitivity to light suppression. In a study by Bojkowski et al, four 
subjects demonstrated suppression of plasma melatonin levels with light intensity o f"  
300 lux but for one subject, this intensity had no effect (Bojkowski et al, 1987). Similar 
findings have been reported by other groups (Lewy et al, 1985)
I .3 .3 .4 .3 .  P h a s e -s h ift in g
The studies o f Ulnerova, using rats maintained in a light-dark schedule o f 12 hours of 
light followed by 12 hours o f darkness, showed that a one minute light pulse before the 
middle of the night induced an immediate decline in pineal NAT activity and resulted in 
an overall phase delay of the NAT rhythm. Conversely, the one minute light pulse 
applied in the late night resulted in a phase advance of the NAT rhythm (Illnerova and 
Vanacek, 1985). Light pulses did not however induce parallel phase shifts in the NAT 
activity, when applied during the evening rise or morning decline o f NAT activity.
Using light pulses to obtain phase response curves for the evening rise and morning 
decline, Illnerova and Vanacek proposed that melatonin secretion is controlled by a dual 
oscillator: an evening oscillator (E) controlling NAT rise, that may be coupled to dusk 
and a morning oscillator (M) controlling NAT decline that may be coupled to dawn. 
Both oscillators can interact with each other (Illnerova and Vanacek, 1982).
Phase shifting effects o f bright light have also been shown in human subjects. 
Czeisler’s group demonstrated human subjects exposed to bright light in the evening
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induced phase delays in the core body temperature and cortisol rhythms (Czeisler et al, 
1986), but shifts in melatonin rhythms were first shown by Broadway. He showed that 
bright light during the Antarctic winter phase shifted the melatonin rhythm to a phase 
similar to that found in summer (Arendt and Broadway, 1986; Broadway et al, 1987). 
Bright light exposure in the morning, given daily over a week has also been shown to 
advance the onset o f the night time production of melatonin (Lewy et al, 1987).
Recently it has been proposed that phase shifting o f the melatonin rhythm can be 
brought about by a 3-hour exposure of the popliteal region (the area just behind the 
knee) to bright light (Campbell and Murphy, 1998). This suggested that humans have 
photoreceptors other than the retina. However similar studies using very high intensity 
light directed at the popliteal area found that plasma melatonin levels were neither 
suppressed or phase shifted (Lockley et al, 1998), indicating that if extraocular 
photoreception exists, then it does not involve the SCN.
I.3.3.5. Factors Influencing Melatonin Production
1 .3 .3 .5 .1 , A g e  E ffe c ts
The effects of age on the production of melatonin have been studied in gerbils, hamsters, 
rats and humans (Reiter, 1992). All studies showed that the melatonin rhythm 
deteriorates with age in two ways. First, there is an overall decrease in the amount of 
melatonin produced and in particular, the amplitude o f the night time peak decreases 
(Reiter et al, 1980; Reiter et al 1981; Touitou et al 1981; Iguchi et al 1982). Second, 
there is a decrease in the length of time that melatonin peaks at night (Nair et al, 1986). 
The deterioration in the characteristics o f the rhythm appears gradually with increasing 
age. Human studies have also demonstrated an age-related decline in urinary 6- 
sulphatoxymelatonin rhythms with increasing age (Sack et al, 1986; Bojkowski and
j
Arendt, 1990). In gerbils and man, it was presumed that the deterioration was due to 
increasing calcification of the pineal gland with age, but this has not been demonstrated.
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A  more favoured mechanism for deterioration is the reduction of the p-adrenergic 
receptors on the pineal membrane, responsible for mediating the effects o f noradrenaline 
released at night from sympathetic neurons within the pineal. Radioligand studies on 
Fisher 344 rats have demonstrated that the density o f pineal p-adrenergic receptors 
decreases with age, without the affinity o f the ligand for the receptor being impaired 
(Greenberg and Weiss, 1978). It has been suggested that p-adrenergic receptor 
deterioration may be linked to food intake as food restricted Fisher 344 rats have been 
shown to preserve NAT activity and serum melatonin levels compared to similar rats 
allowed to feed ad libitum (Henden et al, 1992).
I .3 .3 .5 .2 .  D ru g  E ffe c ts
Studies into the effects of drugs on human melatonin production have been limited to 
certain classes o f drugs. The use o f p-adrenoceptor blockers such as atenolol have 
shown that melatonin production is dependent upon p-adrenergic control, since atenolol 
suppresses plasma melatonin and urinary aMT6s levels at night (Cowen et al, 1985; 
Arendt et al, 1985). Suppression of plasma melatonin and urinary aMT6s can be 
brought about by sodium valproate, a drug which enhances the effects o f GABA, thus 
providing support for the view that GABA is involved in the modulation of pineal gland 
activity (Monteleone et al, 1997). The mechanism of action has not yet been confirmed. 
In addition, the non-steroidal anti-inflammatory drug ibuprofen can also reduce plasma 
melatonin levels (Bird et al, 1986).
Plasma melatonin and urinary aMT6s levels can be increased by administering 
noradrenaline uptake inhibitors such as desipramine and (+)oxaprotaline (Sack and 
Lewy, 1985; Beam et al, 1989; Palazidou et al, 1992) or serotonin uptake inhibitors such 
as fluvoxamine (Demisch et al, 1986). Psoralens used in the treatment o f psoriasis have 
also been shown to increase melatonin production, possibly by reducing the metabolism 
of melatonin (Souetre et al, 1988). The benzodiazepines such as diazepam have the
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ability to phase shift free running rhythms (Ralph and Menaker, 1986) in rodents: some 
have been shown to suppress human plasma melatonin levels (McIntyre et al, 1988).
I .3 .3 .5 .3 .  P osture
Plasma melatonin concentrations have been shown to change with posture in human 
subjects. A reduction of 20 to 30% is seen in plasma melatonin levels during the rising 
phase o f secretion on changing from a standing position to a recumbent position. A  
return to an upright position reverses the effect (Deacon and Arendt, 1994). It is 
thought that the effect is a result of small molecules diffusing into the extracellular space 
during standing that bring about hemoconcentration of albumin-bound melatonin.
1.3.3.6. The Role of Melatonin
1 .3 .3 .6 .1 . P h o to p e rio d is m
Many species have seasonal cycles that take place each year and are controlled by 
changes in daylength i.e. they are photoperiodic. Examples o f this include the 
reproductive cycles o f many animals, changes in coat growth and coat colour.
In most mammalian species including man, melatonin is the chemical signal for whether 
it is day or night, and for many species, it also provides information on daylength. 
During the winter when daylength is short, melatonin is elevated at night for a longer 
duration compared to the summer when daylength is long (Arendt, 1986). This 
phenomenon has been maximised in animal husbandry. For example, early lambing can 
be brought about either by feeding ewes daily with melatonin in the late afternoon from 
mid June onwards or by using melatonin implants, both of which mimic short days and 
can induce early onset of oestrus cycles (Arendt et al, 1983; Kennaway et al, 1987).
Humans were not thought to be photoperiodic, as we are able to control our behaviour in 
different environmental conditions, but some evidence points to the possibility that 
humans do respond to photoperiod. Seasonal variations in the conception rates have
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been observed as clear and reproducible patterns. Differences were observed in where 
the peak occurred in different countries, but this has been put down to the influence of 
economic and cultural factors (Roenneberg and Aschoff, 1990a and 1990b). More 
recently, Wehr has shown that some individuals are able to detect changes in daylength 
causing changes in the duration o f nocturnal melatonin secretion. Wehr compared 
melatonin levels after chronic exposure to long and short artificial nights and found that 
the duration of melatonin secretion in some individuals was longer after exposure to 
long nights and shorter after short nights (Wehr, 1997). It was also found that 
individuals living in urban environments differ in the degree to which melatonin is 
secreted in response to daylength, with 1 in 3 women responding to seasonal changes in 
the length o f solar nights compared to 1 in 8 o f men (Wehr, 1997). The factors 
responsible for these seasonal changes have not yet been identified.
I .3 .3 .6 .2 .  T h e rm o re g u la tio n
In diurnal mammals, CBT shows circadian rhythmicity, CBT being higher during the 
subjective day and then declining at night to reach a nadir between 03:00h and 06:00h 
(Cagnacci et al, 1992). Originally the nocturnal decline was thought to be linked to 
sleep (Barret et al, 1987). However studies have shown that the nocturnal CBT decline 
is still observed in studies where subjects are sleep-deprived or undergoing constant 
routines (Aschoff and Wever, 1981; Moore-Ede et al, 1983).
The rhythm of CBT shows a very close correlation to that of plasma melatonin. The 
nocturnal decline in CBT is completely opposite to the nocturnal rise in melatonin. The 
peak in melatonin occurs when the nadir in CBT occurs and the decline in melatonin is 
immediately followed by a rise in CBT. It has therefore been postulated that melatonin 
acts as a signal to induce the decline of CBT, but this has been questioned.
Administration of exogenous melatonin has been used to investigate the relationship 
between melatonin and CBT. Cagnacci et al demonstrated that administration of 2.5mg
103
of exogenous melatonin significantly reduced the daytime CBT by about 40% 
(Cagnacci et al, 1992). Deacon et al showed that a single dose of 5mg brought about a 
phase advance in CBT and self-rated alertness in addition to phase advancement of the 
endogenous melatonin rhythm (Deacon et al, 1994). Morning and evening 
administration of melatonin also resulted in suppression of CBT for 3 to 4 hours 
following treatment, the degree of suppression being dose dependent (Deacon et al, 
1995).
The circadian rhythm of CBT is regulated by the circadian rhythms of heat production 
and heat loss. The decline in CBT at night is due to increased heat loss and decreased 
heat production (Krauchi and Wirz-Justice, 1994). The mechanism by which melatonin 
affects this rhythm is unclear. Melatonin may affect peripheral blood flow by acting on 
the peripheral blood vessels (Cagnacci et al, 1996). In the rat, melatonin receptors have 
been identified in the peripheral blood vessels (Viswanathan et al, 1990) and these may 
also be present in humans. Alternatively, melatonin may act at the thermoregulatory 
centres of the hypothalamus. Again, melatonin receptors have been identified in this 
area (Morgan et al, 1994). Wirz-Justice and co-workers have shown that this effect is 
posture-dependent (Krauchi et al, 1997).
I.3.3.6.3. Interaction with sleep-wake cycle
Early animal studies showed that exogenous melatonin induces sleep in cats 
(Marczynski et al, 1964). It has also been shown to resynchronise the free-running 
rest-activity cycle of rats by phase advancing, when administered at the activity onset 
(Redman et al, 1983).
Early administrations of melatonin in humans used large doses of up to 6g and weie 
reported to induce sleep, with a side effect of abdominal cramps (Lemer and Norlund, 
1978). The sleep inducing effects were investigated further by Vollrath et al, who 
reported that the effect was acute but transient when given as a lmg intranasal dose
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(Vollrath et al, 1981). Larger single doses have been reported as reducing performance, 
transiently lowering alertness and increasing sleep efficiency (Lieberman et al, 1984) 
and even very low doses in the range of 0.3 to l.Omg have been reported to increase 
total sleep time and stage 2 sleep (Zhdanova et al, 1995).
1.3.3.6.4. Puberty and Development
The pineal gland and melatonin may be involved in the timing of puberty in mammals. 
When near physiological doses of melatonin are given to young male and female rats, a 
long-night profile of melatonin delays the onset of puberty. It is thought that melatonin 
acts on the hypothalamus-pituitary-gonadal axis, affecting gonadotrophin production 
(Lang et al, 1983; Rivest et al, 1986).
Similar studies in humans have not been possible, but there is evidence to suggest that 
melatonin has a role in pubertal development in man. Night-time circulation levels of 
melatonin decline during human pubertal development (Gupta et al, 1983; Waldhauser 
et al, 1984). Bojkowski also showed that urinary aMT6s levels decline with age in 
children (Bojkowski, 1990).
1.3.3.6.5. Melatonin as a Drug
Exogenous melatonin appears to act, at least in part, via the SCN, as melatonin receptors 
have been identified in this area in a number of species (Morgan et al, 1994, Reppert et 
al, 1988). Supporting this, Cassone et al demonstrated that SCN ablation abolishes the 
ability of timed exogenous melatonin doses to phase advance rat locomotor activity 
(Cassone et al, 1986).
Studies on human subjects have shown that timed administration of low dose melatonin 
in healthy subjects (2mg at 17:00h, daily for 4 weeks) results in a phase advance of the 
endogenous rhythm of melatonin (Arendt et al, 1984). It also has the ability to increase 
fatigue thereby mildly inducing sleepiness and improving alertness in the morning.
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(Wright et al, 1986). More recently, exogenous melatonin has been shown to induce 
phase delays in the endogenous melatonin rhythm when administered daily in the early 
morning (Lewy et al, 1992, 1998). Melatonin therefore has clear phase shifting 
properties.
Exogenous melatonin does have effects on the levels or 24 hour rhythms of other 
hormones. Acute administration has been shown to increase growth hormone levels 
(Valcani et al, 1987) although chronic administration has no apparent effect on growth 
hormone levels (Wright et al, 1986). Wright et al also showed that melatonin advanced 
the fall in nocturnal plasma prolactin concentration but did not change plasma cortisol 
levels (Wright et al, 1986). The effects on leuteinising hormone (LH) gave conflicting 
results. Voordouw et al showed that long term administration of melatonin decreases 
LH levels (Voordouw et al, 1992) whilst Cagnacci et al found it to increase levels when 
given acutely in premenopausal women (Cagnacci et al, 1992)
In humans, exogenous melatonin is most commonly administered orally. The 
preparations include gelatine capsules and slow release preparations at different doses, 
most commonly lmg, 2mg and 5 mg and each produce different effects on the plasma 
concentration of melatonin. 2mg gelatine capsules have been shown to give 
reproducible timed peaks in plasma concentration independent of nutritional tus, 30 
to 60 minutes after ingestion, which remains at or around the endogenous nigst time 
levels for 3 to 4 hours. 2mg of a slow release preparation produces high plasma 
concentration levels for 5 to 7 hours after ingestion but the peak time depends on 
nutritional status (Aldhous et al, 1985).
I.3.3.6.6. Phase response curve for melatonin
The construction of a PRC for melatonin has helped to predict the optimum time to 
administer a dose of melatonin to obtain the desired effect in terms of phase shifting.
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The most recent PRC for melatonin was elucidated by Lewy et al. 12 doses of 0.5mg 
melatonin were administered to volunteers at 2 hour intervals. Blood samples were 
drawn at 30 minute intervals and assayed for melatonin. The resulting melatonin PRC 
is shown in figure 10 and has a phase delay zone in the early morning and a phase 
advance zone in the late afternoon (Lewy et al, 1998). As can be seen, there is a 
difference of 12 hours in the phase between the melatonin and light PRC, which 
suggests that the effect of melatonin is opposite to that of light and that endogenous 
melatonin may augment the entrainment of the endogenous pacemaker by light.
1.3.3.7. Melatonin and Circadian Rhythm Disorders
1.3.3.7.1. Jet Lag
Jet lag is a phenomenon that results from rapid flight across several time zones and is a 
common problem that international flight crews and business travellers in particular have 
to contend with. Symptoms include sleep disturbance, disturbed gut function and poor 
performance. It is thought to be due to desynchronisation of individuals' circadian 
rhythms with local time following international travel. In order to adjust to local time, 
circadian rhythms have to advance after an eastward flight and delay following a 
westward flight. Exogenous melatonin administration has been investigated as a means 
of rapidly resynchronising body rhythms.
\n initial study where 5mg melatonin was taken at 18:00h for 2 days before and 4 days 
after a transatlantic flight, subjects taking melatonin reported no jet lag compared to 
placebo-treated controls (Arendtetal, 1986). Further studies have shown improvements 
in resynchronisation of endogenous melatonin and cortisol rhythms (Arendt et al, 
1987). A larger study showed that the effects of jet lag can be improved if melatonin is 
appropriately timed to induce phase delays or phase advances. Subjects travelling 
eastward from the UK to Australia and New Zealand and back, took 5mg melatonin or 
placebo for 2 days before arrival at a local time corresponding to 02:00h at the 
destination time zone, and for 4 days after arrival. Subjects travelling westward, took
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Figure 10. Binned phase shifts after melatonin administration to give a phase 
response curve for melatonin. Each time point represents data from 6 
individuals. Data were averaged into approximately 2-h bins. Adapted 
from Lewy et al, 1998.
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5mg melatonin or placebo for 4 days at local bedtime after arrival. In both groups, jet 
lag was improved in the majority of cases (Skene et al, 1989). A minority of individuals 
(10%) felt worse when taking melatonin, but this was probably due to their own 
circadian status. A later study on international cabin crew used two schedules of 
melatonin administration, where some crew were given 5mg melatonin for 3 days before 
flights and others placebo. Both groups received melatonin after the 3 day pre-flight 
period for 5 days. Of the 2 groups, those taking the placebo followed by 5mg 
melatonin reported less jet lag than those taking melatonin before the flight (Petrie et al, 
1993). In a total of 12 studies on jet lag, 10 showed beneficial effects. In the remaining 
two it was probable that the timing aspect of the melatonin doses was incorrect.
Melatonin has therefore been used by and large with success, but the timing of the 
doses appears to be critical and is more effective if the underlying circadian phase 
position of the individual is known.
L3.3.7.2. Shiftwork
Approximately 20% of the population of developed countries are involved in shift work. 
The result of shiftwork is that there is forced desynchronisation of physiological and 
biological rhythms from the external environment and from each other. Common 
problems associated with this desynchronisation are similar to those in jet lag i.e. 
disturbed sleep, gut function and blunted alertness that affects performance.
Field studies on adaptation to shift work have shown variable results. Some have shown 
that the melatonin rhythm phase shifts (Sack et al, 1992; Quera-Salva et al, 1996) 
whereas others have found no change (Touitou et al, 1990; Roden et al, 1993). A recent 
field study used urinary aMT6s as a marker of the circadian rhythm in night shift 
adaptation. It showed that individuals on a 2 week rotating 12 hour night shift can adapt 
to shift work most commonly by phase delays, adaptation taking about one week 
(Barnes et al, 1998).
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Folkard et al showed that exogenous melatonin administration in night shift workers 
following an 8 hour night shift does improve self rated sleep quality and sleep duration 
(Folkard et al, 1993). Simulated shift work or phase shift studies have shown that 
administration of appropriately timed oral melatonin (5mg) facilitates re-adaptation of 
the melatonin rhythm and also improves self rated sleep, alertness and performance 
(Deacon and Arendt, 1995).
1.3.3.7.3, Blindness
The ability to detect the light-dark cycle is an important aspect of entrainment to a 24 
hour schedule. It follows that individuals such as blind people should therefore have 
disordered circadian rhythmicity. Studies by Miles et al confirmed that totally blind 
individuals do have severe sleep disturbances and free run in terms of core body 
temperature and plasma cortisol rhythms (Miles et al, 1977). Lewy and Newsome 
reported abnormalities in melatonin rhythms in blind individuals that were either free 
running or at an abnormal phase (Lewy and Newsome, 1983). This has been confirmed 
by other studies that show that circadian rhythms of melatonin can be categorised into 
four groups: normally entrained to 24h, entrained to 24h but with an abnormal phase 
position, free running or with no clear pattern (Arendt et al, 1988, Lockley et al, 1997). 
Melatonin has been reported to synchronise the sleep-wake cycle and improve sleep in 
the blind (Aldhous and Arendt, 1991; Sack et al, 1990; Palm et al, 1991). However, long 
term synchronisation has yet to be reported.
1.3.3.7.4. Delayed sleep-phase insomnia
Approximately 10% of individuals that complain of sleep disturbances actually suffer 
from delayed sleep phase insomnia (Weitzman et al, 1981). This is a chronic disorder 
characterised by difficulties in falling asleep at night followed by difficulties in waking 
up in the morning. Often these cases are not recognised and are therefore not treated, or 
they are treated with hypnotics. The basis for the disorder is thought to be an inability 
to achieve large phase advances, once a phase delay of the circadian system has been
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induced by for example late bedtimes at weekends. 5mg doses of melatonin taken at 
22:00h have proved to be effective at helping to advance sleep time (Dahlitz et al, 1991).
1.3.3.8. Light and Human Circadian Rhythm Disorders
1.3.3.8.1. Seasonal Affective Disorder
Seasonal Affective disorder (SAD) or winter depression is characterised by recurrent 
episodes of depression that occur during the autumn and winter, hypersomnia, an 
increased appetite especially for carbohydrates and subsequent weight gain (Wirz- 
Justice et al, 1995; Lewy and Sack, 1987). It is thought that the disorder is due either to 
the increased length of the subjective nights in winter that bring about longer periods of 
decreased core body temperature and increased melatonin secretion, or to a delayed 
phase position.
Bright light has been shown to have beneficial effects in up to 85% of SAD patients 
(James et al, 1985; Wirz-Justice et al, 1986). Lewy et al treated a number of patients by 
exposing them to bright light between the hours of 06:00 and 09:00h and then between 
16:00 and 19:00h and found that the depression was treated effectively (Lewy et al, 
1982; Lewy et al 1984). Other groups have confirmed this (Rosenthal et al, 1984).
The mechanism of action of light has not been elucidated. It was thought that light 
might act by affecting~re levels or secretion of melatonin (Sack et al, 1990), however the 
melatonin rhythm has been shown to be normal in SAD patients (Checkley et al, 1993) 
and unaffected by bright light treatment compared to controls (Murphy et al, 1993). 
Recent data from Lewy’s group suggests that timed melatonin may help in SAD (Lewy 
et al, 1998)
1.3.3.8.2. Advanced and Delayed Sleep Phase Syndromes
In advanced sleep phase syndromes (ASPS), where patients find it difficult to stay 
awake in the evening and wake up very early in the morning and in delayed sleep phase
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syndromes (DSPS), appropriately timed exposure to bright light has been effective in 
producing corrective delays or advances in sleep patterns and circadian rhythms.
Lewy et al exposed a DSPS patient to 2500 lux for 1 hour each day on waking up and 
found that the sleep phase returned to normal in four days (Lewy et al, 1985). DSPS 
and ASPS patients have also been phase shifted using appropriately timed bright light 
of 10,000 lux for 4 to 5 hours (Czeisler et al, 1988). There is no data at present on the 
use of melatonin in these sleep disorders.
1.4. The importance of normal rhythmicity in human health
Normal rhythmicity plays a central role in the co-ordination of a number of important 
behavioural, physiological and biochemical aspects of human health. The most obvious 
of these is the sleep-wake cycle. Sleep is accompanied by increases in melatonin 
secretion, together with increases in pituitary hormones such as prolactin and growth 
hormone, whereas core body temperature and urine volumes decrease. Plasma cortisol 
concentration is low at night and increases during the early morning hours. 
Furthermore, neurotransmitters and their metabolites show circadian rhythmicity.
There are diurnal changes in mood and performance, with mood being at its lowest in 
the morning, alertness improving throughout the day and performance being best during 
the day but at its lowest at night when core body temperature is lowest and plasma 
melatonin levels peak.
Circadian rhythmicity is inherent in a number of more complex physiological processes. 
Blood pressure is lowest at night and higher during the day. There are circadian 
variations in blood coagulation factors with the acrophase times of fibrinogen, factors II, 
VII, VIII and al antitrypsin occurring in the morning (Labreqcque and Soulban, 1991). 
Fibrinolytic activity and particularly plasma levels of tissue-type plasminogen activator
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have a diurnal 24 hour rhythm, which suggest hypercoagulation in the morning hours 
(Adreotti and Kluft, 1991). The immune system also has a strong circadian rhythm 
(Palm et al, 1996).
Circadian rhythms are therefore essential to the health and well being of human 
individuals.
1.5. Circadian rhythms in the Intensive Care Unit
Aschoff and Wever showed that temporal isolation of healthy subjects resulted in the 
free running of the endogenous pacemaker, so that circadian rhythms of subjects 
oscillated with a period of approximately 25h (Aschoff, 1967, Wever 1979).
Patients in Intensive Care Units (ICU) are influenced by conditions that bear similarities 
to those of temporal isolation. Patients are sedated and sometimes paralysed to facilitate 
implementation of mechanical ventilation and therefore lose awareness of the 
environment and environmental changes, such as the time of day and the light-dark 
cycle. The rooms or bed areas in the ICU sometimes have no windows and are often 
artificially lit. Simulation of changes in the light - dark cycle are attempted by nursing 
staff, but are often not adhered to, as emergency admissions or therapeutic procedures, 
require bright light to carry out certain procedures safely (e.g. Tracheal intubation and 
arterial line insertion). In addition, patients are often fed enterally or parenterally and 
given drugs intravenously, both of which are continuous processes and therefore time 
cues from these activities are lost. Ambient temperature is artificially maintained at 
approximately a constant level and so this no longer acts as a zeitgeber.
As a consequence of these factors patients are shielded from the passage of time and the 
normal changes in the day - night cycle and are thus sensory deprived. It is therefore 
likely that just as with healthy individuals that are temporally isolated, the circadian 
rhythms of ICU patients may also become desynchronised from a 24 hour period and
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begin to free run. Sleep deprivation due to noise and therapeutic interventions may 
exacerbate the problem.
Many papers have suggested that sleep disturbance, environmental isolation and sensory 
deprivation may have effects on the circadian rhythmicity of ICU patients, but very few 
studies have investigated it closely. Tweedie et al carried out a retrospective study in 
1989 of core body temperature rhythms of 15 patients who had spent more than 8 days 
on ICU. They found that 80% of patients had a statistically significant circadian rhythm 
of 24 hours. They also found that within individuals the position of the acrophase 
moved from day to day. No patients were found to be free running (Tweedie et al, 
1989). This study involved a small number of patients and the results could not be 
considered as substantial evidence of abnormal circadian rhythmicity in ICU patients. 
Furthermore, although CBT is a good marker of the endogenous pacemaker in normal 
individuals, in ICU patients, it is likely to be influenced by a number of factors such as 
infection, use of drugs such as paracetamol and antibiotics and airbeds that are heated. 
Temperature rhythms are also masked by the effects of stress and high cortisol levels 
both of which are relevant in ICU patients.
Vogel et al looked at 24 hour profiles of growth hormone, prolactin and cortisol in 11 
patients in a chronic vegetative state. Again a 24 hour periodicity was maintained, 
although fewer high amplitude growth hormone peaks were observed, prolactin levels 
were generally higher and the mean peak duration of cortisol was shorter in patients 
(Vogel et al, 1990). The patients in this study are not representative of the majority of 
patients treated on ICU. In addition, patients in a chronic vegetative state do not exhibit 
a normal response to a stressful environment and the hormonal changes recorded may 
have been due to the brain damage.
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More recently, Shilo et al investigated the circadian rhythms of critically ill patients 
using 3 hourly urinary aMT6s estimations and were unable to detect circadian 
rhythmicity in their patients (Shilo et al, 1999), suggesting that circadian rhythmicity is 
suppressed in ICU patients. This is surprising as patients in ICU can often be awake 
and even alert, but ventilator dependent and one would expect a degree of rhythmicity in 
these patients.
There is therefore no substantial evidence to demonstrate conclusively that circadian 
rhythms are disturbed in ICU patients and no studies other than the retrospective CBT 
studies have demonstrated phase shifting in ICU patients.
1.6. The Intensive Care Unit
The ICU is a specialised ward in a hospital dedicated to the management of patients with 
life threatening illnesses, injuries or complications. In most hospitals the ICU is staffed 
by a multidisciplinary team comprised of skilled doctors, highly trained nurses, 
physiotherapists, technical staff, dieticians, pharmacists and radiographers.
Modem Intensive Care or Critical Care Medicine is a speciality which evolved from the 
experience of respiratory and cardiac care, physiological organ support, development of 
pharmacological treatments and specifically targeted therapies, increased understanding 
of the pathophysiology of multiple organ failure and the development of advanced 
technology for both monitoring and patient support.
Today’s ICU’s therefore have access to the most up to date clinical procedures, 
sophisticated continuous monitoring equipment and a wide variety of means for 
mechanical ventilatory support, which are all advantageous in the critical care setting for 
improving patient survival.
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1.6.1. The ICU Environment
ICU’s across the country vary in their size, speciality and patient acuity. Basic 
guidelines have been set out by the Society of Critical Care Medicine for the design of 
ICU’s so as to give patients adequate space, restful surroundings, access to natural 
lighting via windows and limited noise (Society of Critical Care Medicine, 1988).
1.6.1.1. Beds and Bed Areas
Patients can be cared for on a variety of bed types most of which are adjustable and 
allow patients to be placed in horizontal or sitting positions and sometimes tilted from 
side to side. The type of mattress used is varied according to the needs of the individual 
patient. Standard foam mattresses are often used for short-term patients requiring 
postoperative observation whilst more long-term patients are cared for on ah* fluidised 
beds to reduce the incidence of the development of bed sores.
The beds can be situated either in open areas of the unit partitioned by screens or nurses 
workstations or when isolation is required they are cared for in side rooms. The 
positioning of the bed in each area often varies so that patients either face away from the 
windows, towards the windows or side on from the windows.
1.6.1.2. ICU Lighting
Guidelines for the design of ICUs state that ideally all bed areas should have access to 
windows and therefore natural lighting, since this plays an important role in orientation 
to the environment. This is not always possible and often bed areas are artificially lit by 
fluorescent strip lighting. It has been recommended that this should give general 
overhead illumination of 20 foot candles (intensity = 214 lux, irradiance = 72.6pwatts / 
cm2 for cool white light) with emergency lighting for special procedures to be between 
100 and 150 foot candles (intensity = 1076 to 1615 lux, irradiance = 363 to 545 pwatts / 
cm2 for cool white light) (Society for Critical Care Medicine, 1988). In the modem
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ICU, nursing and medical staff are aware of the potential benefits of maintaining a 
regular light-dark cycle. Artificial lights are therefore switched off in the ICU at night to 
try and maintain a near normal day - night cycle, with a minimal amount of light to allow 
for patient observation. This schedule is not however strictly adhered to, as lights will 
often be switched on when patients are transferred between wards and the ICU, or if 
patients develop complications such as a cardiac arrest during the night. In many 
hospitals therefore, complying with these guidelines is difficult due to structural 
limitations and so not all patients are exposed to optimum conditions.
1.6.1.3. ICU Noise
Patients in ICU are exposed to high levels of noise from both staff and equipment. 
Daily ward rounds are carried out throughout the day by both ICU staff and other 
medical teams at which patients are clinically assessed and treatment plans discussed. 
There are nurses by each bedside that carry out hourly observations and talk to the 
patient when carrying out nursing procedures. Relatives also visit the patients regularly 
and talk to them. In addition, the patient is surrounded by various pieces of equipment 
including ventilators, monitors, haemodialysis machines, blood pumps and infusion 
pumps all of which alarm at intervals throughout the day and add to the noise around the 
bedside. A study by Redding showed that noise levels from equipment alarms, 
measured near patients' head, could be as high as between 63 and 92 decibels. This is 
higher than the 40 decibels for day time noise levels and 30 decibels for night time 
levels recommended by the international proposal for noise abatement (Redding, 1977). 
More recently, Cook et al measured the peak sound and the percentage of time that peak 
was reached. Talking, monitor alarms and televisions accounted for the noise for the 
longest period of time, whereas talking and bleeps accounted for the highest mean peak 
sounds (Cook et al, 1997).
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ICU patients are subject to changes in environmental temperature. The aim is to keep 
patients at a comfortable temperature adjustable to between 72° and 78° fahrenheit with a 
relative humidity between 30% to 60% (Society for Critical Care Medicine, 1988), but 
this can change with seasonal variations and air conditioning. Patients are often cared 
for on air fluidised beds in order to reduce the incidence of bed sores. In many 
situations these are temperature controlled and can have an effect on the environmental 
temperature and patient body temperature.
1.6.2. ICU Patients
Most ICU’s are run by Anaesthetists, although patients are admitted under a wide range 
of medical disciplines, the relative numbers depending on the specialities of the hospital. 
The range of specialities is listed in table 1. The Society of Critical Care Medicine has 
made recommendations in the form of guidelines for admitting patients to ICU. In 
broad terms they divide patients into 3 categories. Priority 1 patients are those that are 
critically ill, unstable and in need of intensive treatment such as mechanical ventilatory 
support and continuous treatment with infusions of vasoactive drugs. Priority 2 patients 
are not critically ill when admitted to ICU but require advanced technological monitoring 
and arc at risk for requiring immediate emergency intensive treatment. Priority 3 
patients are critically ill and unstable but have previous or current medical conditions 
that severely reduce the chance that they would benefit from ICU treatment and recover. 
These patients require ICU treatment to relieve acute complications.
1.6.3. Physiological and Technological Support of ICU Patients
The types of patients in ICU vary considerably in terms of disease category, but there 
are many common features in the way patients are cared for and treated once on the 
ICU.
1.6.1.4. Temperature
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Bums
Cardiac Surgery 
Cardiology 
Cold Orthopaedics 
Dermatology
Ear, Nose & Throat (ENT)
Endocrinology
Gastroenterology
General Medicine
General Surgery
Geriatrics
Gynaecology
Haematology
Infectious Diseases
Medical Oncology
Nephrology
Neurology
Neurosurgery
Obstetrics
Ophthalmology
Oral Surgery
Paediatrics
Paediatric Surgery
Pulmonary Medicine
Radiotherapy
Rheumatology
Special Care Babies
Spinal Injuries
Thoracic Surgery
Traumatic Orthopaedics
Transplant Surgery
Tropical Medicine
Urology
Vascular Surgery
Table 1. List of hospital specialities under which patients are admitted to the 
Intensive Care Unit.
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There are a number of clinical indications for mechanical ventilatory support in ICU 
(Pontoppidan et al, 1972). The most common are listed in table 2. The classic 
indication for ventilatory support is reversible acute respiratory failure. However, severe 
respiratory failure resulting from adult respiratory distress syndrome (ARDS) is of 
particular significance as it causes over 150.000 cases per year and with a survival rate 
of 50%, makes it as lethal a disease as lung cancer.
Mechanical ventilation was introduced in 1929 as a means of giving patients with 
respiratory paralysis the time to recover their ability to breathe normally. Artificial 
ventilation is achieved using intermittent positive pressure ventilators. The modem 
forms of these ventilators are volume-cycled ventilators that deliver a constant volume of 
air and oxygen, although the lung mechanics of the patient may be changing.
When mechanical ventilation is initiated the ventilator is set to give the following: -
1.6.3.1. Mechanical Ventilatory Support
a) A mode of ventilation
b) Tidal volume for inflation (Vt)
c) Respiratory rate
d) Inspired minute volume (Vi)
e) Fraction of Inspired Oxygen (FI02)
In addition the peak flow during the inspiratory phase can be set, as this determines the 
inspiratory / expiratory time ratio (I/E ratio).
The common modes of ventilation are Continuous Mandatory Ventilation (CMV), 
Intermittent Mandatory Ventilation (EMV), Pressure Support Ventilation (PS), 
Continuous Positive Airway Pressure (CPAP), Assisted Ventilation and Pressure 
Controlled Ventilation (PCV). The choice of which mode of ventilation to use depends
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CLINICAL INDICATION EXAMPLES
ACUTE RESPIRATORY FAILURE 
Without C02 retention Asthma 
Pneumonia 
Pulmonary oedema 
Pulmonary embolism
With C02 retention Chronic bronchitis 
Emphysema
SEVERE RESPIRATORY FAILURE Adult Respiratory Distress Syndrome
ACUTE 
MYOCARDIAL INFARCTION
CARDIAC FAILURE
SHOCK Septic
Cardiogenic
Hypovolaemic
Anaphylactic
Neurogenic
INCREASED METABOLISM Bums 
Multiple trauma 
Severe infection
POST OPERATIVE STATES Acute Aortic Aneurysm Repair
POISONING Drug overdose 
Carbon monoxide poisoning
Table 2. Common clinical indications for mechanical ventilatory support
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on the clinical picture of the patient. Apart from CPAP, all other modes of ventilation 
require the patient to be intubated.
1.6.3.1.1. Continuous Positive Airway Pressure (CPAP)
In many cases, mechanical ventilatory support requires endotracheal intubation of the 
patient. However, some patients can be treated using CPAP. This mode of ventilation 
allows the patient to breathe spontaneously via a tight fitting anaesthetic face mask with 
a pressure limiting valve connected to an oxygen source. The CPAP machine maintains 
the airway pressure constantly above atmospheric pressure and controls the oxygen 
concentration, temperature and humidity of the inspired gas.
1.6.3.1.2. Positive End Expiratory Pressure (PEEP)
CPAP is often used with PEEP. This is achieved by a pressure-limiting valve in the 
expiratory tubing, that prevents the pressure in the airways returning to atmospheric 
pressure. A positive pressure is thus created in the alveoli at the end of expiration and 
this prevents alveoli collapse.
1.6.3.1.3. Continuous Mandatory Ventilation (CMV)
With this mode of ventilation, the work of breathing is carried out by the artificial 
ventilator. This requires the patient to be paralysed to prevent spontaneous movement.
1.6.3.1.4. Intermittent Mandatory Ventilation (IMV)
IMV allows an intubated patient to breathe spontaneously between mandatory breaths 
delivered by the artificial ventilator at a pre-set rate. Modem IMV systems deliver 
machine breaths when the patient starts to inhale and this is termed “synchronised 
IMV” (SIMV). This mode of ventilation is often used to “wean” a patient off artificial 
ventilatory support. The number of breaths per minute delivered by the machine can 
gradually be reduced so that gradually the patient initiates more breaths himself. A
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disadvantage of IMV is that generation of a breath requires additional work by the 
patient in order to overcome the demand valve systems that provide the breath.
1.6.3.1.5. Assisted Ventilation
The assist mode of ventilation allows the patient to set the breathing pattern and the 
respiratory rate. Each machine breath is initiated by the patient, by lowering the airway 
pressure to open a unidirectional valve in the circuit. The lungs are then inflated to the 
desired volume.
1.6.3.1.6. Pressure Support Ventilation (PSV)
PSV can be used as an alternative method for weaning patients from artificial ventilation. 
It reduces the work done by patients to generate a breath, by supplying a constant 
positive pressure to the airways during inspiration. There are no pre-set tidal volumes 
and the cycles are flow limited and not pressure limited. The patient controls the 
respiratory rate, tidal volume and inspiratory and expiratory time.
1.6.3.1.7. Pressure Controlled Ventilation (PCV)
Unlike the previous modes of ventilation which are volume controlled, PCV involves the 
delivery of a pre-set maximum inspiratory pressure which is then maintained for a 
predetermined time. This mode allows slower, more resistive and less compliant areas 
of the lung to be gradually recruited and become available for gas exchange.
1.6.3.2. Monitoring of ICU Patients
Patients on an ICU require close monitoring of their organ systems because they have 
the potential of becoming unstable. Technological advancements have enabled a number 
of parameters to be continuously monitored at the same time. These include 
temperature, blood pressure, electrocardiography, arterial and venous oxygen saturation, 
cardiac output and end tidal C02.
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1.6.3.2.1. Temperature Measurements
It is possible to obtain three forms of body temperature on ICU using either traditional 
mercury glass thermometers or modern rapid response thermistors: core body 
temperature, peripheral body temperature and axillary body temperature. Measurement 
of the core body temperature is the standard in most ICU’s. It is often obtained using a 
thermistor probe placed in the rectum of the patient, although other methods such as 
thermistors in bladder catheters, pulmonary artery catheters and ear probes may also be 
used. Peripheral body temperature is obtained by placing a thermistor probe on the skin 
surface and axillary body temperature is obtained using a mercury thermometer placed 
under the patients' armpit. The measurements from the latter two methods are 0.5 to
1°C below core body temperature. Although the core body temperature is the ideal 
measurement, this is not always achieved under certain circumstances e.g. diarrhoea.
1.6.3.2.2. Blood Pressure
Blood pressure can be monitored using the cuff method but this method has many 
pitfalls and gives inaccurate results. The standard practice in ICU patients is to measure 
the arterial pressure directly via catheters placed into the radial or femoral arteries, linked 
to monitoring devices by pressure transducers. Measurement of the pulmonary artery 
pressure (PAP), pulmonary capillary wedge pressure (PCWP) and central venous 
pressure (CVP) have been made possible by the increased use of pulmonary artery 
flotation catheters for haemodynamic monitoring.
1.6.3.2.3. Electrocardiography (ECG)
The ECG is a graphical recording of the electrical potentials produced by cardiac tissue 
during contraction. It is obtained by placing electrodes at particular points on the body 
surface and connecting them to a chart recorder or monitor. The connections are such 
that an upright deflection indicates a positive potential and a downward deflection 
indicates a negative potential. Normally ICU patients have a continuous 5 lead ECG 
(leads I, II, III, V and ground lead). A more diagnostic ECG can be obtained from time
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to time, as and when needed, using a 12 lead setup (leads I, II, HI, VI, V2, V3, V4, V5, 
V6, aVR, aVL and aVF).
The ECG is used to detect atrial and ventricular hypertrophy, conduction delay of atrial 
and ventricular electrical impulses, myocardial ischaemia and infarction, dysrhythmias, 
pericarditis, systemic diseases that affect the heart, the effects of drugs, disturbances in 
electrolyte balance especially potassium and to evaluate the function of cardiac 
pacemakers.
1.6.3.2.4. Arterial Oxygen Saturation (%Sa02)
Pulse oximetry is the common indirect and non-invasive method used for monitoring 
%Sa02. The pulse oximeter is placed most commonly on a finger across which an 
infrared and red light are shone. A detector detects the transmitted light. The 
transmission of each wavelength is inversely proportional to the concentration of 
oxyhaemoglobin (Hb02) and reduced haemoglobin (RHb) in the blood. Oxygen 
saturation is calculated as follows: -
%Sa02 = Hb02 x 100
Hb02 + RHb
Arterial pulsations in the finger are caused by blood volume changes and these changes 
cause fluctuations in light transmission. The photodetector picks up these fluctuations 
thus distinguishing the reading from that produced from a vein (Tremper and Barker, 
1989).
1.6.3.2.5. Mixed Venous Oxygen Saturation (%Sv02)
%Sv02 reflects the ability of the body to provide adequate oxygen to meet the metabolic 
requirements of the tissues. Continuous %Sv02 is measured directly in vivo using a 
pulmonary artery flotation catheter. Light from haemoglobin in venous blood is
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reflected back to the catheter and along fibreoptics to a photodetector that measures the 
intensity of the reflected light beam (Putterman, 1989).
1.6.3.2.6. Cardiac Output
Cardiac output (CO) is one of a number of parameters that form a haemodynamic 
profile of a patient and helps to provide a comprehensive evaluation of the 
cardiovascular system. Values for CO are obtained using a pulmonary artery flotation 
catheter connected to a cardiac output computer. The catheter has a thermistor at the 
distal end, which detects a drop in temperature when a bolus of cold saline is injected 
into the pulmonary artery (thermodilution technique). This information is used by the 
computer to produce a temperature-time curve. The area under the curve is inversely 
related to the flow rate in the pulmonary artery and this is taken as the cardiac output 
(Low, 1990).
1.6.3.2.7. End Tidal C02
Carbon dioxide in exhaled gas can be used as a non-invasive measurement of the arterial 
PaC02. Throughout expiration the PC02 rises steadily until it reaches a plateau near 
the end of expiration. When lung function is normal the exhaled PC02 at the very end 
of expiration (End tidal C02), is equivalent to the PC02 in arterial blood. End tidal C02 
is measured by placing a light emitting diode in the exhalation path, which emits an 
infrared light beam across the exhaled gas. A photodetector measures the intensity of 
light transmitted (Snyder et al, 1982; Carlon et al, 1988).
1.6.3.3. Physiotherapy
Once patients are mechanically ventilated via intubation or tracheostomy, they are 
predisposed to pulmonary complications due to pathophysiological changes in lung 
function. These complications include: increased mucus production associated with 
decreased mucociliary clearance; contamination of the lower respiratory tract with upper 
respiratory tract organisms; ventilation-perfusion mismatch; increased deadspace
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ventilation due to increased alveolar pressure and / or pulmonary artery pressure; uneven 
distribution of ventilation due to the disease. Physiotherapy is employed in order to 
decrease the risk of alveolar collapse and pulmonary infection, maintain joint and soft 
tissue range, encourage mobilisation to reduce the side effects of long term bed rest, 
encourage active movements to promote normal musculoskeletal and neurological 
function and reduce the incidence of deep vein thrombosis. The techniques used 
include positioning and postural drainage, manual bagging, percussion and vibration, 
suctioning and patient mobilisation.
1.6.3.4. Haemodialysis
In ICU the main causes of acute renal failure are pre-renal failure and acute tubular 
necrosis. Continuous dialytic therapy is used to relieve many of the symptoms, signs 
and laboratory abnormalities by removing accumulated water, electrolytes and toxins 
from blood as it passes over a semipemieable dialysing membrane. Dialytic therapy 
may be in the form of peritoneal dialysis or haemodialysis. Haemodialysis, in the forms 
of continuous arteriovenous haemofiltration (CAVH) or continuous arteriovenous 
haemodiafiltration (CAVDH), is most commonly used to treat renal failure in ICU 
because many patients are hypercatabolic, have abdominal pathology or are 
cardiovascularly unstable. CAVH involves forcing water and solutes by convection 
from plasma through a semi permeable membrane. A low transmembrane pressure 
gradient is used and haemofiltration up to a rate of 20 ml / min are achieved. CAVHD 
is a modification of CAVH which adds the diffusion effect of dialysis to the convection 
effect of ultrafiltration to obtain an enhanced solute clearance (Hutchison, 1990).
1.6.3.5. Nutrition
Nutritional support is an important consideration in hospitalised patients as it has been 
shown to improve healing and reduce the number of days spent in hospital. It is 
particularly important in ICU patients who are often septic. Sepsis induces a
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hypermetabolic response, which gradually depletes the body's fat and protein stores. A 
progressive protein - calorie malnutrition increases the rate and risk of infection and 
impairs wound healing (Phillips, 1990).
Nutritional support may be administered enterally using the gastrointestinal tract or, 
when this is not appropriate, parenterally using the intravenous route. Of the two, the 
enteral route is preferable, as it is more physiological (Moore et al, 1992). It is also 
thought that enteral feeding prevents the gut atrophy that causes bacterial translocation 
into the systemic circulation and subsequent sepsis leading to multiorgan failure 
(Wilmore et al, 1988). In addition, enteral feeds may be supplemented with specific 
nutritional components such as glutamine, arginine and omega 3 fatty acids which are 
thought to help maintain gut integrity and boost the bodies own immune system 
(McClave et al, 1992).
1.6.3.6. Drug Therapy in the ICU
As a result of their severity of illness, ICU patients require a wide variety of drug 
treatments. These drugs include analgesics for pain relief, inotropes such as 
noradrenaline and adrenaline for treatment of circulatory failure, antihypertensives and 
vasodilators for high blood pressures, sedatives, hypnotics, antibiotics, antimicrobials 
and antifungal drugs for prevention and treatment of infection. A general summary of 
the drugs is shown in table 3 and a detailed description can be found in appendix 1. 
Patients can be on any number and combination of these drugs at one time.
In ICU, patients are often unconscious and so drug therapy is administered 
continuously either via the intravenous route, the rate of administration being controlled 
by syringe pumps or orally through tubes.
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SYSTEM ON 
WHICH DRUGS 
WORK?
CLASS OF DRUG EXAMPLES
Cardiovascular System Inotropes
Vasoconstrictors
Diuretics
Antihypertensives
Anticoagulants
Adrenaline, Dopamine 
Noradrenaline 
Frusemide, Bumetinide 
Enalapril, Glyceryl trinitrate 
Heparin, Epoprostenol
Central Nervous 
System
Hypnotics and Anxiolytics
Analgesics
Antiepileptics
Antidepressants
Anaesthesia
Diazepam, Temazepam 
Paracetamol, Morphine 
Phenytoin, Carbamazepine 
Amitriptyline 
Propofol
Respiratory System Bronchodilators Terbutaline sulphate, 
Ipratropium bromide
Nebulisers Sodium chromoglycate
Gastrointestinal System Ulcer Healing 
Motility Stimulants 
Laxatives
Ranitidine, Cimetidine 
Metoclopramide, Cisapride 
Senna
Endocrine System Diabetes Insulin
Infections Antibiotics
Antimicrobials
Antifungals
Gentamycin, Teicoplanin 
Metronidazole 
Amphotericin, Fluconazole
Immune Suppression Corticosteroid
Immunosuppressant
Prednisolone
Cyclosporin
Table 3. Examples of the range of drugs used in ICU to treat the critically ill.
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The development of sophisticated techniques to provide monitoring and physiological 
support of critically ill patients together with the vast sums of money spent on drugs, 
has made the ICU the most expensive resource in a modern hospital. Increasing 
demands have been made of clinicians by budget holders, hospital managers and 
governments not only to justify and account for the costs incurred, but also to optimise 
patient care.
Consequently, there has been an increased use of scoring systems to help predict patient 
outcome from ICU and as a means of clinical audit, to observe and assess clinical 
practices, identify shortcomings and change practice where necessary.
1.6.4.1. Acute Physiology and Chronic Health Evaluation II (APACHE II)
In 1981, Knaus developed the APACHE scoring system to predict outcome in ICU 
patients (Knaus, 1981). The scoring system assigned points to 34 physiological 
parameters, depending on how far from normal those parameters were, to give an Acute 
Physiology Score (APS). Age and chronic health are also assigned points. The scoring 
system proved to be cumbersome and unpopular in clinical practice and was therefore 
refined by reducing the number of physiological parameters to 12 and it was renamed 
APACHE II. Tables 4a and 4b show the physiological parameters, age and chronic 
health evaluation scores. The scoring system on the Glasgow Coma Scale (GCS) is 
shown in table 4c.
The APACHE II score is assessed on admission to ICU but it is the worst score in 24 
hours that is generally taken as the standard APACHE II score. In the ICU setting the 
scoring is not always straightforward. Patients who are sedated and ventilated have a 
GCS of 15 since neurological problems are unlikely to exist. For patients with acute 
renal failure, the creatinine score is doubled as patients in ICU with acute renal failure
1.6.4. Outcome Prediction Scoring in ICU
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have a higher mortality. The maximum possible APACHE score is 71, but patients are 
more likely to have scores much lower than this. Increasing scores generally correlate 
with a higher mortality, but this is very dependent on the disease category, as some 
patients who initially have high APACHE II scores e.g. post operative coronary artery 
bypass patients, do not result in a high death rate.
1.6.5. Physiological Problems Associated with the ICU
1.6.5.1. Disturbed Sleep
In normal healthy individuals, sleep is believed to be important for its restorative 
properties for both the body and the brain. Sleep is associated with a period of 
increased protein synthesis and cell division for renewal of tissues such as the skin, 
bone marrow, gastric mucosa, bone and brain (Adam and Oswald, 1984). The quality of 
this sleep is more important than the quantity, the most important stages being rapid eye 
movement (REM) sleep, which is when dreaming occurs and slow wave sleep (SWS), 
the deepest form of sleep when breathing and pulse rates are slow and temperature and 
blood pressure are decreased.
It follows therefore that in the critically ill, sleep must be of utmost importance. 
However a study investigating the events most commonly remembered by patients cared 
for on ICU revealed that sleep disturbance was the most common problem recalled. 
Polygraphic monitoring of sleep by Hilton showed that sleep time is greatly reduced in 
ICU patients, sometimes to as little as 6 minutes in 24 hours in one patient (Hilton,
1976).
Many patients attribute sleep disturbance to pain but other factors also play a role. 
Noise from equipment and personnel contribute to sleep disturbances (Redding et al,
1977). Ward rounds, physiotherapy, X - ray, medical and nursing procedures also 
contribute to the sleep disturbance. Studies on small groups of patients by Walker and
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Woods have shown that ICU patients are disturbed at least once and as many as 14 
times per hour (Walker, 1972; Woods, 1972).
1.6.5.2. ITU Psychosis / Post Traumatic Stress Disorder
A number of studies have shown that the incidence of psychological disturbances 
amongst patients treated on ICU is high, giving rise to the phenomenon previously 
known as “intensive care delirium” or “ICU Psychosis” characterised by impaired 
orientation, memory, intellectual function and judgement (Jones et al, 1994; Campbell et 
al, 1986). It is now believed to be a form of post traumatic stress disorder, the 
symptoms of which include recurrent nightmares, hallucinations, sleep deprivation, 
depression and anxiety (Lloyd, 1993). The various forms of psychiatric disturbance 
seen in ICU patients were categorised into the following four groups by Komfeld in 
1969: a) psychiatric reactions that accompany serious medical - surgical illness, notably 
delirium; b) psychiatric reactions produced by the ICU environment; c) psychiatric 
reactions that manifest themselves after discharge from ICU but related to their stay on 
ICU; and d) the emotional reactions of ICU staff (Komfeld, 1972). The ICU 
environment is believed to be an important factor contributing to the development of 
psychosis.
In 1972 Wilson investigated the incidence of delirium postoperatively in 50 patients 
treated for at least 72 hours in a windowless ICU and compared this to the incidence on 
an ICU with windows and found it to be twice as high in the absence of windows 
(Wilson, 1972). This implied that lack of contact with the environment might indeed 
contribute to the development of delirium. A further study by Keep et al, showed that 
patients treated in windowless ICU’s had poorer memories of their stay, a greater sense 
of disorientation as to the passage of time, a greater incidence of sleep and visual 
disturbances and a greater incidence of hallucinations (Keep et al, 1980). Natural light 
and windows are therefore important consideration for ICU patients.
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Added to this, the ICU environment is noisy due to life support equipment, alarms and 
staff talking, all of which contribute to sleep deprivation. Experiments on normal 
healthy subjects have shown that lack of sleep affects mood. Sleep deprived individuals 
become increasingly angry, irritable and anti-social, and depression can be seen even 
after 24 - 48 hours (Finlay, 1991). If sleep is interrupted frequently, ICU patients reach 
the non - REM sleep stages I and II but they rarely reach the beneficial SWS and REM 
sleep stages. Sleep deprivation studies by Williams et al showed that loss of SWS 
leads to individuals feeling withdrawn and physically uncomfortable whilst loss of REM 
sleep leads to feelings of confusion and suspicion (Williams et al, 1967).
There therefore could be a strong link between sleep deprivation due to noise and ICU 
psychosis.
1.6.4.3. Critical Illness Polyneuropathy
“A rapid loss of flesh” as a complication of severe sepsis (a severe systemic response 
to infection) was first observed by Sir William Osier in 1892. Between 1977 and 1981, 
a Canadian group lead by Bolton, observed that ICU patients with no previous 
neurological disease developed a polyneuropathy as a complication of sepsis and 
multiorgan failure, which they called ‘critical illness polyneuropathy” (CIP). In many 
cases this is often preceded by the development of septic encephalopathy. This 
phenomenon has since been recognised as a common occurrence in ICUs, with an 
incidence of approximately 70% of septic patients.
CIP can be difficult to detect clinically, and therefore electrophysiological studies have 
been deemed vital for accurate diagnosis. CIP is characterised by widespread axonal 
degeneration and denervation of the diaphragm and intercostal muscles. CIP therefore 
most commonly presents as a failure of the patient to wean from artificial ventilation, 
resulting in extended ventilator dependence.
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The precise cause of the polyneuropathy is still unknown. Possible contributing factors 
include toxins, drugs and nutritional deficiency. Bolton’s group believe that the 
systemic inflammatory response syndrome plays an important role in its development, 
by activating cellular (lymphocytes, monocytes and neutrophils) and humoral 
(interleukin 1,2 and 6, tumour necrosis factor, coagulation factors, oxygen free radicals 
and proteases) responses, that interact with each other and adhesion molecules. 
“Rolling neutrophils” and fibrin platelet aggregates result and cause obstruction of the 
capillary flow, whilst capillaries become permeable causing local tissue oedema.
Neuromuscular blocking drugs such as pancuronium bromide and vecuronium have 
been reported to induce a reversible axonal motor neuropathy by some groups and when 
used with corticosteroids, have triggered an acute necrotising myopathy. These 
therefore may have a role in the development of CIP. It has also been proposed that 
lack of sleep compounds the problem.
1.7. Research aims of the thesis
The primary hypothesis of this study was that circadian rhythms in critically ill patients, 
treated in an Intensive Care Unit for several days, become desynchronised from a 
normal 24 hour rhythm, due to isolation from external time cues such as the light-dark 
cycle and sleep deprivation. Such desynchronisation could then contribute to the 
development of disorders such as 'ICU psychosis' or cause slow weaning from 
mechanical ventilation as a result of polyneuropathy.
The study aimed to use plasma melatonin, urinary 6-sulphatoxymelatonin and core body 
temperature as the main markers of the endogenous rhythm of the ICU subjects studied. 
The circadian rhythms of TSH, cortisol and prolactin were also investigated for evidence 
of desynchronisation.
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The secondary aims of the study were to identify and quantify some factors in ICU that 
may influence desynchronisation of circadian rhythms, such as: -
a. Light Intensity of the ICU environment
b. Renal Function of ICU patients
The tertiary aim is to identify whether circadian rhythm desynchronisation is related to 
the severity of illness of ICU patients using APACHE II scores as indices of the 
severity of illness.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Study Location
2.1.1. Control Subjects
Studies on healthy control volunteers were carried out in the Clinical Investigation Unit 
(CIU) at the University of Surrey, in March, April and June of 1997. The unit had 6 
beds, all of which had access to artificial and natural lighting. The level of natural 
lighting could be controlled. Lights were switched on during the day between 08:00h and 
22:00h and switched off between 22:00h and 08:00h. Blinds were also left open during 
the day between 08:00h and 22:00h and closed between 22:00h and 08:00h. The 
temperature could also be controlled. A plan of the unit is shown in figure 11.
2.1.2. ICU Patients
All the patients recruited were studied in the ICU at the Royal Free Hospital, Hampstead, 
London. A plan of the unit is shown in figure 12. The ICU had 10 bed areas consisting 
of 4 side rooms (bed areas 1,2,3 and 8) for the care of patients requiring isolation and 6 
open bed areas (bed areas 4,5,6,7,9 and 10) separated by nurse work stations. Eight of 
the bed areas (bed areas 1 to 8) had access to natural daylight via windows. Bed areas 9 
and 10 were some distance from the windows and were predominantly lit by artificial 
fluorescent cool white lighting of irradiance 240pwatts/cm2/foot candle. (Osram Limited,
Wembley, England).
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\Figure 11. Plan of the Clinical Investigation Unit at the University of Surrey.
El Bathroom, H  Beds, H  Workstation, W alls,\ Doors, 
□  Windows, Blinds.
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Following ethical approval from the University of Surrey’s Advisory Committee on 
Ethics, 14 healthy volunteers (friends, relatives, University students and staff) were 
recruited (7M : 7F, aged 17 - 61). All subjects gave written informed consent to 
participate in the study and were screened for drugs of abuse, abnormal biochemistry and 
abnormal haematology. Individuals who had recently undertaken transmeridian travel in 
the previous month or who had abnormal sleeping patterns were excluded from the study. 
Subject details are summarised in Table 5. The presence of normal circadian rhythmicity 
was determined before the study day by measuring urinary 6-sulphatoxymelatonin 
(aMT6s) in 5 timed urine collections over 24 hours and calculating the rhythm 
characteristics using a computerised cosinor programme (written by Dr DS Minors, 
University of Manchester, UK). None of the subjects were taking any form of medication 
other than the contraceptive pill. One subject was a smoker. All subjects abstained from 
alcoholic beverages for 24 hours before the study and during the study. During the study, 
control subjects were allowed to sit or lie down on their beds and only left their beds to 
empty their bladders on the hour. Subjects were not allowed to sleep or nap during the 
day (08:00h to 22:00h). Sleep was permitted between 22:00h and 07:00h but subjects 
were woken up during this period for sample collection. All study subjects were given 
the same breakfast, lunch and supper at the same times on the study days (08:00h, 12:30h 
and 18:00h). These times corresponded to the meal times in the Royal Free Hospital ICU.
2.2.2. ICU Patients
Following ethical approval from the Royal Free Hospital Ethics Committee, 32 ICU
patients (23M: 9F) aged 17 to 81 were recruited following verbal informed consent by
themselves or written informed consent by a relative. Details of these patients, including
the day after their ICU admission on which samples were collected, their admission acute
physiology and chronic health evaluation (APACHE) scores, are summarised in tables 6a
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2.2 Study Subjects
2.2.1 Control Subj ects
Cl 28 F
C2 21 F
C3 21 F
C4 17 M
C5 31 M
C6 17 F
C l 47 F
C8 27 F
C9 30 M
CIO 50 F
Cll 43 F
C12 61 M
C13 25 M
C14 35 M
SUBJECT AGE SEX
Table 5. Details of the Healthy Control Group
ADDITIONAL
DETAILS
Smoker
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to 6d. A list of drugs, which were prescribed for the patients on the days of study, are 
shown in tables 7a to 7d. Patients who were unstable, treated with adrenaline or 
noradrenaline, or with renal failure and on haemodiafiltration, were excluded from the 
study.
2.3. Physiological Measurements
2.3.1. Core Body Temperature
Hourly rectal core body temperature was measured continuously in both healthy 
volunteers and ICU patients using disposable rectal probes (French size 9, total length 
50cm) provided by Mallinckrodt UK, (Northampton, UK), inserted 10cm beyond the 
rectal sphincter. These were connected to either Marquette Tram monitors GE Marquette 
Medical Systems, Milwaukee, Wisconsin, USA or Mallinckrodt monitors (Mallinckrodt 
UK, Northampton,UK.) in ICU and to Mallinckrodt monitors in the University of Surrey 
CIU.
2.4. Environmental Measurements
2.4.1. Light Intensity
Hourly average light intensity readings were measured using a standard light meter 
(Macam Photometries Ltd, Livingstone, Scotland) measuring light intensity in lux. To 
obtain the average light intensity reading, readings were taken in four directions (up, 
down, left, right) at the eye-level of the subject.
2.5 Sample Collection
2.5.1. Urine samples
One hour before the start of the study, the control subjects were instructed to empty their 
bladders and discard all urine produced. They then emptied their bladders and collected
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their urine every hour over the next 24 hours. Each control subject measured the volume 
of urine produced each hour using a measuring cylinder read at eye-level, and poured a 
5ml aliquot into a pre-labelled polypropylene vial, which was immediately frozen at - 
20°c until analysis. To promote urine production, all subjects drank at least 250 mis of 
water per hour over the 24-hour period.
All ICU patients in the study had urinary catheters in situ, which emptied into urinary 
catheter bags. An hour before the start of each study, the urinary catheter bags were 
emptied. Urinary catheter bags were then emptied every hour and the volume measured. 
A 5ml aliquot of the hourly collection was poured into a pre-labelled polypropylene vial, 
which was immediately frozen at -20°c until analysis.
2.5.2. Plasma Samples
5ml blood samples were taken from venous cannulae, (control subjects) or arterial lines 
(ICU patients) at hourly intervals into lithium heparin vacutainers. The venous cannulae 
and arterial lines were kept patent using heparinised saline. Samples were centrifuged at 
2500 rpm for 10 minutes within 5 minutes of collection and the plasma separated off into 
labelled polypropylene vials, which were frozen immediately at -20°c until analysis. 
Night time blood samples were all obtained under dim lighting conditions of <10 lux for 
control subjects and wherever possible for ICU patients. In most cases on ICU the night 
time light was < 10 lux for the entire night. Night time light intensity exceeded this on 15 
out of a total of 40 sets of light intensity readings.
2.5.3. Saliva samples
At hourly intervals over 24 hours control subjects produced 3 to 4 mis of saliva, which 
was placed in polypropylene vials. To aid saliva production, subjects chewed a piece of
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Parafilm. Subjects were instructed not to eat anything 15 minutes before they were to 
produce a saliva sample and to rinse their mouths thoroughly with plain water to prevent 
contamination of samples. Samples were frozen at -20°c until analysis. The smoker in 
the control group did not donate saliva samples.
2.6 Assay Methodology
2.6.1 Urinary 6 - sulphatoxymelatonin (aMT6s) assay
Urinary aMT6s was determined using a modified version of the radioimmunoassay 
method described by Aldhous and Arendt (1988), which takes one day to perform. Urine 
and control samples were diluted 1:250 in 0.1M Tricine buffer (pH 5.5) and incubated for 
15 minutes with a specific antiserum to aMT6s raised in a sheep and then trace amounts
125of I-aMT6s are added. Following a further two hour incubation, the free and antibody 
- bound fractions of aMT6s were separated using a dextran-coated charcoal suspension. 
The free aMT6s fraction was precipitated with the charcoal by centrifugation and the 
radioactivity counted on a gamma counter. A standard curve was constructed 
simultaneously by diluting the standard in charcoal-stripped human urine. The antiserum 
(HP/S/1118 23884), standards and controls were provided by Stockgrand Ltd (University 
of Surrey, Guildford, Surrey, UK). Tricine and activated charcoal were obtained from 
Sigma-Aldrich Co. Ltd, Poole, Dorset, UK. The interassay coefficients of variation were 
15.3%, 14.4% and 18.4% at 3.4, 19.9 and 41.5 ng/ml (n = 37). The minimum detection 
limit (defined as the concentration at 2SD from the mean at maximum bound counts) was 
0.13 ng/ml.
2.6.2 Plasma Melatonin Assay
Plasma melatonin concentrations were determined using the direct radioimmunoassay 
method of Fraser et al. 1983. Plasma and control samples were incubated for 30 minutes
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with a specific antiserum (G/S/704-8483) to melatonin raised in sheep and provided by 
Stockgrand Ltd (University of Surrey, Guildford, Surrey, UK). Trace amounts of tritiated 
melatonin (Amersham Life Science Ltd, Little Chalfont, Buckinghamshire, UK) were 
added. Following an 18-hour overnight incubation, the free and bound fractions of 
melatonin were separated using a dextran coated charcoal suspension. Centrifugation 
precipitated the free melatonin with the charcoal. The supernatant was added to a toluene 
based scintillation fluid containing 2,5-diphenyloxazole (PPO) and dimethyl-POPOP. 
The radioactivity of the antibody-bound fraction in the supernatant was counted using a 
scintillation counter. Tricine and activated charcoal were obtained from Sigma Ltd. PPO 
and POPOP were obtained from Fisons, Crawley, East Sussex, UK. The interassay 
coefficients of variation were 13.1%, 6.3% and 8.6% at 10.6, 40.3 and 142.9 pg/ml (n = 
6). The minimum detection limit was 5pg/ml.
2.6.3. Salivary Melatonin Assay
Salivary melatonin concentrations were determined using a direct radioimmunoassay 
method (Fraser et al, 1983). Saliva and control samples were incubated for 30 minutes 
with a specific antiserum (GHS-100491) to melatonin conjugated to thyroglobulin by a 
short carbon chain at the 2 position. The antiserum had been raised in sheep and was 
provided by Stockgrand Ltd (University of Surrey, Guildford, Surrey, UK). Trace 
amounts of iodinated melatonin were added. Following an 18-hour overnight incubation 
at 4°c, the free and bound fractions of melatonin were separated using a solid phase 
second antibody raised against sheep and goat. Following a Brij-saline wash and 
centrifugation, the radioactivity of the antibody-bound fraction was counted using a 
gamma counter. The antisera, standards and controls were provided by Stockgrand Ltd.
125I-melatonin was obtained from Amersham Life Science Ltd, Little Chalfont, 
Buckinghamshire, UK. The interassay coefficients of variation were 16.0%, 10.9%,
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16.4% and 26.1% at 14.1, 26.2, 65.0 and 154.1pg/ml (n = 8). The minimum detection 
limit was 12 pg/ml.
2.6.4. Plasma Cortisol Assay
Plasma cortisol was measured using a radioimmunoassay adapted from Read et al, Seth et 
al and Riad-Fahmy et al (Read et al, 1977; Seth et al,1978; Riad-Fahmy et al, 1979). 
Plasma and control samples were diluted 1:3 in citrate/phosphate buffer and incubated at 
4°c for 2 hours with a specific antiserum raised in sheep and trace amounts of 125I- 
cortisol. The free and antibody-bound fractions of cortisol were separated using a solid 
phase linked second antibody (cellulose linked donkey anti-sheep IgG). The antibody- 
bound fraction was precipitated by centrifugation and the radioactivity in this fraction 
counted with a gamma counter. The antiserum (S004-201) at an initial dilution of 
1:8000, was obtained from Scottish Antiserum Production Unit, Lanarkshire, Scotland, 
UK. Radiolabel was purchased from Amersham Life Science Ltd, Little Chalfont, 
Buckinghamshire, UK, the initial standard solution was from Sigma-Aldrich Co. Ltd, 
Poole, Dorset, UK, and the solid phase separation system was supplied by Stockgrand 
Ltd, University of Surrey, Guildford, Surrey, UK. The interassay coefficients of variation 
were 17.1%, 20.3% and 11.6% at 47.2, 664 8 and 1019 nmol/1 (n = 7). The minimum 
detection limit was 1.0 nmol/1
2.6.5. Plasma TSH and Prolactin Assays
Plasma TSH and Prolactin concentrations were measured using the Enzymun-Test® 
System on the ES 300 AL instrument (Roche Diagnostics Boehringer Mannheim GmbH, 
Mannheim, Germany) at St Peters Hospital. Chertsey, Surrey. The test was an automated 
ELISA one-step sandwich assay. Plasma samples and controls were incubated in 
streptavidin-coated test tubes with an incubation solution for 30 minutes at 25°c. (In the
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TSH assay, the incubation solution consisted of 80 mmol/1 phosphate buffer pH 7.4, 
biotinylated antibodies and a monoclonal (mouse) anti-TSH antibody - POD conjugate. 
In the prolactin assay, it contained a mixture of 40 mmol/1 phosphate buffer pH 7.4, 
biotinylated anti-prolactin mouse monoclonal antibodies and POD-labelled antibodies). 
After incubation, assay tubes were washed with an Enymun-Test® washing solution to 
remove unbound incubation solution. A substrate-chromogen solution made up of 
ABTS® and phosphate/citrate buffered hydrogen peroxide was then added to cause a 
colour change. Samples were incubated with the chromogen solution for a further 30 
minutes at 25°c. The absorbance of the solution was measured at 25°c at wavelength 
422nm in both assays. All reagents were purchased from Roche Diagnostics, Lewes, 
East Sussex, UK. The interassay coefficients of variation for the TSH assay were 2.7%, 
5.9% and 7.3% at 3.1, 10.9 and 39.9 |LlU/ml (n = 6). The minimum detection limit was
0.05 jxU/ml. The interassay coefficients of variation for the prolactin assay were 15.3%, 
9.3% and 5.8% at 225.0, 473.8 and 1582 jllU/ml (n = 6). The minimum detection limit 
was 21 plU/ml.
2.6.6. Urinary Creatinine Assay
Urinary creatinine concentration was determined using a buffered kinetic Jaffe reaction 
without deproteinisation on the Cobas Integra analyser Roche Diagnostics, Lewes, East 
Sussex, UK. In this method, creatinine in the urine samples and control samples was 
reacted with picric acid and an alkaline solution (potassium hydroxide) to form a yellow- 
red coloured complex. The rate of dye formation was directly proportional to the 
creatinine concentration and was determined by measuring the increase of absorbance at 
512nm. All reagents were provided by Roche Diagnostics. The %CV for the assay was 
0.33% at 21.9mmol/l. The minimum detection limit was 0.04mmol /l.
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2.7.1. Cosinor Analysis
Cosinor analysis is a mathematical model that allows us to describe the various features 
of a circadian rhythm, such as the mean or mesor value (M), rhythm amplitude (A) and 
peak time or acrophase (<})), as illustrated below.
2.7. Data analysis
Figure 13. Diagram to illustrate the features of a circadian rhythm
The most widely used model is the procedure devised by Nelson et al, is one in which the 
time series of data is represented by the 'best fit' to a cosine curve using the method of 
least squares for which the equation is:
Yj = M + A cos (cotj + (])) +ej (Nelson et al, 1979)
where
Yj = a value of a point in the data series 
tj = the time when the point was measured 
M = mesor or mean of the cosine curve 
A = amplitude of the curve
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(j) = acrophase time or phase angle of the maximum value or peak of the 
curve
e; = residual error of the point, assumed to have a mean value of zero
(Redfem et al, 1991)
Cosinor analysis derives a p-value or significant fit, so that p<0.05 means that there is 
<5% chance that the data can fit a straight line as well as a cosine curve. This is derived 
from the variance of the data about the fitted cosine curve and the variance of the fitted 
curve about the mesor. The power of cosinor analysis is that it can be used even when 
sampling is irregular as occurs for urine sampling. However it has the drawback that it 
assumes that the rhythm is sinusoidal in shape. Therefore rhythms such as that of CBT, 
which approximate a cosine curve, will get a good fit, but rhythms such as that of the 
sleep-wake cycle, which assumes a square wave will not give a good fit.
Cosinor analysis was used to determine the significance of fit to a cosine curve for the 
rhythms of core body temperature, plasma melatonin, urinary aMT6s excretion rate, 
salivary melatonin, plasma cortisol, plasma TSH, plasma prolactin, urine creatinine and 
urine volume in healthy volunteers and ICU patients, where studied. The programme 
used to determine the cosinor parameters was developed by Dr DS Minors, University of 
Manchester, Manchester, UK.
2.7.2. Students t tests
For small numbers of subjects or small ‘samples’, the difference in means between two 
groups was determined using two sample unpaired t-tests. This method takes the 
standard error of the sample mean into account and allows the difference between means
(0 = angular frequency of the curve
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or t value to be calculated. Excel 98 was used to determine the t value (Microsoft, 
Seattle, USA).
2.7.3. Repeated measures ANOVA
Repeated measures ANOVA allows us to determine significant differences in group data, 
when subjects are measured at a number of time points. It is a method of analysis that 
allows us to determine whether there are changes in patterns of data over time or to 
compare patterns of change over time across groups. It can be used therefore to see 
whether for example light intensity changes in a room over time over consecutive days 
and can be used to see if the light intensity is different in rooms with windows compared 
to those without windows.
Repeated measures ANOVA statistical analyses were carried out using the 
SuperANOVA computer programme (Abacus Concepts Inc, Berkeley, California, USA).
2.7.4. Duncan’s New Multiple Range Post Hoc Test
The Duncan’s new multiple range test is a multiple comparison procedure or post hoc test 
that used to determine which means differed from which, when repeated measures 
ANOVA finds a statistically significant difference between the means of groups. The 
Duncan’s new multiple range test used was part of the SuperANOVA computer 
programme (Abacus Concepts Inc, Berkeley, California, USA).
2.7.5. Correlation and Linear Regression Analysis
Correlation determines the strength of an association between two variables and involves 
calculation of the correlation coefficient (r). Regression is also used to determine the 
method the relationship between two variables, so that we can determine whether one
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variable can be used to predict another, for which a regression line is constructed on a 
scatter diagram, using the least squares estimate. Correlation and regression analyses 
were carried out using Excel 98 (Microsoft, Seattle, USA)
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CHAPTER 3 LIGHT IN AN INTENSIVE CARE UNIT
3.1. Introduction
The ICU environment, with its high noise levels, constant lighting and frequent 
interruptions of the patients' rest periods for therapeutic procedures, has been 
implicated in many studies as the cause of sleep disturbance. It is thought that this 
leads to deterioration in respiratory function and psychological disturbances, both of 
which are common occurrences in ICU patients (Campbell et al, 1986; Lloyd, 1993). 
Lack of awareness of the environment could complicate matters further, as any 
patients who phase-shift or free run (due to isolation from the light - dark cycle) could 
be wide awake in the middle of the night when nursing staff assume that they are 
asleep. Before carrying out studies on possible abnormalities of circadian rhythms in 
ICU patients, it is necessary to measure the light intensity in an ICU.
A previous study investigated the environmental conditions in the respiratory 
(treating respiratory disease) and medical (treating all diseases) ICU settings and 
found that a normal circadian day-night rhythm was maintained, with peak light 
levels occurring during the daytime. However, the absolute level and timing of the 
peak was dependent on the degree of shading in the room and the position of 
windows (Meyer et al, 1994). The readings were taken at one bed area in each 
hospital setting and over seven days at one time of the year. As a result, variations in 
light intensity within each hospital setting and as a consequence of seasonal change 
were not investigated. These may prove to be of importance when assessing circadian 
status and any related disturbances.
161
For the purposes of this study, light intensity at each bed area in the ICU was 
measured at four times of the year, to test the prediction that light intensity varies 
within an ICU, with those areas without windows having the lowest light intensity 
and being less prone to seasonal variations.
3.2. Materials and Methods
3.2.1. Plan of the Royal Free ICU
Figure 14 is a plan of the ICU indicating the position of the beds and the position of 
the fluorescent strip lighting in the unit. The fluorescent strip lights were cool white 
lights manufactured by Osram as described in chapter 2 (irradiance 
240pwatts/cm2/foot candle).
3.2.2 Measurement of Light Intensity
The light intensity measurements were carried out between 1994 and 1995 at four 
times of the year, in duplicate; around December 21st (longest night), March 21st 
(vernal equinox) and June 21st (longest day) and September 21st (autumnal equinox) 
and a week later in each case. The readings were taken on the hour, every hour, over 
a period of 25 h (08:00h to 08:00h) at each of the ten bed areas in four different 
directions just above the level of the patients’ eyes, using a standard light meter as 
described in 2.4.1.
No attempt was made to influence the normal daily activity of opening or closing 
blinds and switching lights on or off by the nursing and medical staff. Light intensity 
levels representing the same time points for duplicate days studied (n=8), were
162
Figure 14. Plan of the Royal Free Hospital ICU showing the position of the artificial strip 
lighting relative to the position of the beds. HI Beds, Artificial strip 
lights. Beds 4,5,6,and 7 are situated directly under the lights.
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averaged, so as to give an indication of the typical light levels to which the patients 
are exposed. Average light intensity levels from bed areas with windows facing the 
same direction (east facing or south facing) or without windows were averaged to 
give the variation associated with window orientation.
3.3 Results
3.3.1. Individual Bed Areas
Figures 15 to 24 show the variation in average light intensity readings for each bed 
area (beds 1 to 10) at four times of the year (March, June, September and December).
The figures show that in the Royal Free Hospital ICU there is a clear light-dark cycle 
with the dark period ( dark occurring between the hours of 23:00h and 06:00h +/- 1 
hour at each bed area. The dark period tended to be maintained but exceptions did 
occur in September for beds 2 and 3 (figures 16 and 17). Here, the lights were 
switched on during the night for medical procedures to be carried out.
A mean light intensity level of 200 lux in the ICU during the subjective day was 
arbitrarily chosen as the level below which light intensity could not constitute adequate 
daytime levels for ICU patients. Table 8a shows the overall mean of the light intensity 
readings at each bed area. In all but one case (bed 8 in June), the mean light intensity 
was considerably less than 200 lux. Table 8b shows the percentage of total light intensity 
readings that were less than 200 lux between the hours of 08:00h and 20:00h (subjective 
day). In December, light intensity was less than 200 lux all day at six of the ten bed 
areas, all of which were rooms with windows. Bed 5 also seemed to be the room where 
light intensity was low throughout the year as readings of less than 200 lux were recorded 
at thiee times of the year. The table also indicates that there is some improvement in
164
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a)
h lE D N U M B E R M E A N  L IG H T  IN T E N S IT Y  IN  L U X  ± (S E M )
December March June September
1 92 (32) 83 (15) 79 (10) 153 (44)
2 98 (16) 84 (27) 111(16) 253 (58)
3 14(2) 138 (64) 36(4) 112(10)
4 42 (8) 85 (20) 112(19) 96 (22)
5 32(6) 43(7) 134 (21) 50(10)
6 32(6) 68 (13) . 188(38) 122 (45)
7 27(5) 61(15) 201 (40) 253(112)
8 40 (10) 112 (26) 624 (241) 132(55)
9 58 (19) 178 (32) ' 213 (42) 252 (40)
10 97 (16) 166 (30) 88 (20) 143 (21)
b)
[B E D  N U M B E R %  L IG H T  INTENSITY {  R E A D IN G S  < 2 0 0  lu x
December March June September
l 85 92 100 54
2 69 85 85 23
3 100 77 100 77
4 100 77 69 69
5 100 100 54 100
6 100 92 31 77
7 100 92 38 62
8 100 69 8 77
9 62 23 8 0
10 77 23 77 31 !
T ab le  8. T ab les to  sh o w  th e  d iffe ren ce  in  a) m ean  ligh t in tensity  ± S E M  at each  b e d  area  an d
b) p e rcen tag e  o f  average  lig h t in ten sity  read ings less th an  200  lu x  fo r each  bed  area, 
in  M arch , June , S ep te m b er an d  D ecem b er be tw een  0 8 :00h  and  20 :00h
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light intensity in the summer months (June and September) as fewer readings o f  less than 
200 lux were taken during the subjective day. This is probably due to higher light 
intensity and longer days in the summer and hence longer periods o f  natural light 
exposure. Bed areas 9 and 10, with no windows, showed fewer low readings compared 
to the other bed areas. This was because the artificial lights were either switched on or 
o ff giving either the maximum illumination possible or no illumination at all. When 
lights were switched on at beds 9 and 10, light intensity was therefore high. There was a 
substantial variation at each bed area. For example, the lighting was o f  low intensity 
(<2001ux) for 62% o f  the day in December and 0% o f  the day in September for bed 9. 
However at bed 10, the light intensity ranged from 77% o f  the day in December to 23% 
o f  the day in March then back up to 77% o f  the day again in June. Figures 15 to 24 show  
that bed areas 1, 2, 3, 6, 7, and 8 were all exposed to bright light pulses early in the 
morning, with the brightest peak o f  5,875 lux recorded at bed 8. These bed areas had 
access to natural light by windows. Such high peaks were not seen at bed areas 9 and 10, 
which had no windows.
The figures also show that there are differences in the daily distribution o f  light intensity 
at beds with windows compared to those without. At bed areas with windows the 
changes in light intensity were gradual throughout the day except for the early morning 
light peaks. This gradual change was not observed at beds 9 and 10 where lights were 
either on or o ff  producing shaip changes in light intensity throughout the day.
Repeated measures ANOVA using all four months o f  data for each bed area, showed that 
light intensity varied with time, as expected (p < 0.0001), but there was no significant 
overall difference in the average light intensity between bed areas (p < 0.5). However, 
analysis o f  the light intensity at the bed areas by two-factor ANOVA, showed a highly
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significant difference in average light intensity between the bed areas, when each month 
was analysed individually - March (p <  0.0004), June (p <  0.0001), September (p < 
0.004) and December (p < 0.0001).
Repeated measures ANOVA was used to test whether or not light intensity in the ICU 
varied with month. Statistical analysis showed a significant difference in average light 
intensity between the months (p < 0.02) which also varied with time (p < 0.007). 
Duncan’s post hoc test showed that the significant differences in light intensity were 
between December and June (p < 0.05) and December and September (p < 0.05).
3.3.2. Grouped Bed Areas
The bed areas were grouped into those that had windows (n =  8) and those that did not 
have windows (n = 2). Repeated measures ANOVA showed that there was no significant 
difference in the light intensity between those beds with or without windows (p < 0.1).
The bed areas with windows were separated into two further groups based on the 
orientation o f  the windows, east facing or south facing (Figures 25 to 28). No bed area 
had windows that were both south and east facing. The figures illustrate again that the 
bed areas with windows are prone to early morning peaks in average light intensity. 
When light intensity at beds with east facing or south facing windows were compared to 
beds with no windows in each month, Duncan’s post hoc test showed a statistically 
significant difference in light intensity in March (p < 0.05) between rooms with east 
facing windows and rooms with no windows. No significant differences in light intensity 
were found between east facing, south facing and windowless bed areas in any other 
month.
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The results show that the Royal Free Hospital ICU does maintain circadian variations in 
the light-dark cycle, with the dark period occurring between 23:00h and 06:00h +/- 1 
hour. The light - dark cycle was manipulated by the nursing staff, who switched the lights 
o ff between 22:00h and 23:00h and on between 06:00h and 07:00h. The light-dark cycle 
was also subject to seasonal variations between the winter months and summer months. 
The length o f  the dark period therefore was dependent upon both the timing o f  lights on 
and o ff by the nurses and the season.
Although staff attempted to maintain a near normal light-dark cycle, this was not always 
possible, as illustrated by the lights being switched on during the night in two instances to 
deal with medical emergencies. Although this was picked up on just two occasions here, 
it is highly likely that this is a frequent occurrence when unstable or very sick patients are 
on the unit. From the point o f  view  o f  the patients’ circadian rhythms, the switching on 
o f  lights at night is an important aspect to bear in mind, especially i f  the artificial lights 
are directly over the head o f  patients as would be the case for beds 2, 4, 5, 6, 7, 8 and 10. 
Studies on healthy individuals have shown clearly that bright light in the early night can 
cause phase delays whilst light in the late night induces phase advances (Minors et al, 
1991) and so circadian rhythms o f  ICU patients may be influenced in a similar manner. 
For this study, four light intensity readings in four directions were taken at the patient’s 
eye level to obtain the average light intensity readings reported. However readings taken 
at patient eye level with the light meter directly facing the overhead lighting, gave light 
intensity readings o f  700 lux, which is much higher than the average light intensities. 
Patients lying flat on their backs would be exposed to this intensity o f  light, which is 
sufficient to shift circadian rhythms (Czeisler et al, 1986). The early morning bright light
3.4 Discussion
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pulses from sunshine through the windows are also an important aspect to consider in bed 
areas with windows, as such pulses could both suppress plasma melatonin levels and 
significantly phase shift circadian rhythms, i f  appropriately timed with respect to 
circadian phase.
The results also showed that in spite o f  there being a light-dark cycle, the intensity o f  the 
light is often very low during the subjective day. This was more obvious in December 
compared to March, June and September, but light intensity was still low during the day 
in these months at bed areas with windows. A  common practice amongst the nursing 
staff that had a direct influence on light intensity in the ICU, was to close blinds or switch 
o ff overhead lighting i f  it was perceived to be too bright (or produced too much heat) for 
the patient or themselves. Patients were therefore often isolated from changes in the 
natural light-dark cycle during the day. Low light intensity has been shown to be 
sufficient to suppress melatonin levels in healthy individuals (Bojkowski et al, 1987; 
Brainard, 1997), even with light intensity as low as 180 lux (Boivin and Czeisler, 1998), 
which suggests that this might also be the case for ICU patients. However the likelihood 
o f  patients perceiving subtle daily changes in light intensity in the ICU is further 
complicated by the fact that patients are often sedated and have their eyes closed. The 
patients’ orientation on the bed and the location o f  the artificial lights relative to the 
patient w ill also be factors that influence the amount o f  light perceived. The low light 
intensity in the ICU during the day may prevent the light-dark cycle from acting as a 
strong time cue in critically ill patients.
The most surprising finding was that in the ICU studied, there was no difference in the 
overall light intensity at bed areas with windows compared to those without, as was
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predicted. During the subjective day, light intensity tended to be greater than 200 lux for 
more o f  the day but there appeared to be more variation in light intensity throughout the 
day and between the months compared to the bed areas with windows. Light intensity 
changed gradually throughout the day at bed areas with windows, whilst the light 
intensity changes were abrupt and unpredictable during the day at the beds lit solely by 
artificial lights. This demonstrates that within a single ICU, light intensity can vary 
considerably.
The findings from this study emphasise the importance o f  measuring light intensity in 
any future circadian rhythm studies at the times when other measurements and samples 
for analysis are taken.
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CH APTER 4. A C O M P A R IS O N  O F H O U R L Y  P L A S M A  A N D  
SA L IV A R Y  M E L A T O N IN , U R IN A R Y  aM T6s A N D  
C O R E  B O D Y  T E M P E R A T U R E  IN  H E A L T H Y  
VOLUNTEERS.
4.1 Introduction
An ideal method for determining phase properties of the endogenous pacemaker in 
human subjects should be reliable, fast, easy to perform, non-invasive and therefore 
pain free and would allow for frequent recordings or samples to be taken.
Currently core body temperature, plasma melatonin, salivary melatonin and urinary 
aMT6s are amongst the most common circadian rhythm markers, all giving reliable 
determinations o f circadian rhythmicity in healthy individuals in controlled  
environments (Moore-Ede et al, 1983; Fraser et al, 1983; Arendt et al, 1985; Nowak 
et al, 1987; Shanahan and Czeisler,1991), but each has drawbacks when used in a 
field environment.
Core body temperature, although simple, quick, reliable and allowing for continuous 
measurement, is invasive in that accurate measurement requires rectal access. Plasma 
melatonin also has the drawback of being invasive, requiring frequent venipuncture or 
insertion of a venous cannula for frequent sampling. Urinary aMT6s determination 
involves a non-invasive method o f sample collection but frequent sampling is 
difficult in field studies. It is currently common practice for subjects to collect urine 
samples in batches at 3,4 or 6 hourly intervals with a longer 8 or 12 hour collection 
overnight, but these sampling intervals, although widely used, have been criticised for 
being too infrequent. Salivary melatonin also has a non-invasive method of 
collection and is relatively easy to analyse. However salivary melatonin levels are
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believed to be influenced by chewing, which stimulates saliva flow rate (Miles et al, 
1985), a number of dietary factors and resuires subjects to be awake. Comparative 
studies on all four parameters have not been performed to date.
M iles et al have measured melatonin in plasma and saliva samples and found that 
there was a good correlation (r=0.97) between both measurements (Miles et al, 1985), 
with the nocturnal salivary melatonin concentration being 76% lower than that of  
plasma melatonin. Similar results were shown by McIntyre et al, 1987. Furthermore, 
Nowak et al compared serum and salivary melatonin concentrations with urinary 
aMT6s excretion rates and showed a significant correlation between plasma and 
salivary melatonin concentrations (r = 0.81, p< 0.001) and between plasma melatonin 
and urinary aMT6s excretion rate (r = 0.72, p< 0.001) (Nowak et al, 1987). In their 
study, although saliva samples were collected every 2 hours, plasma samples every 2 
to 4 hours urine samples pooled into 2 hourly samples, only five subjects were 
studied and the relationship between these parameters and core body temperature was 
not investigated.
The aims of this study were to: -
a) Compare the circadian rhythmicity o f core body temperature, plasma 
melatonin, salivary melatonin and urinary aMT6s using hourly measurements,
b) Determine the phase relationships o f core body temperature, plasma 
melatonin, salivary melatonin and urinary aMT6s using hourly measurements 
and to determine the correlations between the parameters o f circadian 
rhythmicity
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4.2 M aterials and M ethods
14 healthy volunteers were studied in the CIU at the University o f Surrey as described 
in detail in Chapter 2. Volunteers were required not to drink any alcohol on the night 
before the study days and to refrain from caffeine containing drinks on the study 
days. All volunteers were asked to empty their bladders at ll:0 0 h  when they arrived 
at the CIU before commencing the study, and had an hour to rest before the start o f  
the study at 12:00h. Between 12:00h on day one in the CIU to 12:00h on day two, 
hourly core body temperature (CBT) measurements, plasma samples, urine samples 
and saliva samples were collected as described in 2.1.2. The one volunteer who 
smoked (C l) did not provide saliva samples. The saliva and plasma samples were 
analysed for melatonin concentrations and the metabolite aMT6s was measured in the 
urine samples using the methods described in Chapter 2.
4.3 Results
4.3.1. Individual Subject Data
A  circadian rhythm was observed in plasma and salivary melatonin concentration, urinary 
aMT6s excretion rate and CBT in all subjects, the rhythm characteristics varying 
considerably between individuals (figures 29 to 42).
Cosinor analysis o f the data showed that the plasma melatonin rhythm, for each 
individual was highly significant at a level o f p < 0.001, the percentage rhythm 
ranging from 51.2% in subject C6 to 81.2% in subject C4 (table 9a). 13 o f the 14 
subjects had significant rhythms for urinary aMT6s (table 9b). Subject C l2 showed 
no significant rhythm for urinary aMT6s with cosinor analysis, probably due to the 
fact that night time levels dramatically increased and decreased three times. Two or
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Figure 29. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate and
plasma melatonin concentration and b. hourly core body temperature and plasma melatonin
concentration over 24 hours for subject Cl.
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Figure 30. Graphs to show the variation in a. hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C2.
189
a.
■ 1 1 LIGHT INTENSITY
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:1 
Time of Day (hours)
I 10 lux or less
11 to 199 lux
200 to 499 lux
500 to 999 lux
>  1000 lux
Plasma melatonin concentration 
Salivary melatonin concentration 
■ Urinary a M T 6 s  excretion rate
b.
100 T
i
co
cVuco
U
.Ec©
2u
2
Jcu
L I G H T  I N T E N S I T Y
I 10 lux or less
11 to 199 lux
200 to 499 lux
500 to 999 lux
> 1 0 0 0  lux
Plasma melatonin concentration 
Core body temperature
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00 
Time of Day (hours)
Figure 31. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin and b. hourly core body temperature and plasma melatonin
concentration over 24 hours for subject C3.
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Figure 32. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate, 
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma 
melatonin concentration over 24 hours for subject C4.
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Figure 33. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C5.
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Figure 34. Graphs to show a. The variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C6.
193
a.
LIGHT INTENSITY
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00 
Time of Day (hours)
I 10 lux or less
I*JS
1
a2 
c.©
a3uo
6
H
Plasma melatonin concentration 
Salivary melatonin concentration 
■ Urinary a M T 6 s  excretion rate
b.
L I G H T  I N T E N S I T Y
■
I
10 lux or less
11 to 199 lux
200 to 499 lux
500 to 999 lux 
>  1000 lux
Plasma melatonin concentration 
Core body temperature
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00 
Time of Day (hours)
Figure 35. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate, 
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma 
melatonin over 24 hours for subject C7.
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Figure 36. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C8.
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Figure 37. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C9.
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Figure 38. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C10.
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Figure 39. Graphs to show a. the variation in light intensity, urinary aMT6s excretion rate, plasma and
salivary melatonin concentration and b. hourly core body temperature and plasma melatonin
concentration over 24 hours for subject C11.
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Figure 40. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate, 
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma 
melatonin concentration over 24 hours for subject C l2.
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Figure 41. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate,
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma
melatonin concentration over 24 hours for subject C13.
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Figure 42. Graphs to show a. the variation in hourly light intensity, urinary aMT6s excretion rate, 
plasma and salivary melatonin concentration and b. hourly core body temperature and plasma 
melatonin concentration over 24 hours for subject C 14.
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a. Plasma Melatonin b. Urinary aMT6s
%R p-value
Cl 63.8 <0.0001
C2 67.0 <0.0001
C3 57.3 <0.0001
C4 81.2 <0.0001
C5 66.9 <0.0001
C6 51.2 0.0004
C7 71.8 0.0001
C8 59.1 <0.0001
C9 63.0 <0.0001
CIO 75.0 <0.0001
Cll 61.8 <0.0001
C12 69.6 <0.0001
C13 72.7 <0.0001
C14 61.8 <0.0001
c. Salivary Melatonin
%R p-value
Cl - -
C2 35.7 0.007
C3 77.4 <0.0001
C4 71.7 <0.0001
C5 54.7 0.0002
C6 33.6 0.014
C7 77.7 <0.0001
C8 45.2 0.0013
C9 13.0 0.2152
CIO 77.5 <0.0001
C ll 47.7 0.0011
C12 64.7 <0.0001
C13 33.8 0.0106
C14 23.8 0.07
%R p-value
Cl 61.1 <0.0001
C2 69.1 <0.0001
C3 79.8 <0.0001
C4 78.4 <0.0001
C5 72.5 <0.0001
C6 59.9 0.0001
C l 77.9 <0.0001
C8 73.6 <0.0001
C9 81.2 <0.0001
CIO 76.8 <0.0001
C ll 78.7 <0.0001
C12 46.6 0.0014
C13 81.1 <0.0001
C14 76.2 <0.0001
NS
d. Core Body Temperature
NS
NS
NS
NS
NS
NS
NS
%R p-value
Cl 70.0 <0.0001
C2 24.6 0.0446
C3 46.1 0.0011
C4 66.2 <0.0001
C5 70.9 <0.0001
C6 6.9 0.45
C l 68.4 <0.0228
C8 29.1 <0.0001
C9 58.3 <0.0001
CIO 85.3 <0.0001
C ll 73.7 <0.0001
C12 83.1 <0.0001
C13 63.8 <0.0001
C14 84.8 <0.0001
Table 9. Summary o f the results o f cosinor analysis to show the percentage 
rhythm (%R) and degree of significance (p-value) o f the a. plasma 
melatonin, b. urinary aMT6s, c. salivary melatonin and d. core body 
temperature rhythms for the control subjects (n=14). NS = Not 
significant
A  level o f  significance o f  p= or <0.0001 was used in order to ensure that 
| the detection o f  a significant rhythm by cosinor analysis was more 
stringent.
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three large episodic rises in urinary aMT6s excretion rate were seen in most o f the 
volunteers except for subjects C2 and C l 1 who had one single nocturnal rise. Similar 
episodic patterns in the plasma melatonin rhythm were only detected in subjects C4, 
CIO and C l3. Interestingly, subject C6 again had a lowest significant percentage 
rhythm at 59.9% for urinary aMT6s excretion rate. The salivary melatonin data gave 
the poorest reflection o f the rhythmic nature o f melatonin production compared to the 
plasma and urine data, as it produced several sharp increases in concentration during 
daylight hours as shown in figures 30, 32, 34, 37, 41 and 42. However in all subjects 
a sustained night time elevation o f salivary melatonin was observed. The 
consequence o f having poor baseline levels of salivary melatonin concentration was 
that only 6 control subjects (C3, C4, C5, C7, CIO and C l2) showed significant cosine 
rhythms (table 9c). Significant rhythmic changes in CBT were observed in 10 of  
th el4  control volunteers and again in these subjects, the percentage rhythm varied 
from 29.1% in subject C8 to 85.3% in subject CIO (table 9d). O f particular interest is 
the observation that all but one subject showed a small dip in CBT just after 12 mid­
day which was the point at which the subjects were given lunch. This did not appear 
to be related to changes in the other parameters measured. Tables 10 to 13 show the 
mesor, amplitude and acrophase times derived from the rhythms that were statistically 
significant (plasma data, n=14; saliva data n=6; urine data n=13; CBT data, n=10).
The comparative total plasma melatonin, salivary melatonin and urinary aMT6s 
production over 24 hours are shown in table 14.
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SUBJECT M
(pg/hr)
A
(pg/hr)
0
(hours)
%R
C l
C2
C3
C4
C5
C6
C l
C8
C9
CIO
C l l
C12
C13
C14
0.37
0.42
0.78
0.94
0.57
0.34
2.00
0.44
0.92
0.80
0.62
0.55
0.99
0.53
0.46
0.59
1.01
1.15
0.72
0.42
3.14
0.60
1.10
0.98
0.79
0.54
1.20
0.59
05:24
04:18
04:42
03:18
04:18
04:36
04:54
04:00
04:42
03:18
04:06
04:12
04:54
04:36
61.1
69.2
79.8
78.4
72.5
59.9
77.9
73.6
81.2 
76.8
78.7 
46.6 
81.1 
76.2
M ean
SEM
0.73
0.11
0.95
0.18
04:22
0:09
72.4
2.7
Table 10. Table to show the mesor (M), amplitude (A), acrophase time (([)) and
percentage rhythm (%R) derived from cosinor analysis o f the variation in 
urinary aMT6s excretion rate over 24 hours in healthy volunteers (n=14).
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SUBJECT M
(pg/m l)
A
(pg/ml)
*
(hours)
%R
C l 14.18 13.95 04:00 63.8
C2 35.37 33.37 03:05 67.0
C3 21.90 21.51 03:57 57.3
C4 34.54 44.79 02:38 81.2
C5 16.80 19.53 02:15 66.9
C6 8.03 5.54 03:24 51.2
C l 35.84 52.31 03:37 71.8
C8 19.31 23.63 03:33 59.1
C9 14.51 16.78 03:26 63.2
CIO 23.63 28.57 02:40 75.0
C l l 13.80 12.74 02:51 61.8
C12 21.81 18.83 02:03 69.6
C13 23.24 22.47 03:46 72.7
C14 16.38 13.01 04:25 61.8
M ean 21.45 23.36 03:15 65.9
SEM 2.34 3.42 00:11 2.1
Table 11. Table to show the mesor (M), amplitude (A), acrophase time (0) and 
percentage rhythm (%R) derived from cosinor analysis o f the variation in 
plasma melatonin concentration over 24 hours in healthy volunteers (n =  
14).
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SUBJECT M
(pg/m l)
A
(pg/m l) (hours)
%R
C l NO SAMPLES
C2 31.70 17.27 02:48 35.7
C3 25.93 19.60 04:45 77.4
C4 36.50 30.16 03:45 71.7
C5 20.41 6.68 03:12 54.7
C6 16.39 5.05 03:57 33.6
C l 25.60 21.05 04:33 76.7
C8 12.99 4.79 02:44 45.2
C9 23.30 8.64 23:11 13.0
CIO 17.75 9.14 03:49 77.5
C l l 10.71 3.42 02:35 47.7
C12 17.94 6.66 03:42 64.7
C13 31.74 16.58 03:48 33.8
C14 14.55 4.51 05:44 23.8
M ean 21.96 11.81 05:16 50.4
SEM 2.20 2.30 01:30 6.1
Table 12. Table to show the mesor (M), amplitude (A), acrophase time (0) and
percentage rhythm (%R) derived from cosinor analysis o f the variation in 
salivary melatonin concentration over 24 hours in healthy volunteers 
(n=13).
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SUBJECT M
(°c)
C l 37.07
C2 37.53
C3 36.96
C4 36.62
C5 36.91
C6 37.30
C l  37.28
C8 37.54
C9 36.58
CIO 37.05
C l l  37.11
C12 36.76
C13 36.69
C14 36.61
M ean 36.88
SEM  0.07
A (j) %R
(°c) (hours)
0.40 17:34 70.0
0.15 15:43 24.6
0.29 17:17 46.1
0.38 15:06 66.2
0.29 17:42 70.9
0.07 06:24 6.9
0.28 19:48 68.4
0.13 16:12 29.1
0.46 17:12 58.3
0.65 16:24 85.3
0.31 15:12 73.7
0.45 17:06 83.1
0.51 17:54 63.8
0.57 18:36 84.8
0.42 17:15 71.0
0.04 00:24 3.9
Table 13. Table to show the mesor (M), amplitude (A), acrophase time (<J>) and 
percentage rhythm (%R) derived from cosinor analysis o f the variation in 
core body temperaure over 24 hours in healthy volunteers (n=14). The 
mean and SEM are calculated from the individuals with significant cosinor 
rhythms (n = 11).
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plasm a m elatonin  
production  
ng/24h
Total Salivary m elatonin  
production  
ng/24h
Total Urinary aM T6s 
excretion  
ng/24h
0.28 No sample 49.78
0.53 0.79 58.08
0.54 0.64 84.87
0.47 0,45 49.73
0.40 0.51 65.03
0.19 0.39 97.94
0.87 0.63 211.65
0.47 0.32 72.01
0.35 0.57 165.83
0.57 0.44 176.63
0.25 0.21 41.88
0.47 0.37 130.26
0.53 0.82 249.71
0.38 0.33 150.40
Table 14. Quantitative comparison of total plasma melatonin, salivary melatonin, 
and urinary aMT6s concentration ( ng/24h ) per 24 hours for healthy 
volunteers (n = 14).
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4.3.2. Group Data
Figure 43 shows the mean variation in plasma melatonin concentration, salivary 
melatonin concentration and urinary aMT6s excretion rate and figure 44 compares the 
mean plasma melatonin concentration and mean core body temperature for the 
control subjects as a group. The baseline levels o f plasma melatonin, salivary 
melatonin and urinary aMT6s excretion rate were low  during the subjective day, 
although that o f salivary melatonin was higher than expected. This was a result of the 
sharp increases in salivary melatonin concentration produced by some subjects during 
the daytime. A ll the melatonin variables showed a nocturnal rise in concentration. 
Core body temperature had an inverse relationship to the hormones being high during 
the day and dropping during the night.
Statistical analysis o f the data, by correlation and regression, showed a significant 
correlation between mean plasm a m elatonin and mean salivary m elatonin  
concentrations (r = 0.88, p< 0 .05), the mean plasma melatonin concentration and 
urinary aMT6s excretion (r = 0 .87 , p<0.05), and between the mean salivary
melatonin concentration and urinary aMT6s excretion rate (r = 0.83. p < 0 .05)
(figures 45 to 47).
In figure 45 however, the regression line intercepts the y-axis at a mean salivary 
melatonin concentration o f  13.889 pg/ml, when the plasma concentration is 0 pg/ml. 
This result is almost certainly incorrect and related to the abnormal daytime salivary 
melatonin levels obtained, as other studies have shown that salivary melatonin 
concentrations are approximately 30% that o f  plasma concentrations i.e. lower than 
plasma melatonin concentrations (Nowak et al, 1987: Voultsios et al, 1997).
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Figure 45. Scatter diagram to show the correlation and regression line between mean plasma
melatonin concentration and mean salivary melatonin concentration at each time point (n = 25) in
healthy volunteers (n = 13).
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R2 = -0.2012 
r = 0.87
y = 0.033 lx
M ean Plasm a M elatonin Concentration pg/ml
Figure 46. Scatter diagram to show the correlation and regression line between mean plasma
melatonin concentration and mean urinary aMT6s excretion rate at each time point (n = 25) in
healthy volunteers (n = 14) Intercept for the regression line was at zero.
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Figure 47. Scatter diagram to show the correlation and regression line between mean urinary aMT6s
excretion rate and mean salivary melatonin concentration at each time point (n = 25) in healthy
volunteers (n = 13)
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M ean Core Body Tem perature °C
Figure 48. Scatter diagram to show the correlation and regression line between mean core body
temperature and mean plasma melatonin concentration at each time point (n=25) in healthy
volunteers (n =14).
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Figure 49. Scatter diagram to show the correlation and regression line between mean core body
temperature and mean salivary melatonin concentration at each time point (n=25) in healthy
volunteers (n=13).
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37.4
M ean Core Body Tem perature °C
Figure 50. Scatter diagram to show the correlation and regression line between mean core body 
temperature and mean urinary aMT6s excretion rate at each time point (n=25) in healthy volunteers 
(n=14)
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Interestingly, statistically significant negative correlations were seen between each o f  the 
mean hormone concentrations and mean core body temperature as shown clearly by 
figures 48 to 50.
Onset and offset times were calculated in two different ways before analysis. In the first 
method, onset was defined as the first plasma, saliva or urine level exceeding the mean + 
2sd o f  the baseline daytime levels (those values between 12:00h and 20:00h that were not 
followed by three consecutive increases in concentration). Offset was defined as the 
timing o f  the last value occurring after the acrophase, that exceeded the mean + 2sd o f  
baseline daytime levels followed by two further decreases. Comparison o f  onset times by 
correlation and regression showed no correlation between plasma melatonin onset time 
and urinary aMT6s onset time. This is an expected result as the onset o f  plasma 
melatonin precedes that o f  urinary aMT6s by approximately 1 hour, as shown in other 
studies (Bojkowski et al, 1987). Using this definition, onset and offset times could not be 
determined for salivary melatonin as the baseline was so unstable in may cases. 
Furthermore, offset times for urinary aMT6s could not be determined as urinary aMT6s 
levels had not reached baseline levels by the end o f  the study period for most subjects.
A  second definition o f  onset and offset was therefore used. Here the onset and offset 
points were defined as the mid-point between the mean o f  the baseline concentration 
during the daytime and the peak level reached during the night. Onset times, offset times 
and peak duration could be calculated using this method. Abnormal daytime peaks i.e. 
acute increases in salivary melatonin concentration occurring between 12:00h and 
23:00h, greater than 3 times the assay detection limit (12pg/ml), were omitted from the 
calculation o f  the mean baseline for salivary melatonin.
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Figure 51. Comparison of the mean peak onset times, offset times and peak duration between 
plasma melatonin (P), salivary melatonin (S), urinary aMT6s (U) and the trough core body 
temperature (C). in healthy volunteers (n=14)
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Correlation studies on the night time onset and offset times and peak duration o f  plasma 
and salivary melatonin concentrations, urinary aMT6s excretion rate and CBT showed no 
significant correlation. A  comparison o f  the onset and offset times and peak duration for 
each parameter measured is shown in figure 51. Here the results show that plasma and 
salivary melatonin levels rose shortly after midnight at means o f  00:17h and 00:02h 
respectively, followed at 01:43h by a rise in urinary aMT6s excretion. The earlier onset 
for salivary melatonin compared to plasma melatonin is likely to be a result o f  the poor 
salivary melatonin data obtained, as it is generally accepted that plasma melatonin levels 
rise first. The onset time o f  the decline in CBT commenced after the onset time o f  
plasma melatonin secretion, at a mean o f  00:5Oh. The offset times occurred in the order 
o f  plasma melatonin first at a mean o f  06:07h followed by that o f  salivary melatonin and 
urinary aMT6s. Paired t-tests showed that the mean offset times o f  the salivary 
melatonin compared to those o f  plasma melatonin were not statistically different 
(0.1<p<0.05). However a highly significant difference was found between the mean 
offset times o f  plasma melatonin compared with that o f  urinary aMT6s (pO.OOl) and 
between the mean salivary melatonin offset time compared to that o f  urinary aMT6s 
(0.002<p<0.001). The rise in CBT occurred after the offset times o f  the hormones at a 
mean o f  08:54h. The duration o f  the peaks were o f  similar length for the hormone 
concentrations ranging from 5 hours 50 minutes for plasma melatonin to 6 hours 36 
minutes for salivary melatonin. The duration o f  the CBT trough was longer at 8 hours 4 
minutes.
Correlation analysis on the cosinor data found a highly significant correlation between 
the plasma melatonin and salivary melatonin amplitudes (r=0.80, p<0.05) and the plasma 
and urinary aMT6s amplitudes (figures 52 and 53). However, no significant correlation
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Figure 52. Correlation and regression between the plasma melatonin amplitude and salivary
melatonin amplitude in healthy volunteers (n=6)
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Plasm a m elatonin am plitude (pg/m l)
Figure 53. Correlation and regression between plasma melatonin amplitude and urinary aMT6s 
amplitude in healthy volunteers (n=13)
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Figure 54. Correlation and regression line between plasma melatonin mesor and urinary aMT6s
mesor for healthy volunteers (n=13)
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Figure 56. Comparison o f amplitude, mesor and (|) for plasma melatonin-P, salivary melatonin-S 
(pg/ml), urinary aMT6s-U (pg/hr) and CBT-C (oc) in healthy subjects (n=6).
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was observed between the core body temperature amplitude and plasma melatonin 
amplitude, salivary melatonin amplitude or urinary aMT6s excretion rate amplitude.
Correlations were detected between the plasma melatonin and urinary aMT6s mesor (r =  
0.72, p<0.05) and <|> values (r=0.72, p<0.05) (figures 54 and 55), between the mesor 
values o f  the plasma melatonin and salivary melatonin rhythms (r=0.69, p<0.05), 
between the urinary aMT6s mesor and CBT mesor (i~0.63, p<0.05), between <f> for 
plasma melatonin and salivary melatonin (r=0.62, p<0.05) and between the + values for 
urinary aMT6s and CBT (r=0.69, p<0.05).
Figure 56 compares the mean mesor, mean amplitude and mean + values o f  the plasma 
melatonin, salivary melatonin, urinary aMT6s and core body temperature rhythms o f  the 
six volunteers who had significant rhythms for all the parameters. It shows that plasma 
melatonin peaked ahead o f  the salivary melatonin and urinary aMT6s rhythms at 02:51 h. 
4> for salivary melatonin and urinary aMT6s occurred approximately one hour later at 
03:56 and 03:58 h respectively. Paired t-tests o f  the acrophase data showed a highly 
significant difference between the mean acrophase time o f  plasma melatonin and urinary 
aMT6s but showed no significant differences between mean acrophase times o f  the 
plasma melatonin and salivary melatonin or between the mean acrophase times o f  
salivary melatonin compared that o f  urinary aMT6s.
4.3.3. Comparison o f  rhythm characteristics o f  lh , 2h, 3h and 4h urine collections.
To investigate the effect o f  talcing hourly urine samples for urinary aMT6s excretion rate 
estimation compared to 2h, 3h, or 4h urine samples, the hourly data from this study was 
used to calculate average urinary aMT6s excretion rates for these time periods. The
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SUBJECT lh 2h 3h 4h
C l 0.36 0.37 0.37 0.38
C2 0.42 0.42 0.42 0.43
C3 0.77 0.78 0.78 0.79
C4 0.95 0.95 0.95 0.96
C5 0.57 0.58 0.58 0.59
C6 0.38 0.38 0.38 0.38
C7 1.46 1.49 1.49 1.50
C8 0.44 0.44 0.44 0.45
C9 0.90 0.91 0.91 0.93
CIO 0.79 0.80 0.80 0.80
C l l 0.61 0.56 0.56 0.56
C12 0.61 0.62 0.62 0.62
C13 0.98 0.92 1.00 1.01
C14 0.52 0.52 0.52 0.53
Table 15. Table to show the change in mesor for urinary aMT6s excretion rate 
(jig/hr) that results from increases in urine collection period, between lh, 
2h, 3h and 4h collection periods, calculated from the hourly urinary 
aMT6s excretion rate.
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SUBJECT lh 2h 3h 4h
C l 0.46 0.45 0.45 0.45
C2 0.59 0.58 0.57 0.54
C3 1.02 1.01 0.99 0.93
C4 1.14 1.13 1.12 1.04
C5 0.72 0.72 0.70 0.68
C6 0.48 0.47 0.47 0.46
C7 2.09 2.08 2.05 1.95
C8 0.60 0.59 0.59 0.57
C9 1.10 1.10 1.08 1.04
CIO 0.98 0.94 0.94 0.89
C ll 0.78 0.67 0.67 0.64
C12 0.65 0.62 0.62 0.62
C13 1.20 1.16 1.16 1.12
C14 0.60 0.60 0.60 0.57
Table 16. Table to show the change in amplitude (gg/hr) for urinary aMT6s 
excretion rate that results from increases in urine collection period, 
between lh , 2h, 3h and 4h collection periods, calculated from the hourly 
urinary aMT6s excretion rate.
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SUBJECT lh 2h 3h 4h
C l 5.73 6.44 7.03 6.83
C2 4.73 5.25 5.88 5.16
C3 5.13 5.79 6.25 5.73
C4 3.80 4.28 5.01 4.12
C5 4.80 5.32 5.86 5.27
C6 4.93 5.58 6.24 5.43
C7 5.27 5.93 6.31 5.43
C8 4.40 4.92 5.50 5.08
C9 5.07 5.60 6.20 5.69
CIO 3.80 4.39 4.92 4.19
C ll 4.53 4.76 5.11 4.87
C12 4.33 4.99 5.55 4.78
C13 5.33 6.54 6.37 5.98
C14 5.00 5.54 5.89 5.53
Table 17. Table to show the change in acrophase time (hours - decimal time) for 
urinary aMT6s excretion rate that results from increases in urine collection 
period, between lh , 2h, 3h and 4h collection periods, calculated from the 
hourly urinary aMT6s excretion rate.
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SUBJECT lh 2h 3h 4h
C l 60.6 63.6 67.2 73.9
C2 69.4 75.7 76.0 80.9
C3 79.7 82.4 87.1 87.0
C4 78.7 86.4 89.9 89.1
C5 72.6 79.7 83.7 82.3
C6 66.6 69.3 80.2 80.6
C7 56.0 77.7 80.7 81.5
C8 73.9 76.8 81.2 81.1
C9 80.4 83.9 86.8 86.9
CIO 77.3 82.1 88.0 90.7
C ll 74.7 68.0 72.8 83.0
C12 74.2 87.3 88.3 88.1
C13 80.8 85.6 89.3 85.0
C14 75.7 80.6 84.1 85.8
Table 18. Table to show the change in percentage rhythm (%) for urinary aMT6s 
excretion rate that results from increases in urine collection period, 
between lh , 2h, 3h and 4h collection periods, calculated from the hourly 
urinary aMT6s excretion rate.
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resulting data was then analysed using cosinor analysis to determine the degree o f  fit to a 
cosine curve. Tables 15, 16, 17 and 18 show the mesor, amplitude, acrophase time and 
percentage rhythm respectively. There was no apparent change in the mesor as collection 
interval was increased, which was confirmed by repeated measures ANOVA (p < 0.06). 
Increasing the collection time period resulted in a decrease in amplitude (table 16). 
Repeated measures ANOVA showed that this was highly significant (p < 0.0001) and 
Duncan’s post hoc test showed that the amplitude at 4h was significantly different from 
that at lh , 2h and 3h (p < 0.01). A  significant difference was also seen between the 
amplitudes at lh  and 3hr collections (p < 0.01), but no significant differences in 
amplitude were found between lh  and 2h collections.
Acrophase time increased with increase in collection time. Repeated measures ANOVA  
showed significant differences in acrophase time between each collection time period (p 
< 0.01), except between the 2h and 4h collections.
The percentage rhythm also improved as the time o f  collection was increased, which was 
significant (p < 0.0001, repeated measures ANOVA). Duncan’s post hoc test showed 
that the significant differences were between each collection time (p < 0.0001), except 
between 3h and 4h.
To summarise, increasing collection time resulted in a decrease in amplitude, an increase 
in acrophase time and percentage rhythm, with no significant change in mesor, as 
illustrated by figure 57.
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1Time of Day (hours)
b.
Time of Day (hours)
c.
Time of Day (hours)
d.
Time of Day (hours)
i 0.95
1.14 
3.80 
= 78.7
= 0.95
11.13 
4.28 
= 86.4
= 0.95 
= 1.12 
5.01 
= 89.9
= 0.96 
= 1.04 
<4.12 
= 89.1
Figure 57. Graphs to illustrate the change in mesor (M), amplitude (A), acrophase time (0) and 
percentage rhythm (%R) with increasing collection time (a. lh, b. 2h, c.3h, d. 4h) for subject C4.
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The present study is the first to compare hourly plasma melatonin concentrations with 
hourly salivary melatonin concentration, urinary aMT6s excretion rate and core body 
temperature.
In comparing the methodologies, there was good correlation between all the 
measurements, but estimation o f  plasma melatonin concentration and urinary aMT6s 
excretion provided data that consistently showed statistically significant diurnal rhythms 
in all subjects.
Estimation o f  salivary melatonin was simple in terms o f  sample collection and assay 
procedure and the results from the grouped data showed a clear diurnal rhythm. In 
individual subjects however, poor results were produced, characterised by high baseline 
concentrations during the subjective day and sharp ‘spikes’ in concentration for both the 
day and night time estimations o f  salivary melatonin.
One source o f  error may have been the frequency o f  saliva sampling over the 25h study 
period. Subjects may have encountered difficulties in producing sufficient sample and 
inadvertently caused their mouths to bleed a little, thus contaminating samples. Most 
studies in which saliva was collected for melatonin determinations either collected 
samples over a shorter length o f  time (Voultsios et al, 1997; McIntyre et al) or at fewer
i
intervals (Vakkuri, 1985; Nowak et al, 1987). A  second explanation for the poor 
individual results is that the samples were possibly contaminated by tiny food particles. 
M iles et al reported that salivary melatonin levels can be raised as a result o f  
contamination by foods particles (Miles et al, 1989) and stressed the need for thorough
4.4. Discussion
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mouth-washing for 5 minutes, 15 minutes before sample collection. Care was taken in 
the present study to ensure that all volunteers adhered to this recommendation by rinsing 
their mouths thoroughly with non-carbonated bottled water, 15 minutes before sample 
collection. However it is still possible that some small food particles remained following 
rinsing and entered the saliva samples. The meals themselves may also have influenced 
salivary melatonin concentration. Reiter’s group showed that a number o f  plants, 
especially those o f  the rice family, actually contain melatonin (Hattori et al, 1995). Care 
was taken to avoid substances known to affect melatonin levels such as caffeine- 
containing foods and drinks (Wright et al, 1997). It is possible however that some o f  the 
foods used to feed subjects may have contained melatonin or that the period o f  abstinence 
from caffeine was too short and needed to be from 24 hours before the study days. 
Subsequent studies by this laboratory investigated the effect on the salivary melatonin 
assay o f  some snacks such as crisps, cheese and chocolate biscuits and showed that those 
substances did not influence salivary melatonin levels significantly (unpublished data). 
Other unpublished studies by this laboratory suggest that Complan should be used as a 
drink in clinical trials on using salivary melatonin as a circadian rhythm marker, since no 
spikes were observed in these experiments. Finally poor salivary melatonin results could 
have been due to the assay itself. The present study was the first in this laboratory to use 
the GHS-100491 antibody in a trial such as this. It is possible that the antibody produced 
poor binding in the assay or was influenced to a greater degree by contaminants in the 
saliva samples than a previously used antibody. This could account for both the high 
baseline and the sharp surges in concentration. As a consequence o f  this study, the 
G HS-100491 antibody is no longer being used in salivary melatonin assays by this 
laboratory.
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The urinary aMT6s data was o f  interest as all but two subjects (C2 and C l l )  showed 
episodic nocturnal excretion rates. This has rarely been observed in studies where two, 
three or four hourly urine samples have been taken. This effect may be due to changes in 
renal function during the night in terms o f  concentrating ability o f  the collecting ducts 
and the loop o f  Henle, changes in volume excretion or both. The effect may also be 
related to episodic secretion o f  plasma melatonin, but although this was observed in some 
individuals (C4 and CIO), it was not a consistent finding in all subjects. However, the 
comparative studies on urine collection time highlighted the importance o f  frequent 
sampling, which allow such details to be revealed in the rhythm o f  urinary aMT6s 
excretion rate. The comparative analysis also demonstrated that although the mesor o f  
the circadian rhythm is unaffected and percentage rhythm improves with longer 
collection periods, significant changes in amplitude and acrophase time result. Therefore, 
this study demonstrates that urinary aMT6s rhythm characteristics derived from 3h or 4h 
urine collections are not precise reflections o f  the endogenous clock or the pattern o f  
urinary aMT6s excretion. However, in view o f  the good correlations seen with plasma 
melatonin (Ross et al, 1995), such intervals o f  sampling will provide an acceptable 
estimate o f  the circadian rhythm o f  urinary aMT6s excretion.
The general observation that circadian rhythmicity varies between individuals was 
highlighted by subject C6, who at 17 years o f  age at the time o f  this study, had poor 
rhythmicity in terms o f  plasma melatonin concentration, urinary aMT6s excretion rate 
and CBT, with no self-perceived sleep problems. This subject was therefore an exception 
to findings o f  Bojkowski et al and other workers, which showed that the production o f  
melatonin decreases with an increase in age (Bojkowski et al, 1990).
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Comparing the hormone parameters, it was predicted that plasma melatonin onset, offset 
and acrophase time would be before that o f  salivary melatonin and urinary aMT6s 
excretion rate. Although the offset time and acrophase time data suggested that this 
might be the case, paired t-tests did not confirm this. Analysis o f  the offset times by 
paired t-tests showed a significant difference between plasma melatonin values and 
urinary aMT6s values and salivary melatonin and urinary aMT6s values, but not between 
plasma melatonin and salivary melatonin values. Furthermore, a significant difference in 
mean acrophase times was only found between plasma melatonin and urinary aMT6s. 
The onset time o f  salivary melatonin preceded that o f  plasma melatonin in this study by 
15 minutes. This may be a true result but is more likely to be inaccurate due to the 
problems encountered with the measurement o f  salivary melatonin in this study.
Cagnacci et al have suggested that melatonin has hypothermic functions and that 
endogenous melatonin acts as a physiological regulator o f  the normal night time decline 
in CBT (Cagnacci et al, 1992; Cagnacci et al 1995). The results o f  the present study 
showed that the onset and offset o f  the nocturnal rise in plasma melatonin concentration 
preceded the onset and offset o f  the decrease in CBT by 33 minutes and 2 hours 47 
minutes respectively. These results are consistent with Shanahan and Czeisler’s findings 
that the fitted maximum o f  the endogenous melatonin rhythm consistently precedes that 
o f  core body temperature under constant conditions (Shanahan and Czeisler, 1991). In 
addition, a highly significant negative correlation was found between the mean core body 
temperature and the mean plasma melatonin concentration, mean salivary melatonin 
concentration and urinary aMT6s excretion rate, although correlations between the 
amplitudes were not found. These results further strengthen the current evidence that 
there is a close relationship between melatonin and core body temperature.
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CHAPTER 5. INVESTIGATION OF CIRCADIAN RHYTHMS IN 
CRITICALLY ILL PATIENTS USING HOURLY URINARY 
aMT6s, PLASMA AND SALIVARY MELATONIN, AND 
CORE BODY TEMPERATURE AS MARKERS OF THE 
ENDOGENOUS RHYTHM.
5.1. Introduction
Intensive care patients are thought to be prone to disturbances in their circadian rhythms 
due to isolation from environmental changes and sleep disturbance.
Core body temperature (CBT) has a strong endogenous component, which reliably 
reflects the rhythm of the endogenous pacemaker in healthy subjects (Moore-Ede et al, 
1983). It can be measured easily using rectal probes or by taking tympanic membrane 
temperature measurements (Sato et al, 1996).
In 1989, Tweedie et al carried out a retrospective study of CBT in 15 ICU patients, 
taking data from nursing charts. They found that in 80% of the patient days studied, a 
significant 24 hour rhythm existed, but the peak of the acrophase varied both between 
patients and within patients (Tweedie et al, 1989). Nuttall et al also earned out a 
retrospective study of core body temperature and urine volume rhythms and found that 
ICU patients had rhythmicity in both these parameters, but they were abnormal (Nuttall 
et al, 1998). The time of the temperature nadir was distributed around the clock for ICU 
patients studied. ICU patients are however prone to fever and sometimes hypothermia 
and are often treated with drugs such as paracetamol, which reduce temperature. These
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factors would influence the circadian rhythm of CBT, making CBT an unreliable marker 
of the endogenous pacemaker in ICU patients.
More recently, Shilo et al have looked at the circadian rhythm o f urinary aMT6s 
excretion rate in ICU patients with an ICU stay of more than four days (Shilo et al, 
1999). Actigraphy was used to determine the amount o f sleep and 3 hourly urine 
collections were taken to determine urinary aMT6s levels. Actigraphy showed that ICU 
patients do not sleep but appear to nap. In addition, they found abnormal urinary aMT6s 
excretion rhythms with an abolishment o f the nocturnal rise in 12 of 14 patients studied. 
This data provides evidence that ICU patient circadian rhythms are abnormal, but the 
quality of the urinary aMT6s data may have been affected by the reduced frequency of  
sampling. Chapter 4 showed that the use o f collection periods longer than 2h results in a 
dampening o f the amplitude o f the urinary aMT6s rhythm and if  urinary aMT6s levels 
are low, this may result in non-detection of rhythmic activity.
The aims of the present study were: -
a. To investigate the reliability o f retrospective CBT measurement as a 
marker o f circadian rhythmicity in critically ill patients.
b. To determine whether circadian rhythmicity may be investigated in ICU 
patients using hourly urinary aMT6s measurements.
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c. To determine whether there is evidence of phase shifting o f circadian
rhythms in critically ill patients using urinary aMT6s as a rhythm marker.
c. To investigate circadian rhythms in critically ill patients using plasma 
melatonin as a circadian rhythm marker.
5.2. Materials and Methods
5.2.1. Retrospective study of core body temperature in critically ill patients 
Twelve ICU patients (8M : 4F, aged 17 -  66), who had been treated on the ICU for more 
than 6 days, were selected for the investigation. Patients were selected randomly but 
care was taken to choose patients who had CBT recorded rather than peripheral 
temperatures. Details of these patients are summarised in table 19.
Hourly CBT readings were retrospectively taken from the nursing bedside charts at the 
Royal Free Hospital, London. Temperature was recorded hourly via a rectal probe 
(French size 9, total length 50cm) provided by Mallinckrodt UK, (Northampton, UK) 
inserted just beyond the internal sphincter. These were connected to Marquette Tram 
monitors (GE Marquette M edical System s, M ilwaukee, W isconsin , U SA ) or 
Mallinckrodt monitors (Mallinckrodt UK, Northampton,UK.).
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SUBJECT AGE SEX REASON FOR DAYS ON OUTCOME
ICU ADMISSION ICU
T1
T2
26 M Post operative liver
transplant
36 F Respiratory failure
Died
Died
T3 16 M Acute renal and liver 
failure
Died
T4 29 M Head and spinal
fractures following a fall
86 Survived
T5 66 M Post aortic aneurysm 
repair
16 Died
T6 44 M Brain stem 
infarct
Died
T7 47 F Pneumonia and 
respiratory failure
29 Survived
T8 30 M Human immuno 
-deficiency virus
30 Died
T9 24 F Cellulitis, sepsis. 10 Survived
T10 57 M Post operative removal 9 Died
of apical aspergilloma
T i l  66 F Subarachnoid 10 Died
haemorrhage
T12 36 F Fulminant liver failure 11 Survived
Table 19. Details o f the ICU patients for which retrospective core body temperature 
was investigated (n = 12).
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5.2.2. Investigation of circadian rhythms in critically ill patients using urinary aMT6s as 
a circadian rhythm marker of the endogenous pacemaker
To investigate whether urinary aMT6s excretion could be used as a marker o f  
endogenous rhythms in the critically ill, 12 ICU patients (9M:3F, aged 28 to 79), were 
recruited follow ing verbal informed consent from the patients or written informed 
consent from their relatives. Table 20 gives a summary of the patient details and a 
detailed background can be found in 2 .2 .2 . Patients were stable, were not 
haemodiafiltered and were not on adrenaline or noradrenaline.
Hourly light intensity readings were taken and urine samples collected from urinary 
catheter bags as described in chapter 2 from 08:00h on day 1 to 08:00h on day 2. Urine 
samples were analysed for urinary aMT6s concentration using the method of Aldhous 
and Arendt as described in 2.6.1 (Aldhous and Arendt, 1988).
5.2.3. Investigation of circadian rhythms in critically ill patients using urinary aMT6s 
and core body temperature as circadian rhythm markers o f the endogenous clock
11 ICU patients (9M : 2F, aged 17 to 81), were recruited following verbal informed 
consent from the patients or written informed consent from their relatives. Table 21 
gives a summary of the patient details and a detailed background can be found in 2.2.2. 
The patients were stable, did not require inotropic support (not given adrenaline or 
noradrenaline) and were not in renal failure.
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SUBJECT AGE SEX REASON FOR BED NUMBER OUTCOME
ICU ADMISSION ICU
R l 51 M Pneumonia 7 Survived
R2 66 F Asthma 9 Survived
R3 61 M Post operative 1 Survived
liver transplant
R4 66 M Gastric pullup 2 Died
R5 79 M COAD, cardiac arrest 9 Died
R6 77 F Partial gastrectomy, 4 Died
COAD
R7 28 M Intracerebral bleed 6 Survived
following fall.
R8 65 F Overdose 9 Survived
R9 76 M Post VT arrest. 7 Survived
R20 48 M Post operative 10 Survived
liver transplant
R21 53 M Guillain-Barre 4 Survived
Syndrome
R22 41 M Meningitis 2 Survived
Table 20. Details o f the ICU subjects studied to investigate the nature o f  circadian
rhythms in critically  ill patients using urinary aM T6s excretion  as a
circadian rhythm marker.
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SUBJECT AGE SEX REASON FOR BED NUMBER OUTCOME
ICU ADMISSION ICU
RIO
R l l
R12
R13
R I4
R15
R16
R17
R18
R19
R23
Table 21.
67 M Post operative aortic
aneurysm repair
77 M Respiratory arrest due
to cerebral vascular 
aneurysm
75 M Guillain-Barre
Syndrome
Survived
Survived
Died
62 M Pneumonia, sepsis. 10 Survived
39 M Pancreatitis, GI bleed Survived
17 F Pancreatitis Died
81 M CO AD, chronic
cardiac failure
Survived
53 F Post laparotomy bleeding 1 Survived
42 M Cerebral abscess Survived
35 M Removal of 
mediastinal mass
Survived
78 M Respiratory failure 
and sepsis
Survived
Details o f  the ICU subjects studied to investigate the nature o f circadian
rhythms in critically ill patients using urinary aMT6s excretion and core
body temperature as circadian rhythm markers.
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Hourly light intensity readings, core body temperature readings and urine samples were 
measured and taken as described in chapter 2 from 12:00h on day 1 to 12:00h on day 2. 
Urine samples were analysed for urinary aMT6s concentration using the method of  
Aldhous and Arendt as described in 2.6.1 (Aldhous and Arendt, 1988).
5.2.4. Investigation into phase shifting o f circadian rhythms in critically ill patients 
using urinary aMT6s excretion and core body temperature as circadian rhythm 
markers o f the endogenous pacemaker
10 ICU patients (8M : 2F, aged 17 to 77), for which informed consent had been obtained 
from either themselves or their relatives, were studied on more than one occasion. 
Details o f these patients are given in chapter 2 and summarised in Tables 22. 8 o f the 
patients were studied on two occasions one week apart (R l, R6, R8, R l l ,  R12, R18, R19 
and R20). 2 patients (R14 and R15) were studied on three occasions, the first two study 
days being a week apart and the third being two weeks after the second study day (week 
4). Patients R l to R12 were studied for 24 hours starting at 08:00h on day 1 and patients 
R14 to R20 were studied for 24 hours starting at 12:00h on day 1. Tables 23a and 23b 
list the drugs with which patients were treated on each of the study days.
Urine samples were taken from all subjects at hourly intervals and analysed for urinary 
aMT6s concentration and excretion rate using the method o f Aldhous and Arendt 
described in Chapter 2 (Aldhous and Arendt, 1988). 6 of the 10 patients had core body 
temperature measurements taken using the method described in 2.3.1.
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SUBJECT AGE SEX REASON FOR BED NUMBER OUTCOME
ICU ADMISSION ICU
R l
R6
R8
R l l
R12
R14
R15
R18
R19
R20
Table 22.
51 M Pneumonia Survived *
77 F Partial gastrectomy, 4
COAD
Died *
65 F Overdose Survived *
77 M Respiratory arrest due 
to cerebral vascular 
aneurysm
Survived
75 M Guillain- Barre 
Syndrome
Died
39 M Pancreatitis, G l bleed 3 Survived
17 M Pancreatitis Died
42 M Cerebral abscess Survived
35 M Removal o f 5
mediastinal mass
Survived
48 M Post operative 
liver transplant
10 Survived *
Details o f the ICU subjects studied to investigate phase shifting o f  
circadian rhythms in critically ill patients using urinary aMT6s excretion 
and core body temperature as circadian rhythm markers. ( * identifies 
patients for which core body temperature measurements were not taken)
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5.2.5. A  comparative study o f plasma melatonin levels from arterial and venous blood 
samples
In ICU, the majority of patients have arterial lines in situ in order to monitor blood 
pressure and to allow medical and nursing staff to take blood samples easily. These were 
the lines from which samples were to be taken for a study investigating circadian rhythms 
using plasma melatonin as a marker o f the endogenous rhythm. M ost circadian rhythm 
studies in the past have used healthy controls and venous samples for the analysis of 
plasma melatonin and results o f comparative studied have not been published.
In order to determine whether arterial and venous samples would give equivalent values 
for plasma melatonin, blood samples were taken simultaneously from the arterial and 
venous lines o f five ICU patients. The samples were centrifuged, stored at -20°c until 
analysis and analysed for plasma melatonin concentrations as already described in 2.6.2, 
using the method of Fraser (1983).
5.2.6. Investigation o f circadian rhythms in critically ill patients using plasma 
melatonin, urinary aMT6s and core body temperature as circadian rhythm 
markers of the endogenous clock
9 ICU patients (6M:3F, aged 23 to 76) were recruited following informed consent from 
either themselves or their relatives. Details of these patients are summarised in table 24. 
Patients who were unstable, treated with adrenaline or noradrenaline, or with renal failure 
and on haemodiafiltration, were excluded from the study.
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REASON FOR BED NUMBER OUTCOME
ICU ADMISSION ICU
R24 72 M
R25 76 M
R26 49 F
R27 66 M
R28 65 F
R29 33 F
R30 23 M
R31 29 M
R32 69 M
SUBJECT AGE SEX
Respiratory and cardiac 
failure
Post oversewing of 
duodenal ulcer
Tuberculosis
Faecal peritonitis 
Respiratory failure
Respiratory failure 
post overdose
Post surgery for 
stab wounds
Cerebral abscess
Post gastrointestinal 
surgery
7 Survived
4 Survived
11 Died
8 Died
9 Survived
3 Survived
10 Survived
6 Survived
10 Survived
Table 24. D etails o f the ICU subjects studied to investigate the nature o f circadian
rhythms in critically ill patients using plasma m elatonin, urinary aMT6s
excretion and core body temperature as circadian rhythm markers.
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Hourly light intensity readings, core body temperature readings, plasma and urine 
samples were measured and taken as described in chapter 2 from 12:00h on day 1 to 
12:00h on day 2. Urine samples were analysed for urinary aMT6s concentration using 
the method of Aldhous and Arendt as described in 2.6.1 (Aldhous and Arendt, 1988). 
Plasma samples were analysed for plasma melatonin concentrations using the method of 
Fraser et al, 1983 as detailed in chapter 2.
5.3. Results
5.3.1. Retrospective study of core body temperature in critically ill patients 
The variation in retrospective CBT for complete days spent in the ICU for patients T1 to 
T12 (08:00h to 08:00h constituting a whole day) are shown in figures 58 to 70, together 
with repeated cycles o f the mean CBT of healthy volunteers at the same time points 
(from Chapter 4). A lso shown are details o f relevant interventions that may have 
affected ICU patient CBT, such as the use o f space blankets or temperature lowering 
drugs such as paracetamol.
There was evidence of circadian rhythmicity in all the ICU patients but a recurring 
pattern on each consecutive day was not observed in any o f the patients. However 
similarities in the timing of the peaks and troughs were observed in the CBT rhythms of 
some ICU patients compared to normal subjects, particularly subjects T4, T5, T6, T9, 
T10 and T 11, on some days.
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Cosinor analysis o f the data for individual days (taken from 08:00h to 08:00h) showed a 
significant fit to a cosine curve on some days o f a patients' ICU stay but not on all days. 
Figures 58 to 70 show the cosinor data for the days when a significant fit (percentage 
rhythm >60%, p<0.001) was found. A total o f 97 patient-days o f retrospective CBT data 
were studied and of these, 48 days had significant cosine rhythms (49.5%). Individual 
patients had statistically significant cosine fits for 14% to 80% (median 61.3%) of the 
time spent in ICU.
Tables 25 and 26 show the mean mesor (±SD) and mean amplitude (±SD) respectively 
for each patient. When the mean mesor and mean amplitudes were compared to the 
mesor and amplitudes from the healthy volunteers (figures 70 and 71) a significant 
difference was detected between the two groups. Unpaired student t-tests showed that 
the mean mesor values o f the ICU group were statistically higher than the mesors from 
the controls (p = 0.04) and the mean amplitude values were also statistically higher in the 
ICU group (p = 0.007).
Figures 72a and 72b show the daily acrophase times from the days with significant 
cosine rhythms for each patient. Patient T10 is not plotted as only one day with a 
significant rhythm was found. The position o f the acrophase in the ICU patients shows 
very abnormal rhythms. In some patients there are possible phase delays (T l, T3, T4 
and T12), in some patients there is some evidence for possible phase advances (T2) and 
other patients appear to have acrophase times that oscillate (T5, T6, T8, T9 and T il ) .
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Patient Mean Mesor °c (±SD) Days stm
T1 37.06 (0.47) 5
T2 36.63 (0.61) 8
T3 36.92 (0.54) 5
T4 38.44 (0.65) 9
T5 37.01 (0.79) 15
T6 37.36 (0.70) 6
T7 38.77 (0.42) 7
T8 37.16(0 .84) 8
T9 37.82 (0.83) 9
T10 38.24 (0.41) 7
T i l 37.95 (0.98) 9
T12 36.55 (0.54) 9
Median (range) 37.25 (36.55 - 38.44)
Table 25. The mean mesor (±SD) of the core body temperature rhythms ( °c) o f ICU 
patients, including those days when cosinor analysis showed no 
statistically significant rhythm.
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Table 26.
PATIENT M EAN AM PLITUDE
T1 0.57 (0.40)
T2 0.57 (0.39)
T3 0.95 (0.22)
T4 0.36 (0.30)
T5 0.56 (0.86)
T6 0.61 (0.34)
T7 0.49 (0.34)
T8 0.46 (0.19)
T9 0.81 (0.51)
T10 0.35 (0.19)
T i l 0.56 (0.50)
T12 0.36 (0.30)
M edian (range) 0.57 (0.18 - 0.86)
The mean amplitude (±SD) o f the core body temperature rhythms (oc) of 
ICU patients, including those days when cosinor analysis showed no 
statistically significant rhythm.
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Figure 72a. Graphs to show the daily position of acrophase time of core body temperature rhythms in ICU patients on days 
when cosinor analysis showed a statistically significant 24 hour rhythm. Days without a significant rhythm 
have been omitted, with days on either side, with significant rhythms, joined by a dashed line.
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Figure 72b Graphs to show the daily positon of acrophase time of core body temperature rhythms in ICU patients on days 
when cosinor analysis showed a statistically significant 24 hour rhythm. Days without a significant rhythm 
have been omitted, with days on either side, with significant rhythms, joined by a dashed line.
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5.3.2. Investigation of circadian rhythms in critically ill patients using urinary aMT6s as 
a circadian rhythm marker o f the endogenous pacemaker 
Urinary aMT6s concentration was measured for each sample and urinary aMT6s 
excretion rate calculated to take the urine volume excreted into account. Figures 73 to 84 
show the variation in urinary aMT6s excretion rate over 24h for each ICU patient studied.
The studies on healthy volunteers in Chapter 4 showed that the urinary aMT6s excretion 
pattern is diurnal with increased urinary aMT6s excretion occurring during the subjective 
night with a mean acrophase time o f 04:22h (± SEM 9 min).
Comparison of the mean mesor and amplitude values o f ICU patients with those from 
healthy volunteers, showed that both were reduced in the ICU patients (table 27).
Rhythm Parameter Healthy Volunteers (n = 14) ICU Patients (n = 6)
Mean mesor 0.73 0.48
Mean amplitude 0.95 0.31
Table 27. Table to show the mean mesor and amplitudes for healthy volunteers and 
ICU patients with significant cosine rhythms (p < 0.001).
The ICU patients showed a number of variations in urinary aMT6s excretion rhythm that 
could be broadly categorised into 4  groups: -
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a. Normal rhythmicity
Two patients had an apparently normal pattern of urinary aMT6s excretion. Subjects R3 
and R7 (figures 75 and 79), produced urinary aMT6s with diurnal rhythms that were 
maximal during the subjective night and low during the daylight hours. Cosinor analysis 
of the rhythms showed that the pattern o f urinary aMT6s excretion had a significant fit to 
a cosine curve (pcO.OOl) and the acrophase time corresponded to that o f the healthy 
controls studied here (mean 04:22h ±SD 00:35, n=14) and laboratory values (mean 
04:36h ±SD 01:24, n=130) at 03:42h for subject R3 and 04:36h for subject R7 (table 28).
b. Apparent phase shifting
i
! 4 patients had a diurnal pattern o f  excretion o f  urinary aMT6s, but the time o f  peak 
production appeared to be phase shifted (patients R2, R4, R5, and R22). Cosinor analysis 
showed a significant fit to a cosine curve (pcO.OOl), but the acrophase time was shifted 
by more than twice the standard deviation o f  acrophase times seen in healthy subjects 
(mean 04:36h ±SD 01:24, n=130) (table 28). With just one 24h period studied, the 
direction o f  shift could not be ascertained.
6. Gross abnormalities
Two subjects (R l and R20) displayed urinary aMT6s excretion rhythms that had no 
discernible rhythm which were characterised by the presence o f a number o f ‘spikes’ in 
urinary aMT6s excretion throughout the 24h study period. These are shown in figures 73 
and 82.
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S u b je c t M e so r  A m p litu d e  0  % R
(p g /h r) ( |ig /h r ) (h o u rs)
R l 1.02 0.03 03:36 0.53 NS
R2 0.48 0.49 08:48 59.71 **
R3 0.31 0.23 03:42 60.28 **
R4 0.66 0.32 00:12 61 .60**
R5 0.69 0.44 10:42 53.81**
R6 0.29 0.13 07:42 32.34 n s
R7 0.50 0.30 04:36 58.87 **
R8 0.23 0.05 23:24 13.04 n s
R9 0.24 0.07 01:12 32.42NS
R20 0.40 0.08 08:42 3.13 ns
R21 0.08 0.04 01:30 24.64 n s
R22 0.23 0.10 23:06 83.02**
Table 28. Table to show the mesor, amplitude, acrophase time ((j>) and percentage
rhythm (%R) derived from cosinor analysis with a period o f 24h for 
urinary aMT6s excretion rate in ICU patients (n = 12). ***’ denotes 
significant rhythms ( p<0.001 ) and NS denotes non-significant rhythms.
A  level o f  significance o f  p= or <0.0001 was used in order to ensure that 
the detection o f  a significant rhythm by cosinor analysis was more 
stringent
284
Three ICU subjects appeared to have no discernible rhythm due to apparent suppression 
of the rhythm (subjects R6, R8 and R21), although a peak was observed at approximately 
the correct time in subject R6. Cosinor analysis confirmed these observations.
A light-dark cycle was not observed at all bed spaces during the periods o f study. 
Patients R4, R7, R20 and R22 either had very short periods when light intensity was less 
than 10 lux or no such period. Bright light o f between 200 and lOOOlux was recorded at 
5 bed areas in the early morning (patients R2, R3, R4, R8 and R9), which would be o f  
sufficient intensity to phase shift urinary aMT6s rhythms. There appeared to be no link 
between the lighting conditions and presence or absence o f a significant urinary aMT6s 
excretion rate. A ll the patients with significant rhythms (normal or phase shifted) were in 
rooms with a clear light-dark cycle, with night time light intensity <10 lux. However 
subjects R l, R8, R9 and R21 had very abnormal rhythms although they too had a distinct 
light-dark cycle at their bed areas.
5.3.3. Investigation of circadian rhythms in critically ill patients using urinary aMT6s 
and core body temperature as circadian rhythm markers o f the endogenous clock
Figures 85 to 95 show the variation in urinary aMT6s excretion rate and core body 
temperature in ICU patients when both were measured simultaneously.
d. Rhythm suppression
The urinary aMT6s excretion data showed similar results to the previous investigation.
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2 96
Three ICU patients (R17, R19 and R23) had diurnal patterns o f urinary aMT6 excretion 
that had a significant fit to a cosine curve (pcO.OOl) with an acrophase peak time of  
approximately 04:00h. A further 2 patients showed significant cosine rhythms for 
urinary aMT6s excretion rate, but the acrophase time occurred at a later time. For patient 
RIO, the acrophase time was at 08:00h, whilst for patient R l 1 the acrophase occurred at 
10:12h. The remaining patients did not have significant cosinor rhythms, either as a 
result of gross abnormalities in urinary aMT6s excretion rate associated with sharp peaks 
in urinary aMT6s excretion (patients R13 and R14), or as a result of suppression o f the 
rhythm (patients R12, R15, R16). This data is summarised in table 29.
The variation in CBT showed many abnormalities, particularly as all but patient R17, 
were febrile (CBT >38.0 °c) during the study period. Cosinor analysis o f the CBT  
revealed statistically significant rhythms in three patients (R14, R15 and R16) as shown 
in table 30. However, these patients were febrile and it is therefore highly likely that the 
true CBT rhythm was masked.
Light intensity was low (<200 lux) for most o f the day at each bed area, with only 4  
patients being exposed to intensities o f > 200 lux during the day (R15, R18, R19 and 
R23). However this did not relate to the presence of a significant rhythm as subjects R15, 
R18 and R23 had abnormal rhythms. A ll the bed areas had diurnal light-dark cycles 
although daytime light intensity was <2001ux and yet normal or phase shifted rhythms 
were observed at some of these bed areas (subjects R10, R l l ,  R17) and abnormal 
rhythms were observed at others (R12, R13, R14, R16).
2 9 7
Subject Mesor Amplitude 0 %R
(pg/hr) (pg/hr) (hours)
RIO 0.25 0.24 08:00 61.15 **
R l l  0.52 0.52 10:12 70 .70**
R12 0.15 0.03 18:54 10 .31 ns
R13 0.39 0.07 03:24 7.04 ns
R14 2.19 0.80 06:00 20.74 ns
R15 0.20 0.07 10:18 47.41 NS
R16 0.14 0.02 02:42 14.22 ns
R17 0.13 0.13 04:54 70 .62**
R18 0.18 0.07 07:36 49.49 NS
R19 0.25 0.17 04:18 51.71 **
R23 0.50 0.30 04:36 58.87 **
Table 29. Table to show the mesor, amplitude, acrophase time (0) and percentage
rhythm (%R) derived from cosinor analysis with a period o f 24h for 
urinary aMT6s excretion rate" in ICU patients (n = 11). ***’ denotes 
significant rhythms (p < 0.001) and NS denotes non-significant rhythms.
29 8
Subject Mesor Amplitude <J> %R
(°c) (°c) (hours)
RIO 37.89 0.10 10:30 3.86 ns
R l l  36.70 0.15 16:34 30.17 ns
R12 38.84 0.11 19:54 17.26 NS
R13 37.91 0.17 01:32 23.05 ns
R14 37.99 0.64 01:10 88.40**
R15 38.28 0.43 21:36 54.67 **
R16 37.67 0.32 22:24 56.02 **
R17 " 37.39 0.13 19:24 44:57 NS
R18 37.94 0.21 05:22 24.73 NS
R19 38.39 0.19 05:08 27.99 ns
R23 38.58 0.29 02:38 23.35 NS
Table 30. Table to show the mesor, amplitude, acrophase time (<j>) and percentage 
rhythm (%R) derived from cosinor analysis with a period of 24h for core 
body temperature in ICU patients (n = 11). ***’ denotes significant
rhythms (p < 0.001) and NS denotes non-significant rhythms.
2 9 9
5.3.4. Investigation into phase shifting o f circadian rhythms in critically ill patients 
using urinary aMT6s excretion and core body temperature as circadian rhythm 
markers o f the endogenous pacemaker
Figures 96 to 105 show the variation in urinary aMT6s excretion rate and, where 
measured, variation in core body temperature for patients studied at weekly intervals.
5 patients showed significant improvements in the pattern o f urinary aMT6s excretion 
rate from grossly abnormal or suppressed rhythms to clear diurnal rhythms with an 
apparent acrophase time that was either near normal (R l, R8 and R18) or phase shifted 
(R15 and R19).
Table 31 shows the changes in mesor and amplitude and Table 32 shows the change in 
acrophase time, p-value and percentage rhythm for the urinary aMT6s excretion rate 
rhythm on each o f the study weeks. On the second and fourth weeks, five patients 
showed an increase in amplitude and went on to survive ICU (R l, R8, R18, R19 and 
R20). The amplitude in patient R15 also improved and clinically at the time of study, the 
patient was improving in health. H owever, this patient suddenly developed a 
pneumothorax and died from that, rather than the pancreatitis that brought them to ICU 
admission. Patients R l l  and R14 showed a decrease in amplitude from values that were 
higher than the other patients. They also survived ICU. A ll but one patient (R12) 
showed an improvement in the p-value o f the rhythm suggesting improvements in the 
rhythm characteristics. Patient R12 died from the disease with which they presented in 
ICU.
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Figure 96 . Graphs to show urinary a M T 6 s  excretion rates on a. w eek one and b. w eek 2 fo r subject R l .
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Figure 97. Graphs to show urinary aM T6s excretion rates on a. week one and b. week 2 for subject R6
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Figure 98. Graphs to show urinary aMT6s excretion rates on a. week one and b. week 2 for subject R8
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Figure 99. Graphs to show urinary aMT6s excretion rates on a. week one and b. week 2 for subject Rl 1
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Figure 100. Graphs to show urinary aM T6s excretion rates on a. week one and b. week two for subject R12
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Figure 102. Graphs to show urinary a M T 6 s  excretion rates on a. w eek one, b. w eek tw o  and c. w eek
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R l 1.02 0.03 0.22 0.25
R6 0.29 0.13 0.29 0.13
R8 0.23 0.05 0.29 0.26
R l l 0.52 0.52 0.62 0.43
R12 0.15 0.03 0.09 0.01
R14 2.19 0.80 5.34 0.31 0.64 0.31
R15 0.20 0.07 2.42 0.35 0.34 0.42
R18 0.18 0.07
):iY
'10
m
QYi
-v.ii
life
n
0.17 0.13
R19 0.25 0.17 0.85 0.77
R20 0.40 0.08 0.26 0.21
Table 31. Summary o f the mesor (M) and amplitude (A) derived from cosinor 
analysis of urinary aMT6s excretion rhythms of ICU patients studied on 2 
or 3 study days at weekly or 2 weekly intervals.
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p-val %R
R1 3.6 0.94 0.5 3.2 0.0001 76.6
R6 2.1 0.35 9.6 7.7 0.01 6.5
R8 23.4 0.23 13.0 5.2 0.007 37.6
Rll 10.2 0.0001 70.7 9.0 0.0002 54.6
R12 18.9 0.32 10.3 10.8 0.85 1.5
R14 6.0 0.09 20.7
|L%
1 
'■if 7
12.6 0.90 1.04 3.3 0.009 36.0
R15 10.3 0.001 47.4 9.9 0.045 25.6 14.7 0.0001 64.6
R18 7.6 0.0008 49.5 4.0 0.0001 66.8
R19 4.3 0.0005 51.7 4.0 0.0003 54.58
R20 8.7 0.72 3.1 6.8 0.0001 62.6
Table 32. Summary o f the acrophase time (0), p-value and percentage rhythm (%R) derived 
from cosinor analysis o f urinary aMT6s excretion rhythms of ICU patients studied 
on 2 or 3 study days at weekly or 2 weekly intervals.
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On consecutive study days, the patients appeared to be exposed to the same or similar 
changes in average light intensity. Major differences in the light intensity were that 
subject R15 had a shorter dark period (<10 lux) on the second study week, patient R18 
had a longer dark period on the second week and patient R20 had no dark period on week  
one of study. Urinary aMT6s excretion rhythms appeared to improve in these patients 
when exposed to a longer period of light <10 lux, but it is unlikely that the improvements 
seen were solely due to this.
5.3.5. A  comparative study o f plasma melatonin levels from arterial and venous blood 
samples
Plasma melatonin concentrations in arterial and venous samples were similar as shown in
figure 106. However further statistical analysis o f  the data comparing arterial and venous
plasma melatonin concentrations were not carried out, as meaningful conclusions could
not be drawn from a sample size as small as n=5. Furthermore, although paired samples
were taken at different times o f  the day, the number o f  samples taken were insufficient to
/
provide detailed information about the influence circadian changes on arterial and venous 
plasma melatonin concentrations.
5.3.6. Investigation o f circadian rhythms in critically ill patients using plasma 
melatonin, urinary aMT6s and core body temperature as circadian rhythm  
markers of the endogenous clock
The variation in plasma melatonin concentration and urinary aMT6s excretion rate over 
24h are shown in figures 107a to 115a. Urinary aMT6s excretion rates varied with 
rhythm characteristics observed in the previous investigations. Four patients had 
significant rhythms with cosinor analysis (p<0.001) and of these, patient R30 appeared to 
have a normal diumal pattern of urinary aMT6s excretion rate with an acrophase
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Figure 106. Graph to show arterial plasma melatonin concentration compared w ith venous 
plasma melatonin concentration for samples taken simultaneously from ICU 
patients (n = 5).
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Figure 107. Graphs to show the variation in a. urinary aM T6s excretion rate and plasma melatonin
concentration and b. plasma melatonin concentration and core body temperature over 24  hours fo r subject
R24.
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Figure 108. Graph to show the variation in a. urinary aMT6s excretion rate and plasma melatonin 
concentration and b. plasma melatonin concentration and core nody temperature over 24 hours for subject 
R25.
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Figure 109. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration and
b. plasma melatonin concentration and core body temperature over 24 hours for subject R26.
317
a.
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00
Time of Day (hours)
b.
- Plasma Melatonin Concentration pg/ml
- Urinary aMT6s Concentration ug/hr
LIGHT INTENSITY
I
|
■
□
10 lux or less
11 to 199 lux
200 to 499 lux
500 to 999 lux
>1000 lux
- Plasma Melatonin Concentration pg/ml
- Core Body Temperature oC______
■a 35
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00
Time of Day (hours)
Figure 110. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration and
b. plasma melatonin concentration and core body temperature over 24 hours for subject R27.
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Figure 111. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration and
b. plasma melatonin concentration and core body temperature over 24 hours for subject R28.
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Figure 112. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration 
and b. plasma melatonin concentration and core body temperature over 24 hours for subject R29.
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Figure 113. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration 
and b. plasma melatonin concentration and core body temperature over 24 hours for subject R30.
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Figure 114. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration and
b. plasma melatonin concentration and core body temperature over 24 hours for subject R 31.
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Figure 115. Graphs to show the variation in a. urinary aMT6s excretion rate and plasma melatonin concentration
and b. plasma melatonin concentration and core body temperature over 24 hours for subject R32.
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time o f 03:42h, whilst the rhythms o f excretion rate in patients R26, R27 and R29 were 
phase shifted (table 33). The remaining five patients showed no evidence o f a significant 
rhythm and either had significantly deranged excretory patterns (R24, R28) or suppressed 
levels o f excretion (R25, R31, R32).
Cosinor analysis o f  the plasma melatonin data showed that five o f  the patients had 
significant rhythms (table 34). Three o f  the patients (R26, R29 and R30) had significant 
rhythmic patterns for both urinary aMT6s excretion rate and plasma melatonin. Patient 
R27 had a significant rhythm for plasma melatonin with cosinor analysis, but using the 
more stringent p-value o f  <0.001, the rhythm parameters fell short o f  this cut-off point as 
the p-value was 0.002. The analysis is most likely to have been affected by the high 
baseline values between 12:00h and 19:00h.
Two patients had no significant rhythm in urinary aMT6s excretion rate but did have 
significant rhythms in plasma melatonin (R24 and R28). This suggests that some factor 
interferes either with the metabolism o f  melatonin or with the urinary aMT6s assay itself, 
resulting in the abnormal urinary aMT6s excretion patterns observed in these patients. 
However the fact that not all the patients had diurnal patterns o f  plasma melatonin 
concentration indicates that there are many factors that affect both urinary aMT6s 
excretion rate and plasma melatonin concentration. Four patients had significant cosine 
rhythms for core body temperature (table 35), but most o f  the patients were febrile (CBT 
> 38°c) and this is likely to have masked the true rhythms.
3 2 4
Subject Mesor Amplitude <|> %R
(jig/hr) (|lg/hr) (hours)
R24 1.41 0.53 15:36 37.64 ns
R25 0.06 0.01 00:30 3.72 NS
R26 0.44 0.34 05:48 65.45 **
R27 0.24 0.22 06:12 70 .04**
R28 2.76 0.55 22:24 19.95 NS
R29 1.59 1.98 06:30 64 .72**
R30 0.38 0.28 03:42 76.03 **
R31 0.15 0.02 22:54 7.87NS
R32 0.25 0.08 08:42 23.91 NS
Table 33. Table to show the mesor, amplitude, acrophase time (<j)) and percentage
rhythm (%R) derived from cosinor analysis with a period of 24h for 
urinary aMT6s excretion rate in ICU patients (n = 9). ***’ denotes
significant rhythms (p < 0.001) and NS denotes non-significant rhythms.
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Subject Mesor Amplitude <(> %R
(pg/ml) (pg/ml) (hours)
R24 14.33 7.86 04:23 84.85 **
R25 14.33 3.93 04:49 39.25 NS
R26 17.10 16.22 01:50 86.52 **
R27 14.17 7.52 01:13 42.83 NS
R28 32.43 13.07 00:50 54.58 **
R29 16.58 17.88 03:35 71.93 **
R30 11.75 9.30 02:19 73 .35**
R31 7.40 1.08 00:36 12.24 n s
R32 6.68 1.27 02:03 26.36 n s
Table 34. Table to show the mesor, amplitude, acrophase time (<|)) and percentage
rhythm (%R) derived from cosinor analysis with a period o f 24h for 
plasma melatonin concentration in ICU patients (n = 9). ***’ denotes 
significant rhythms (p < 0.001) and NS denotes non-significant rhythms.
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S u b je c t M e so r  A m p litu d e  (j) %R
(°c) (°c) (h o u rs)
R24 37.30 0.22 00:52 25.75 NS
R25 38.14 0.17 22:24 44.51 NS
R26 38.73 0.22 04:41 20.78 NS
R27 37.45 0.23 16:27 72.74 **
R28 37.83 0.19 22:21 12.13 n s
R29 37.07 0.14 04:39 14.91 NS
R30 38.02 0.44 20:26 49.40 **
R31 37.58 0.14 19:31 58 .82**
R32 37.91 0.35 02:10 62.81 **
Table 35. Table to show the mesor, amplitude, acrophase time (<])) and percentage
rhythm (%R) derived from cosinor analysis with a period o f 24h for core 
body temperature in ICU patients (n = 9). **** denotes significant
rhythms (p <  0.001) and NS denotes non-significant rhythms.
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5.4.1. Age comparisons
Figure 116 illustrates the age distribution o f the ICU patients compared to that o f the 
healthy volunteer control group and the in-house laboratory age-range. Many patients in 
the ICU group were older, but when the data was analysed by the unpaired Student t test, 
there was no significant difference between the mean age o f the ICU patient group and 
the mean ages o f the laboratory or study control groups.
5.4.2. Total 24 urinary aMT6s excretion and total plasma concentration comparisons 
Figures 117 and 118 show the total plasma melatonin produced per 24 hours and urinary 
aMT6s per 24 hours respectively in the healthy controls compared to ICU patients and in 
house laboratory ranges. Analysis of the data by the unpaired Students’ t test showed no 
difference in the means o f total plasma melatonin produced and total urinary aMT6s 
excreted per 24 hours.
5.4.3. The influence o f windows on normal rhythms
It is possible that the presence or absence o f windows by a bed area may be related to the 
presence or absence o f normal rhythms. Only 8 patients out o f 32 were treated in bed 
areas without windows. Figure 119 shows how many patients treated in bed areas 
without windows had the rhythm abnormalities defined in 5.3.2. The graph shows that 
six o f the eight patients treated at bed areas without windows had rhythm abnormalities, 
which suggests a possible link. However the total number of patients is too small to
5.4. Data Analysis
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draw any firm conclusions. Furthermore, there were more patients with no rhythms at 
bed areas with windows than without.
5.5. D iscussion
The results presented here provide substantial evidence to suggest that circadian rhythms 
in critically ill patients are abnormal and can be phase shifted.
5.5.1. Core Body Temperature
The retrospective CBT data indicated that circadian rhythms in ICU patients were 
abnormal. Significant 24h rhythms were detected on some patient days in ICU, but not 
all the days. There were also many abnormalities in the daily acrophase time.
These findings are similar to those o f Tweedie et al, who found significant 24h rhythms 
in 80% of the days studied (Tweedie et al, 1989), who were able to quantify the 
abnormalities to some extent. Abnormal patterns in timing of the CBT rhythm acrophase 
were classified as follows: -
Type 1: Day by day shifts in acrophase about a stable mean value
Type 2: Day by day shifts o f acrophase about a mean value that appears to
become later or earlier 
Type 3: Large swings o f acrophase suggesting both types o f behaviour
shown in type 1.
Type 4: Behaviour showing characteristics of more than one of the above.
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However this study picked up significant rhythms on only 49.5% o f the patient days 
studied compared to 80% in Tweedie's study. This may be a reflection o f the degree o f  
illness o f the patients looked at in this study. It is possible that the patients here were 
more sick. Many of the patients had very high temperatures and in some cases very low  
temperatures and some were also artificially warmed with the aid o f space blankets or 
placed on air fluidised beds. Tweedie’s study also showed that the mean amplitudes o f  
CBT in their patients were normal (median 0.41°c, ranging from 0.28°c to 0.5 l°c), 
suggesting few incidences o f fever or mild hypothermia. This study had higher values 
for the CBT amplitude (median 0.57°c, ranging from 0.18°c to 0.86°c), again suggesting 
sicker patients.
It is possible that the data presented here was heavily masked by factors such as fever, 
use of paracetamol and space blankets thus and accounted for the decreased incidence of 
significant cosine rhythms. The analysis may also have been influenced by the 
completeness o f core body temperature data on the nursing charts. An expected practice 
in the Royal Free Hospital ICU was to take hourly observations and record these on the 
nursing charts. However this study found that this was not rigidly adhered to (possibly 
because nurses were attending to the physical and medical needs of the patient) and CBT 
readings were not always recorded resulting in large gaps o f data as shown in subjects 
T l, T7, T8 and T i l .  In some cases, the readings also varied between axilla temperature 
and core body temperature on the same day and therefore data could not be used as these 
are different measurements.
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The prospective measurement o f CBT allowed for the reliable collection o f CBT data, 
and the results from these studies confirmed that the CBT rhythms were abnormal as 
peak temperatures did not always occur during the late afternoon as in healthy subjects. 
In all cases however, the patients had high CBT readings (>38°c) at some point during 
the study periods due to fever associated with infection. All patients were being treated 
with at least one antibiotic or antifungal drug on the study days. Paracetamol ( lg  dose) 
was used to reduce high temperatures in one third o f the patients. Other factors that 
would have influenced CBT include the use o f space blankets and air fluidised beds.
In the ICU setting the measurement o f CBT using rectal access has further drawbacks in 
that it is influenced by bouts o f diarrhoea. Diarrhoea causes rectal probes to fall out. 
Care was taken to ensure that patients with diarrhoea were not included in the study but 
some patients may have had episodic bouts that may have influenced CBT readings.
In conclusion the use o f CBT (retrospective and prospective) as a marker of circadian 
rhythms in critically ill patients does give an indication as to the rhythmicity o f the 
patient but cannot be considered as reliable due the many possible masking influences 
present in ICU.
5.5.2. Urinary aMT6s excretion rate
The use of urinary aMT6s excretion as a marker of circadian rhythms in the critically ill 
is ideal from a practical view  point, because o f the ease o f sample collection in the
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majority o f patients. M ost patients have urinary catheters in situ, which empty into 
catheter bags and allow for frequent sampling.
The urinary aMT6s excretion data in this study detected rhythmic activity in urinary 
aMT6s excretion and allowed for the identification of four patterns o f excretion rate over 
24h: normal rhythmicity, phase shifted rhythms, abnormal with frequent fluctuations and 
abnormal but arrhythmic. These findings are contrary to those o f Shilo et al, who found 
that urinary aMT6s rhythms were suppressed in the majority of their ICU patients using 
3h urine collections (Shilo et al, 1999).
The study measuring urinary aMT6s excretion rate on two or three occasions at weekly 
intervals strengthened the argument for phase shifting o f circadian rhythms in ICU 
patients but also showed that changes associated with the normalisation of rhythmicity 
occurred. Evidence for the latter came from the increase in amplitude o f some rhythms 
and the development o f significant diurnal changes in rhythms from grossly abnormal 
patterns o f urinary aMT6s excretion in other patients.
These findings suggest that there may be a progressive change in the circadian 
rhythmicity o f urinary aMT6s excretion in critically ill patients from a picture o f poor 
rhythm (gross fluctuations or no rhythm) to a diurnal pattern but phase shifted and finally 
to a normal pattern of excretion. Such a progression and any correlation of these stages 
with the improvement in health o f ICU patients might be picked up by comparing the 
incidence o f these stages with ICU outcome indices such as the APACHE II (acute
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physiology and chronic health evaluation) scoring. There may also be a correlation with 
the degree o f sedation that may be found by correlation with Glasgow coma scoring. 
These are both investigated in Chapter 8.
The measurement of urinary aMT6s excretion rate in ICU patients is not however 
without its drawbacks. The grossly abnormal patterns o f urinary aMT6s excretion 
observed in some subjects are very likely to be the result o f drug interference either with 
the urinary aMT6s assay or with the metabolism of melatonin to aMT6s.
The pineal gland is stimulated by adrenaline and noradrenaline via a  and p receptors
(Klein et al, 1992), thus stimulating melatonin production. Patients treated with 
exogenous forms o f these catecholamines were therefore excluded from the study. 
However it was difficult to recruit patients that were free from dopamine. Dopamine is a 
precursor o f both noradrenaline and adrenaline and therefore could have a similar effect 
on melatonin production. Exogenous dopamine is commonly used in ICU at low doses 
(l-5|ig/kg/m in) to maintain renal output by increasing renal blood flow (Goldberg, 1974)
but it also has been shown to have a direct diuretic effect on renal tubules (Duke and 
Bersten, 1992). Therefore exogenous dopamine could affect urinary aMT6e excretion in 
a number of ways.
Many patients are treated in ICU with benzodiazepines such as midazolam for analgesia 
and sedation or lorazepam and temazepam for their hypnotic and sleep promoting
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effects. Studies have shown that benzodiazepines influence the circadian pacemaker by 
suppressing melatonin production (McIntyre, 1988) and in hamsters, induced phase 
advances and delays depending on the time o f  administration (Ralph and Menaker, 1986).
The interaction o f  the drugs used in ICU with the metabolism o f  melatonin has not been 
thoroughly investigated and it is possible that the abnormal fluctuations observed were 
due to the influence o f  the drugs on melatonin metabolism. Propofol is a widely used 
anaesthetic agent used in ICU and has been shown to inhibit the cytochrome P450 
isozym es CYP1A1, as well as CYP2B1 and CYP2E1 (Chen et al, 1995). The CYP1A  
subfamily is believed to be involved in the metabolism o f  melatonin (Yeleswaram et al, 
1999). The possibility that the grossly abnormal rhythms observed in this study were 
caused by drug interference could be tested by determining the incidence with which 
such rhythms appear with individual drugs. This test was not carried out because all the 
ICU patients studied here were on several drugs at one time and such a test would not 
therefore be able to accurately pinpoint individual drugs that cause the gross 
abnormalities seen. Another method o f  testing the link between grossly abnormal urinary 
aMT6s excretion patterns and individual drugs would be to treated individuals with only 
one drug and observe the effect on urinary aMT6s levels over 24 hours. Such a test 
would however be impossible to carry out in ICU patients because o f  the severity o f  
illness o f  this patient population.
Urinary aMt6s excretion rhythms may also be influenced by renal function .o f  ICU 
patients, which may be a result o f  drug action on renal function or renal disease. The 
influence o f  renal function on urinary aMT6s excretion rate is the subject o f  Chapter 7.
3 38
The present study was the first to use plasma melatonin as a marker o f  circadian rhythms 
in critically ill patients. In 7 out o f  9 patients studied, a diurnal pattern o f  melatonin 
concentration was observed, although cosinor analysis showed that only 5 were 
significant. In these 5 patients plasma melatonin rhythms were either phase shifted or 
normal.
Again, plasma melatonin levels will have been influenced by the drugs used in ICU such 
as the benzodiazepines and catecholamines, in the same was as for urinary aMT6s 
excretion.
O f particular importance was the observation that a normal diurnal plasma melatonin 
profile was shown, in the presence o f  a grossly abnormal pattern o f  urinary aMT6s 
excretion rate. This observation strengthens the argument that urinary aMT6s excretion 
is influenced by other factors and suggests that in the ICU population, plasma melatonin 
is a more reliable marker o f  the endogenous pacemaker than either urinary aMT6s 
excretion or CBT.
5.5.3. Plasma melatonin
3 3 9
CHAPTER 6 INVESTIGATION OF CORTISOL, PROLACTIN AND 
THYROID STIMULATING HORMONE CIRCADIAN  
RHYTHMICITY IN CRITICALLY ILL PATIENTS
6.1. Introduction
Many hormones have characteristic 24-hour patterns o f secretion, with temporal 
relationships to the time of day and the sleep-wake cycle in human subjects. These 
include the adrenal hormone, cortisol, and the pituitary hormones, prolactin (PRL) and 
thyroid stimulating hormone (TSH).
In healthy subjects with a normal sleep-wake cycle (nocturnal sleep), cortisol, under the 
control o f adrenocorticotrophic hormone (ACTH) is secreted in a circadian pattern with 
peak plasma cortisol concentrations in the early morning between 06:00h and 08:00h and 
trough levels occurring around midnight (Krieger et al, 1971). Cortisol secretion is thus 
related to the light-dark cycle. Czeisler et al showed that if  the sleep-wake schedule 
remains constant and bright light is given in the early evening between 19:40h and 
23:40h, the circadian rhythm of plasma cortisol concentration also shifts (Czeisler et al, 
1986). TSH secretion is pulsatile but is also circadian with a significant increase in 
concentration in the early morning (Greenspan 1986). Prolactin release is also pulsatile, 
with both sleep and circadian components that cause plasma prolactin levels to rise at 
night (Sassin, 1972). This nocturnal rise is more strongly associated with sleep  
(Sassin,1973) than with the endogenous pacemaker.
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It has been suggested that the pineal gland influences pituitary function in humans 
(Wetterberg, 1983) possibly through a decrease in dopaminergic activity at night brought 
about by increased melatonin secretion (Rao and Mager, 1987). Melatonin receptors 
have also been identified in the pars tuberalis o f the rat pituitary gland, suggesting  
involvement of the pituitary gland in the mechanism of action of melatonin (Morgan et 
al, 1994; W illiams et al, 1995). Studies investigating the relationship o f exogenous 
melatonin with pituitary and adrenal hormones have produced conflicting results. 
Exogenous melatonin (5mg for 4 days at 17:00h) has been shown to advance cortisol 
circadian rhythms in some studies (Kostoglou-Athanassiou et al) but had no effect in 
others (Wright et al, 1986; Strassman et al, 1988). Similar conflicting findings have 
been observed for prolactin, where 2mg exogenous melatonin given daily at 18:00h over 
2 months had no effect on prolactin circadian rhythms (Terzolo et al, 1990) or phase 
advanced the rhythms using 2mg given at 17:00h (Wright et al, 1986).
It is possible that disturbances in the circadian rhythmicity seen in plasma melatonin and 
urinary aMT6s excretion in the ICU subjects may also be present in the circadian rhythms 
of other hormones, such as cortisol, prolactin and TSH.
The aims of this study were to determine whether the circadian rhythms of cortisol, TSH  
and prolactin are abnormal in critically ill patients and whether there are any temporal 
relationships between the circadian rhythms o f these hormones and that o f plasma 
melatonin.
6.2.1. Cortisol
Hourly blood samples from 14 healthy controls and 9 ICU patients were collected  
following informed consent from them (controls) or their relatives (ICU patients) as 
described in detail in 2.5.2. Details o f the ICU subjects are summarised in table 36. A  
detailed background o f the ICU patients is given in 2.2.2. Plasma cortisol levels were 
measured using a radioimmunoassay method as described in 2.6.4.
6.2.2. Prolactin and TSH
Plasma prolactin and TSH levels were measured in 14 healthy controls and 4 ICU 
patients using the Enzymun-Test® System  on the ES 300 AL instrument (Roche 
Diagnostics Boehringer Mannheim GmbH, Mannheim, Germany) at St Peters Hospital, 
Chertsey, Surrey, as described in detail in 2.6.5.
6.3. Results
6.3.1. Control Subjects
Figures 120, 121 and 122 show the mean variation in hourly plasma cortisol, plasma 
prolactin and plasma TSH over 24 hours. Clear diurnal variations were observed in the 
rhythms of plasma cortisol and plasma TSH. Plasma cortisol levels decreased at night 
and then rose during the early morning, reaching peak levels at between 08:00h and 
10:00h. Plasma TSH increased in the early evening reaching peak levels in the early 
morning between 01:00h and 04:00h. The pattern of plasma prolactin variation was less
6.2. Materials and Methods
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SUBJECT AGE SEX REASON FOR BED NUMBER OUTCOME
IC U  ADM ISSION IC U
R24 72 M Respiratory and cardiac 7
failure
Survived **
R25 76 M Post oversewing of
duodenal ulcer
Survived **
R26 49 F Tuberculosis 11 Died
R27 66 M Faecal peritonitis Died **
R28 65 F Respiratory failure Survived
R29 33 F Respiratory failure
post overdose
Survived
R30 23 M Post surgery for 
stab wounds
10 Survived
R31 29 M Cerebral abscess Survived
R32 69 M Post gastrointestinal 
surgery
10 Survived
Table 36. Details o f the ICU subjects studied to investigate the nature o f the 
circadian rhythms of plasma cortisol, plasma prolactin and plasma TSH in 
critically ill patients. **** indicates those subjects in which plasma 
prolactin and plasma TSH were measured.
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w ell defined although higher levels were observed at night. The mean prolactin levels 
were influenced by the unusually high concentrations of subject C8.
These rhythm characteristics were clarified by cosinor analysis o f the hormone rhythms, 
the results o f which are shown in tables 37, 38 and 39. Twelve o f the fourteen control 
subjects had plasma cortisol rhythms that had significant fits to a cosine curve at a 
significance level o f p<0.001. The mean acrophase time o f the cortisol rhythm occurred 
at 09:42h (±SEM =21 minutes). All subjects had significant cosine rhythms with respect 
to plasma TSH variation with a mean acrophase at 03:56h (±SEM = 20 minutes). In 
comparison, only four o f the control subjects had significant cosine fits for the plasma 
prolactin rhythm.
6.3.2. ICU patients
Figures 123 to 131 show the variation in plasma cortisol levels over 24 hours, for the ICU 
subjects, compared to the mean plasma cortisol levels of healthy subjects. Table 40 
shows the mesor, amplitude, acrophase time and percentage rhythm derived from the 
analysis of the ICU patient cortisol rhythms by cosinor analysis. In all but one subject, 
the rhythmic variation o f plasma cortisol concentration appeared abnormal, as there was 
no evidence of clear diurnal variation. Only one ICU patient, R29, had a plasma cortisol 
rhythm which showed a significant fit to a cosine curve and an acrophase time that 
occurred at approximately the same time as control subjects. Patient R31 appeared to 
have a normal rhythm, but the sharp spike at 20:00h influenced cosinor analysis of the
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SUBJECT M
(mIU/1)
A
(mIU/1)
♦
(hours)
%R
C l 235 137 06:18 41.9 n s
C2 269 217 03:53 32.9 NS
C3 179 28 01:39 3.6 NS
C4 362 135 23:44 46.5 NS
C5 336 60 06:51 22.8 NS
C6 251 262 04:26 66.7 **
C l 338 95 03:38 33.1 NS
C8 1459 464 00:45 28.0 NS
C9 251 91 02:24 35.1 NS
CIO 199 106 03:37 60.3 **
C l l 242 55 01:50 17.8 NS
C12 111 54 23:27 57.5 **
C13 143 92 04:45 63.0 **
C14 231 43 04:12 10.8 NS
Mean 176 128 09:03 61.8
SEM 30.9 45.8 04:48 1.96
Table 37. Table to show the mesor (M), amplitude (A), acrophase time ((j)) and
percentage rhythm derived from cosinor analysis o f plasma prolactin 
rhythms in healthy control subjects. **** indicates rhythms with a 
significant fit to a cosine curve at a level o f p < 0.001 and NS indicates 
rhythms with no significant fit. The mean and SEM values are calculated 
from the rhythms that showed a significant fit (n = 4).
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SUBJECT M
(nmol/I)
A
(nmol/1)
$
(hours)
%R
C l 349 163 13:09 45.2 NS
C2 397 174 09:34 63.7 **
C3 233 159 11:33 58.9 **
C4 347 186 08:15 63.2 **
C5 150 88 08:56 63.9 **
C6 345 286 10:37 89.4 **
C l 196 151 10:33 68.1 **
C8 315 240 10:18 86.9 **
C9 233 114 09:54 21.4NS
CIO 224 179 09:20 50.6 **
C l l 175 144 06:57 65.7 **
C12 185 160 09:32 78.1 **
C13 230 205 10:51 62.6 **
C14 160 123 10:08 62.0 **
Mean 246 175 09:42 67.7
SEM 24.0 15.0 00:21 3.29
Table 38. Table to show the mesor (M), amplitude (A), acrophase time (0) and 
percentage rhythm derived from cosinor analysis o f plasma cortisol 
rhythms in healthy control subjects. ***' indicates rhythms with a 
significant fit to a cosine curve at a level o f p <  0.001 and NS indicates 
rhythms with no significant fit. The mean and SEM values are calculated 
from the rhythms that showed a significant fit (n = 12).
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SUBJECT M
(mU/1)
A
(mU/1)
$
(hours)
%R
C l 2.67 1.13 05:51 73.9 **
C2 1.70 0.95 03:39 94.4 **
C3 2.30 1.35 04:15 90.7 **
C4 2.04 1.15 02:00 90.4 **
C5 3.41 1.26 04:00 80.8 **
C6 1.36 0.69 05:14 83.9 **
C l 2.19 0.84 03:15 89.1 **
C8 2.97 1.04 02:33 64.5 **
C9 1.61 0.35 05:35 50.2 **
CIO 2.56 1.04 03:08 91.6 **
C l l 1.79 0.58 02:21 84.0 **
C12 3.12 1.23 02:58 94.8 **
C13 0.91 0.33 05:20 77.7 **
C14 2.73 1.36 04:57 86.4 **
M ean 2.24 0.95 03:56 82.3
SEM 0.19 0.09 00:20 3.34
Table 39. Table to show the mesor (M), amplitude (A), acrophase time (0) and
percentage rhythm derived from cosinor analysis o f plasma TSH rhythms 
in healthy control subjects. **** indicates rhythms with a significant fit to 
a cosine curve at a level of p <  0.001 and NS indicates rhythms with no 
significant fit. The mean and SEM values are calculated from the rhythms 
that showed a significant fit (n = 14).
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SUBJECT M A 0 %R
(nmol/1) (nmol/1) (hours)
R 2 4 5 6 5 5 9 1 4 : 3 0 2 2 . 8  N S
R 2 5 3 2 4 5 4 0 9 : 3 8 2 3 . 7  N S
R 2 6 5 0 1 1 0 9 0 6 : 0 4 2 4 . 1  N S
R 2 7 8 5 8 1 0 6 1 4 : 2 0 2 . 1 6  N S
R 2 8 3 8 9 4 0 1 5 : 2 0 3 9 . 7  N S
R 2 9 1 4 5 8 3 0 7 : 4 9 4 6 . 8  * *
R 3 0 5 3 2 1 3 0 1 : 4 6 1 . 6 4 N S
R 3 1 2 4 5 5 7 12:02 3 3 . 9  N S
R 3 2 1 0 8 1 6 0 1 4 : 3 8 0 . 3 8  N S
Table 4 0 .  Table to show the mesor (M), amplitude ( A ) ,  acrophase time (< j> )  and 
percentage rhythm derived from cosinor analysis of plasma cortisol 
rhythms in ICU patients. **** indicates rhythms with a significant fit to a 
cosine curve at a level of p <  0 . 0 0 1  and N S  indicates rhythms with no 
significant fit.
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data. In addition two patients had plasma cortisol levels that were particularly high 
(subjects R27 and R32).
The rhythmic variation of plasma prolactin and TSH concentrations are shown in figures 
132 to 135. Table 41 shows the results of cosinor analysis. Again, the rhythmic 
variations of three of the subjects show no clear variations throughout the study day. 
Only subject R26 had significant cosinor rhythms for both hormones, with a clear diurnal 
pattern of production.
Of interest is subject R26 who had similarities in the rhythmic variations of all three 
hormones, particularly the three episodic periods between 22:00h and 12:00h. 
Correlation analysis showed a highly significant correlation between the plasma prolactin 
and plasma TSH rhythms at each time point (r = 0.92, figure 136), but weaker 
correlations were found when the plasma cortisol rhythm was compared to that of plasma 
TSH (r = 0.58) and plasma prolactin (r = 0.61). This is an important observation as TRH 
stimulates prolactin release.
Correlation analysis was also used to determine whether there was any relationship 
between the plasma melatonin rhythms and plasma cortisol, plasma prolactin and plasma 
TSH rhythms at each time point. Weak correlations were found between plasma 
melatonin and plasma TSH for subject R24 (r = 0.55) and subject R26 (r = 0.59).
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a.
Time of Day (hours)
 • Patient R24
— O— Controls
Time of Day (hours)
-•-- Patient R24
— Controls
Figure 132. Graphs to show the variation in a. plasma prolactin concentration and b. plasma TSH
concentration over 24 hours for subject R24 compared to mean variations (±SEM) of the hormones
in controls.
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a.
Time of Day (hours)
 * Patient R25
— o— Controls
Time of Day (hours)
—— ♦-- Patient R25
— ©— Controls
Figure 133. Graphs to show the variation in a. plasma prolactin concentration and b. plasma TSH
concentration over 24 hours for subject R25 compared to the mean variations (±SEM) of the
hormones in controls.
363
a.
900
1000
“I 1------1------ 1-----------1-1-----------1-1----------- 1-1-----------1-1-----------1-1----------- 1-1---------- [-1-----------1-1----------- 1-1------[------1
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00
Time of Day (hours)
 • Patient R26
— O— Controls
b.
— •-- Patient R26
- -9— Controls
I
a
Js
Io
H
03
a
3.5
3.0
2.5
2.0
1.5 
1.0 
0.5 
0.0
12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 10:00 12:00
Time of Day (hours)
Figure 134. Graph to show the variation in a. plasma prolactin concentration and b. plasma TSH
concentration over 24 hours for subject R26 compared to mean variations (±SEM) of the hormones
in controls.
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a.
Time of Day (hours)
 • Patient R27
— O —  Controls
Time of Day (hours)
-#—  Patient R27 
—  Controls
Figure 135. Graphs to show the variation in a. plasma prolactin concentration and b. plasma TSH
concentration over 24 hours for subject R27 compared to mean variations (±SEM) of die hormones
in controls.
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a.
SUBJECT M
(mIU/1)
A
(mIU/1)
♦
(hours)
%R
R24 312 87 11:27 48.0 NS
R25 768 63 23:27 24.4 NS
R26 261 61 05:15 64.5 **
R27 288 61 01:56 32.0 NS
SUBJECT M
(mU/1)
A
(mU/1)
♦
(hours)
%R
R24 0.71 0.16 05:32 32.1 NS
R25 1.63 0.17 14:50 18.9 NS
R26 2.52 0.96 05:02 79.8 **
R27 1.04 0.06 12:51 13.1 NS
Table 41. Tables to show the mesor (M), amplitude (A), acrophase time ((j>) and 
percentage rhythm derived from cosinor analysis of a. plasma prolactin 
rhythms and b. plasma TSH rhythms in ICU patients. **** indicates 
rhythms with a significant fit to a cosine curve at a level of p < 0.001 and 
NS indicates rhythms with no significant fit.
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Plasma prolactin concentration (mIU/1)
Figure 136. Graph to show the correlation between plasma prolactin concentration and plasma TSH 
concentration at each time point (n=25) for subject R26.
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Plasma melatonin levels in the control group peaked six hours ahead of plasma cortisol 
peak. To determine correlations between plasma melatonin and plasma cortisol rhythms 
in the ICU patients, the plasma melatonin data was displaced in time by six hours and 
data was analysed. Using this method, only one patient, R29 showed a positive 
correlation (r = 0.72, p<0.05) between plasma melatonin and plasma cortisol levels 
(figure 137). This patient was the only patient who had a significant rhythm for plasma 
cortisol concentration with cosinor analysis.
Subjects R27 and R32 also showed an interesting feature in that plasma cortisol was 
released in an episodic pattern throughout the day.
6.4. Discussion
Control subjects showed clear diurnal circadian rhythmicity for both plasma cortisol and 
plasma TSH rhythms in most of the subjects studied. This was not the case for plasma 
prolactin, where only four subjects had significant cosine rhythms. The prolactin rhythm 
is thought to be closely associated with sleep. In this study, the control subjects were 
woken up every hour on the hour during the night to produce urine and saliva samples. 
This may have disturbed the normal pattern of production. Furthermore, prolactin 
secretion is known to be pulsatile and it is possible that the hourly collections used in this 
study were too infrequent to detect the rhythmic changes.
Compared to the control subjects, the circadian changes in plasma cortisol, plasma 
prolactin and plasma TSH of the ICU patients appeared to be abnormal in most cases.
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Plasma melatonin concentration (pg/ml)
Figure 137. Graph to show the correlation between plasma melatonin and plasma prolactin 
concentrations at each time point for patient R29, following displacement of the melatonin data by 6 
hours so that peaks coincided.
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is possible that the abnormal rhythms in these hormones are linked to the abnormalities 
seen in plasma melatonin rhythms but the poor correlations between the hormones and 
plasma melatonin suggest that this is not the case.
It is very likely that the abnormal rhythms observed are related to other influences. One 
of these is stress. In the ICU there are a number of sources of stress, which include 
sepsis, pain, hypotension, mechanical ventilation, surgical intervention and therapeutic 
interventions such as physiotherapy. The adrenal gland plays a major role in the 
adaptation to stress, by producing catecholamines, mineralocorticoids and glucocorticoids 
such as cortisol, to help maintain plasma volume, cardiac output, vascular tone and blood 
glucose. Plasma cortisol levels of ICU subjects can increase to two or three times normal 
levels under such circumstances (Felicetta and Sowers, 1987).
The circadian rhythms may also have been affected by the sleep patterns of the ICU 
patients. Many studies have suggested that sleep in ICU patients is poor due to stress, 
noise, and therapeutic interventions (Finlay, 1991; Wood, 1993), with patients having 
disturbed sleep or no sleep. Studies by Opstad on healthy subjects have showed that the 
combination of stress (by exercise), sleep deprivation and low calorie intake over a period 
of five days can result in the abolition of the circadian rhythmicity of a number of 
hormones including plasma TSH and plasma cortisol (Opstad, 1994).
Two patients (R27 and R32) showed episodic patterns of hormone production. It is 
highly likely that these were related to the drugs they were treated with. Both patients
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were being given hydrocortisone (see 2.2.2), which would suppress cortisol production. 
Other corticosteroids such as prednisolone and dexamethasone would also influence 
cortisol concentrations by suppression. It has also been shown that benzodiazepines such 
as alprazolam, suppress cortisol concentrations (McIntyre et al, 1993). Some of the 
patients (R25 and R29) were treated with similar benzodiazepines (temazepam and 
lorzepam).
7
It is likely that the abnormal rhythms seen in the ICU patients is due to a combination of 
the above effects, which can be clarified by further studies on the relationship between 
sleep and circadian rhythms of hormones. However from this study it appeared that there 
were no relationships between the abnormalities observed in plasma melatonin rhythms 
and those of plasma cortisol, prolactin and TSH.
371
CHAPTER 7 STUDY TO INVESTIGATE THE EFFECTS OF RENAL
FUNCTION ON URINARY aMT6s DETERMINATION 
IN CRITICALLY ILL PATIENTS
7.1. Introduction
A frequent event associated with critical illness is renal impairment and most 
commonly, acute renal failure (ARF). ARF has been defined as the abrupt decline in 
glomerular filtration rate (GFR) as a result of ischaemic or toxic injury to the kidney 
(Nissenson, 1998) and is classified into three broad groups: pre-renal, post-renal and 
intrinsic renal failure. Pre-renal failure is the result of poor kidney perfusion brought 
about a reduced cardiac output, a decrease in intravascular volume such as that 
associated with peritonitis and pancreatitis or a decrease in extracellular fluid as 
occurs with shock or dehydration. Post-renal failure is brought about by an 
obstruction that prevents the normal flow of urine. Severe infection, glomerular 
lesions, vascular lesions or acute tubular necrosis (ATN) can bring about intrinsic 
renal failure. ATN occurs when the tubular epithelium become necrosed and is 
associated either with or without basement membrane damage. In ICU the most 
common manifestations are pre-renal and ATN. The causes of ARF are almost 
always multifactorial, with hypovolaemia, sepsis, low cardiac output states, raised 
intra-abdominal pressure, rhabdomyolysis, the use of nephrotoxic drugs and 
radiocontrast dyes all contributing to some degree (Breen and Bihari, 1998).
A prominent clinical sign of renal failure is oliguria, a urine output of less than 
0.5ml/kg/hr (<400 mis per day). However non-oliguric renal failure is more common 
and is associated with a persistent rise in plasma creatinine > 200ji,mol/l, even when
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the haemodynamic and mechanical causes of renal failure are absent or corrected 
(Fisher, 1990).
It is likely that altered renal function in critically ill patients may influence urinary 
aMT6s excretion rates and bring about abnormal circadian rhythms of urinary aMT6s 
excretion, such as those seen in chapter 5.
The aim of this study was to determine whether the renal function of ICU patients 
varies over a 24-hour study period using urine volume to assess the degree of oliguria 
and creatinine clearance as a measure of glomerular filtration rate. An additional aim 
was to determine whether there was any correlation between urinary aMT6s excretion 
rate and renal function, using urine volume and creatinine clearance as renal function 
indices.
7.2. Materials and Methods
The hourly urine samples of 12 ICU patients (10M:2F, aged 17 to 81) were analysed 
for urine creatinine levels using the method described in 2.6.6. Details of the patients 
studied are summarised in table 42. The ICU patients were pre-screened for the 
absence of ARF using plasma creatinine concentrations, plasma urea concentrations 
and urine volume on the three days preceding the study days. Patients receiving 
haemodialysis treatment were excluded from the study.
The Chemical Pathology Laboratory, Royal Free Hospital, London, measured plasma 
creatinine and urea concentrations, as part of the routine daily biochemistry using an 
enzymatic colorimetric (Creatinine PAP) method developed by Boehringer
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SUBJECT AGE SEX ADMISSION DIAGNOSIS
R14 39 M Pancreatitis, gastrointestinal bleed,
liver cirrhosis.
R15 17 F Haemorrhagic pancreatitis
R16 81 M Chronic obstructive airways disease,
congestive cardiac failure
R17 53 F Bleeding post laparotomy
R18 42 M Cerebral abscess
R19 35 M Post operative removal of
atrioventricular mass
R20 48 M Post liver transplant
R21 53 M Guillain-Barre
R22 41 M Meningitis secondary to acoustic
neuroma removal
R23 78 M Respiratory failure, sepsis.
R24 72 M Respiratory and cardiac failure
R25 76 M Post-operative oversewing of
duodenal ulcer
Table 42. Details of the ICU patients studied to investigate the effects of renal
function on the rate of urinary aMT6s excretion. M = male, F = female.
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Mannheim GmbH, Mannheim, Germany (Guder et al, 1986). Urine creatinine 
concentrations in urine samples, taken hourly over 24 hours, were measured by the 
Clinical Biochemistry Department, Royal Surrey County Hospital, Guildford, Surrey, 
using the method described in Chapter 2.
For the purposes of this study, creatinine clearance was defined as the volume of 
plasma theoretically cleared of creatinine by the kidney per minute and was 
calculated using the formula: -
[Creatinine] ljm m  x Urine Volume (ml)
Creatinine Clearance (ml/min) = ________________________________
[Creatinine] PLASMA x Collection period (min)
7.3. Results
7.3.1. Renal Function
Table 43 summarises the results of the basic renal function tests for the period of 
study on each patient. Plasma creatinine concentrations fell within the normal range 
for all but one ICU patient (R20) studied. Only two patients had plasma urea 
concentrations that were within normal limits (R15 and R22). The remaining patients 
had plasma urea concentrations that were above the normal range and subject R20 in 
particular had extremely high levels. Patient R20 could have been considered as a 
borderline case of acute renal failure. However at the time of study the patient was 
not haemodiafiltered. Total 24-hour urine volumes excreted by the patients were all 
in excess of lOOOmls with a mean of 2114.75mls/24hrs. These results suggest that
375
SUBJECT Plasma Creatinine Plasma Urea
Concentration Concentration
(|Jmol/l) (mmol/1)
Total Urine 
Volume 
(ml/24hrs)
R14 56 10.3 2395
R15 60 2.5 3045
R16 110 13.2 2805
R17 80 9.1 1953
R18 93 12.9 1786
R19 87 11.9 1808
R20 169 35.7 3088
R21 74 7.2 1467
R22 71 4.4 1268
R23 120 23.1 1452
R24 108 18.8 2238
R25 97 8.4 2072
Table 43. Plasma creatinine concentration, urea concentration and urine volume for 
ICU patients studied (n = 12). (Normal range for plasma creatinine = 60 -  
120pmol /1 and for plasma urea = 3 -6 .5  mmol/1.)
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none of the patients were in acute renal failure at the time of study but renal function 
was impaired or influenced by factors such as the drugs with which they were treated
7.3.2. Comparison of urine volume with urinary aMT6 excretion rate
The variations in urine volume compared to that of urinary aMT6s excretion rate over
24 hours for each ICU patient are shown in figures 138a to 149a.
Early studies in healthy individuals showed that urine volume excreted is at a 
maximum during the day and low at night. The rhythmic variations in urine volume 
in the ICU group studied here showed many differences to the normal pattern of 
production. Only subject R15 showed a near normal pattern of urine production with 
higher volumes during the day between 12 noon and 21:00 h. Five subjects (R16, 
R17, R19, R21 and R24) appeared to produce larger volumes during the late night 
and early morning period between midnight and 08:00 h. An episodic pattern of 
production throughout the day was shown by subjects R14, R20, R23 and R25. No 
apparent change in urine volume over 24 hours was observed in subjects R18 and 
R22. The large peak in urine volume seen in subject R17 was due to a dose of 
frusemide being given to the patient to improve urine output.
Compared to urinary aMT6s excretion rate, changes in urine volume appeared to be 
reflected in the changes to urinary aMT6s excretion rate, the pattern of the rhythm 
showing similarities. This is illustrated clearly in the rhythmic changes of urinary 
aMT6s excretion rate and urine volume for subjects R20, R21, R23 and R25.
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a.
•c
■ Urine Volume
■Urinary aMT6s
Time of Day (hours)
b.
Time of Day (hours)
c.
Xp
Creatinine Clearance 
■ Urinary aMT6s
«
£
aX3
- Urinary aMT6s concentration 
■ Urinary aMT6s excretion rate
Time of Day (hours)
Figure 138. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R14.
378
a.
Time of Day (hours)
b.
Xp
Time of Day (hours)
C.
■ Urine Volume
■ Urinary aMT6s
Creatinine Clearance 
- Urinary aMT6s
■ Urinary aMT6s concentration
■ Urinary aMT6s excretion rate
Time of Day (hours)
Figure 139. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subjectR15.
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Time of Day (hours)
b.
Time of Day (hours)
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- Urinary aMT6s
- Urinary aMT6s concentration
- Urinary aMT6s excretion rate
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Figure 140. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R16.
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Figure 141. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subjectR17.
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Figure 142. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6 concentration over 24 hours for subject
R18.
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Figure 143. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R19.
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Figure 144. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R20.
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Figure 145. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R21.
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Figure 146. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subjectR22.
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Figure 147. Graphs to show the variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R23.
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Figure 148. Graphs to show that variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R24.
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Figure 149. Graphs to show tha variation in urinary aMT6s excretion rate compared to the variation in
a. urine volume, b. creatinine clearance and c. urinary aMT6s concentration over 24 hours for subject
R25.
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7.3.3. Comparison of creatinine clearance with urinary aMT6s excretion rate 
Studies in healthy subjects have shown that creatinine clearance (and therefore 
glomerular filtration rate) is higher during the subjective day compared to night. This 
pattern of rhythmicity for creatinine clearance was not observed in any of the ICU 
subjects as shown in figures 138b to 149b, as creatinine clearance fluctuated over the 
24-hour study period. However as with urine volume, the 24-hour profile of 
creatinine clearance showed similarities with the urinary aMT6s excretion rate 
pattern, as illustrated by subjects R14, R16, R17, R18, R20, R23 and R25 in 
particular.
7.3.4. Comparison of urinary aMT6s concentration and urinary aMT6s excretion 
rate
To investigate the influence of urine volume on the profile of urinary aMT6s, urinary 
aMT6s concentration in ng/ml was plotted against urinary aMT6s excretion rate to 
produee figures 138c to 149c. There were similarities in the profiles for some 
subjects such as patients R14, R18 and R19 suggesting that urine volume did 
influence the excretory pattern of urinary aMT6s. However this was not a consistent 
observation and for many of the subjects the circadian rhythms of the two appeared 
very different as in subjects R16, R17, R20, R23 and R24. This illustrated that in 
some ICU patients, urine volume either did not influence the circadian rhythm of 
urinary aMT6s or was not the only factor influencing the rhythm.
7.3.5. Cosinor analysis
Cosinor analysis of the data to fit a 24-hour period showed that there were no significant 
rhythms for the changes observed in urine volume or creatinine clearance in these 
patients.
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The data was analysed statistically using the statistics package within Excel 98 to 
determine whether there were any correlations between urine volume, creatinine 
clearance and urinary aMT6s excretion rate in each subject. High peaks were removed 
from the data of patient R17, because they were caused by the administration of a dose of 
frusemide causing a large excretion of urine volume, which weighted the analysis. 
Statistically significant correlations were found between urine volume and urinary aMT6s 
excretion rate in 6 of the subjects [R16 (r = 0.73), R17, (r = 0.73), R20 (r = 0.87), R21 (r 
-  0.85), R23 (r = 0.86) and R25 (r = 0.86)], as shown in figures 150 to 156. Further 
statistically significant correlations were found between creatinine clearance and urinary 
aMT6s excretion rate in 5 subjects [R16 (r = 0.82), R20 (r = 0.87), R21 (r = 0.88), R23 (r 
= 0.88) and R25 (r = 0.86)] and are shown in figures 157 to 161. Only four of the 12 
subjects demonstrated a significant correlation between urinary aMT6s concentration and 
urinary aMT6s excretion rate. These were R18 (r = 0.83), R19 (r = 0.94), R22 (r = 0.81) 
and R24 (r = 0.82). Creatinine clearance showed a significant correlation with urine 
volume in 7 of the subjects as shown in table 44.
7.4. Discussion
The results from this study lead us to believe that the majority of the ICU patients studied 
did not have acute renal failure. However, the circadian rhythms of urine volume and 
creatinine clearance appeared abnormal, which suggests that other factors may influence 
these parameters.
Studies on healthy individuals showed that both urine volume excreted and glomerular 
filtration rate (GFR) have circadian rhythms that are highest during the day coinciding
a
7.3.6. Correlation analysis
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Figure 150. Scatter graph to show the correlation between urinary aMT6s excretion rate and urine
volume for subject R16.
Urine Volume (mis)
Figure 151. Scatter graph to show the correlation between urinary aMT6s excretion rate and urine
volume for subject R17.
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Urine Volume (mis)
Figure 152. Scatter graph to show the correlation between urinary aMT6s excretion rate and urine
volume for subject R20.
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Urine volume (mis)
Figure 153. Scatter diagram to show the correlation between urinaiy aMT6s excretion rate and urine
volume for subject R21.
395
Urine Volume (mis)
Figure 154. Scatter diagram to show the correlation between urinary aMT6s excretion rate and urine
volume for subject R23.
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Urine Volume (mis)
Figure 155. Scatter diagram to show the correlation between urinary aMT6s excretion rate and urine
volume for subject R25
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Hourly Creatinine Clearance (mls/min)
Figure 156. Scatter diagram to show the correlation between urinary aMT6s excretion rate and
creatinine clearance for subject R16.
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Hourly Creatinine Clearance (mls/min)
Figure 157. Scatter diagram to show the correlation between urinary aMT6s excretion rate and
creatinine clearance for subject R20.
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H o u r l y  C r e a t i n i n e  C l e a r a n c e  ( m l s / m i n )
Figure 158. Scatter diagram to show the correlation between urinary aMT6s excretion rate and
creatinine clearance for subject R21.
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Hourly Creatinine Clearance (mls/min)
Figure 159. Scatter diagram to show the correlation between urinary aMT6s excretion rate and
creatinine clearance for subject R23.
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Figure 160. Scatter diagram to show the correlation between urinary aMT6s excretion rate and
creatinine clearance for subject R25.
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SUBJECT Urinary aMT6s 
excretion rate 
vs
Urine volume
Urinary aMT6s 
excretion rate 
vs
Creatinine Clearance
Urine Volume 
vs
Creatinine Clearance
R14 0.11 0.49 0.74 **
R15 0.43 0.42 0.47
R16 0.73** 0.82** 0.59
R17 0.73** 0.38 0.38
R18 0.47 0.56 0.90**
R19 0.52 0.33 0.57
R20 0.87** 0.87*’ 0.92**
R21 0.85** 0.88** 0.94*’
R22 0.37 0.43 0.90**
R23 0.86** 0.88** 0.95**
R24 -0.11 0.32 0.82**
R25 0.86** 0.86** 0.52
Table 44. Table to show the correlation coefficients calculated when urinary aMT6s 
excretion rate was compared against urine volume and creatinine 
clearance and for the comparison of urine volume against creatinine 
clearance for critically ill patients (n=12). ‘**’ highlights the relationships 
with significant correlations (r >0.70).
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with activity and lowest at night. (Koopman et al, 1989). The amplitude of the urine 
volume rhythm varies considerably but that of GFR is small in comparison (Koopman et 
al, 1989). An example of the normal circadian profiles of urine volume excreted and 
GFR are shown in figure 161.
Moore-Ede proposed that renal circadian rhythmicity in healthy subjects is determined by 
a variety of factors that may be broadly grouped as a) exogenous, b) intra-renal 
endogenous and c) extra-renal endogenous (Moore-Ede et al, 1982). Exogenous sources 
include the intake of food and water. Studies in rats have shown that urinary excretion of 
water and electrolytes is at a maximum when food intake is maximum (Cambar et al,
1981), but unchanged with constant intravenous infusions or intragastric infusions of 
sodium chloride or nutritive feeds (Roelfsema and Van der Heide, 1982; Roelfsema et al,
1982). The intra-renal factors are possible intra-renal endogenous oscillators that 
generate the excretion rhythms (Moore-Ede et al, 1982). The extra-renal sources of 
variation are numerous and are summarised in table 45. In ICU patients, drastic changes 
are observed in many of these parameters, particularly heart rate, blood pressure and 
renal blood flow (determined by the cardiac output). The stress response causes plasma 
cortisol levels to be elevated in ICU patients (Hawker, 1988) as shown by the results in 
Chapter 6. Cortisol has a vasodilator effect on the renal vasculature, which involves 
nitric oxide, and increases GFR by increasing the glomerular plasma flow rate (Connell et 
al, 1987; De Matteo and May, 1997).
The picture is further complicated by the fact that the drugs used in ICU often influence 
renal function and may also affect the metabolism and excretion of melatonin. Many of 
the patients in this study were being treated on one or more such drugs. Nephrotoxic
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Figure 161. Graph to show the circadian rhythms of glomerular filtration rate 
(GFR) and urine volume in healthy subjects. Adapted from Koopman 
etal, 1989.
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EXTRA-RENAL SOURCE OF RENAL 
RHYTHMICITY
EXAMPLES
Blood Plasma constituents 
Proteins 
Electrolytes 
Nitrogen compounds 
Other solutes
Systemic nervous control Cholinergic
Adrenergic
Denervation
Vascular Factors Blood pressure 
Heart rate 
Renal vessels 
Glomerulus 
Renal blood flow 
Glomerular filtration rate 
Renin-angiotensin system 
Vasoactive hormones 
Other hormones
Tubular factors Reabsorption processes 
Secretion processes 
Hormones (anti-diuretic hormone, 
parathyroid hormone, aldosterone) 
Metabolism factors
Table 45. Summary of the extra-renal factors that cause circadian rhythmicity in 
urine excretion. Adapted from Cambar et al, 1992.
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drugs, including amphotericin and the aminoglycosides (gentamicin, tobramycin and 
amikacin) can cause damage to the kidney and thus influence urine volume or glomerular 
filtration rate (Sonheimer and Migdal, 1987). Of the ICU patients studied in this chapter, 
only patient R22 was being treated with gentamycin and had abnormal creatinine 
clearance, urine volume and urinary aMT6s excretion rates. Cytochrome P450 isozymes, 
especially the isozyme CYP1A subfamily, have been shown to be involved in the 
melatonin metabolism (Yeleswaram et al, 1999). Other drugs metabolised by these 
isozymes therefore have the potential for interfering with the melatonin metabolism, 
leading to changes in the excretion of melatonin metabolites, such as urinary aMT6s. It 
has already been demonstrated that the anaesthetic, propofol, exhibits a concentration- 
dependent inhibitory effect on CYP1A1 as well as CYP2B1 and CYP2E1 (Chen et al, 
1995). Furthermore, propofol can also cause a reduction in the systemic vascular 
resistance leading to a fall in blood pressure (Oh, 1990), including renal blood pressure, 
thus influencing creatinine clearance and urine volume excretion. Of the 12 ICU 
patients studied, two were treated with propofol (R15 and R19), and both had abnormal 
creatinine clearance rhythms. Patient R15 had no clear urinary aMT6s rhythm, but this 
patient was also being treated with dopamine (catecholamine), frusemide (thiazide 
diuretic) and midazolam (benzodiazepine) which would also influence urinary aMT6s 
levels and urine volume excreted. Dopamine at low doses (5pg/kg/min) is commonly 
used in ICU because of its vasodilatory effects on dopaminergic renal and mesenteric 
vessel receptors, causing increased urine flow. Patient R14 was also treated with low 
dose dopamine. The thiazide diuretics, frusemide and bumetanide, bring about a large 
increase in urine volume excretion, by inhibiting water reabsoiption in the ascending 
limb of the loop of Henle. This effect was seen clearly shown by patient R17. Patients 
R14, R15, R16 and R25 were also treated with thiazide diuretics.
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The use of creatinine clearance as a marker of GFR is not ideal in healthy individuals 
because some creatinine is secreted by the renal tubules, giving higher creatinine 
clearances than inulin (Payne 1986). In ICU patients, creatinine clearance estimates are 
further affected if the patients are catabolic, which is often the case. This results in the 
increased breakdown of creatine to creatinine and raises the concentration of circulating 
creatinine. Inulin clearance is a better marker, but it is more invasive, requiring a single 
injection of inulin followed by serial blood sampling. The frequency of sampling means 
that it is not ideal for use in the ICU environment where the patients are already receiving 
many other drugs and having other blood samples taken. Prediction equations, such as 
the Cockcraft-Gault equation are sometimes used to predict GFR but these have also been 
shown to be inaccurate in the ICU setting (Wells and Lipman, 1997).
The results from this study showed that even when acute renal failure is absent, renal 
function may be influenced by other factors. Care should therefore be taken in 
interpreting data from ICU patients when circadian rhythm markers such as urinary 
aMT6s are used. Although raised plasma melatonin concentrations have been reported in 
chronic renal failure (Touitou et al, 1985, Viljoen et al, 1992), plasma melatonin is 
possibly the more reliable circadian rhythm marker to use in studies on ICU patients 
without renal failure.
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CHAPTER 8 INVESTIGATION OF THE RELATIONSHIP BETWEEN 
URINARY aMT6s EXCRETION, PLASMA MELATONIN 
PRODUCTION AND PATIENT ICU OUTCOME
8.1. Introduction
The circadian rhythm abnormalities observed in previous chapters may be influenced not 
only by the isolation from environmental time cues and poor sleep but also by the 
severity of illness of the patient. A number of methods by which severity of illness can 
be graded, are used in ICU. One of the most commonly used schemes is the acute 
physiology and chronic health evaluation, version 2 (APACHE II), developed by Knaus 
in 1981. APACHE II is used to predict outcome in ICU by assigning points to 12 
physiological parameters, age and the presence of chronic liver, cardiovascular, 
respiratory, renal and haematological disease. The maximum possible APACHE score is 
71 and higher scores generally correlate with an increase in mortality.
The aim of this investigation was to determine whether the presence of abnormal rhythms 
and abnormal melatonin production is related to an increased severity of illness, using 
APACHE II as a disease severity index. In addition, this study aimed to determine 
whether there is a link between rhythm abnormality and ICU outcome.
8.2. Materials and Methods
On each study day for all ICU patients recruited, data was collected from the ICU nursing 
charts so that the study day APACHE score could be calculated as described in chapter 1. 
The data was taken at 24:00h ±lhr and included the parameters listed in table 46. The
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Table 46.
Mean arterial pressure
Heart rate
Respiratory rate
pH
Plasma sodium concentration 
Plasma potassium concentration 
Plasma creatinine concentration 
Plasma haemoglobin concentration 
White blood cell count 
Fraction of inspired oxygen (Fi02)
Pa02
PaCo2
Glasgow coma score
Patient age
Temperature (core body temperature or axilla)
List of data taken from the ICU nursing staff charts for the calculation of 
APACHE II score.
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APACHE scores were calculated by entering the data into the Royal Free Hospital 
Intensive Care Audit computer programme written by the author for the ICU.
8.3. Results
Table 47 shows the calculated study day APACHE II scores for the subjects studied on 
one occasion and table 48 shows the APACHE II scores for subjects studied on two or 
three occasions at weekly intervals.
Higher APACHE II scores are usually related to poor outcome but the results show that 
this is not always the case. No patient studied on a single occasion had very high 
APACHE II scores. Of the patients with an APACHE II score of greater than 20, 2 died 
(R26 and R20) and 2 survived (R2 and R23), whilst two patients with relatively low 
APACHE II scores (between 10 -15) died.
Correlation analysis found no significant correlations between the APACHE II scores and 
total urinary aMT6s excreted (ng/ml/24h) or total plasma melatonin production 
(ng/ml/24h).
The ICU patients were divided into four groups based on the types of rhythms and 
rhythms disturbances observed in urinary aMT6s excretion rate as defined in 4.3.2. 
These groups were those with grossly abnormal rhythms, no rhythm, normal rhythms and 
phase-shifted rhythms. A comparison of the APACHE II scores in each group is shown
411
ICU SUBJECT APACHE II SCORE ICU OUTCOME
R2 21 Survived
R3 11 Survived
R4 10 Died
R5 15 Died
R7 12 Survived
R9 10 Survived
RIO 17 Survived
R13 16 Survived
R16 9 Survived
R17 4 Survived
R21 8 Survived
R22 16 Survived
R23 21 Survived
R24 10 Survived
R25 17 Survived
R26 23 Died
R27 20 Died
R28 8 Survived
R29 4 Survived
R30 4 Survived
R31 5 Survived
R32 13 Survived
Table 47. Study day Apache IE scores and ICU outcome for ICU subjects for which 
circadian rhythmicity was investigated on one occasion.
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Study day 1 Study day 2 Study day 3
ICU SUBJECT APACHE II SCORE ICU O U T C O M E
Rl 18 7 Survived
R6 22 9 Survived
R8 18 5 Survived
R ll 8 20 Survived
R12 23 16 Died
R14 23 17 20 Survived
R15 15 23 19 Died
R18 19 10 Survived
R19 10 2 Survived
R20 12 6 Survived
Table 48. Study day Apache II scores for ICU subjects for which circadian 
rhythmicity was investigated on two or three occasions.
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in figure 162. Unpaired Student t tests showed no significant differences in the mean 
APACHE I I  scores in each group (p>0.1 for each comparison).
Rhythmic variations in plasma melatonin concentration were grouped in the same way as 
for urinary aMT6s excretion (figure 163) and again there were no significant differences 
in the means of each group using unpaired students t test (P>0.1 for each comparison).
Correlation analyses were performed using the APACHE I I  scores and parameters of 
cosinor analysis of the urinary aMT6 s excretion rate. No significant correlations between 
study day APACHE I I  scores and the mesor, amplitude, acrophase time and percentage 
rhythm were found for either the whole ICU  patient group or for patients with significant 
cosine rhythms.
Similarly, no significant correlations were found between the APACHE I I  scores and the 
mesor, amplitude, acrophase time and percentage rhythm values derived from cosinor 
analysis of the plasma melatonin data.
When the patients were divided into 2 groups based on ICU  outcome, unpaired Students t 
tests showed no significant differences in the means of total urinary aMT6 s excretion 
(ng/ml/24h) or total plasma melatonin production (ng/ml/24h) between those patients 
who survived and those that died. Figures 164 and 165 show the distribution of total 
urinary aMT6 s excretion (ng/ml/24h) and total plasma melatonin production (ng/ml/24h) 
respectively for those patients that survived and those that died.
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Figure 166 shows the change in study day APACHE I I  score on each study day of 
subjects studied on more than one occasion. Two patients appeared to get more ill with 
an increase in APACHE I I  score (patients R11 and R15) on week 2. Both these patients 
showed a decrease in the percentage rhythm and an increase in mesor on week 2 , but the 
amplitude decreased in patient R l l  and increased in patient R15 (figure 167). Eight 
patients showed a decrease in APACHE I I  score suggesting an improvement in disease 
severity, but only five of these patients showed improvements in the percentage rhythm.
In week 3, the APACHE I I  data suggest that patient R15 was improving in health and this 
was associated with an increase in percentage rhythm. However this patient died due to a 
haemorrhage associated with a therapeutic intervention. In the same week patient R14 
had a worse APACHE I I  score than the previous week and this patient survived ICU.
8.4. Discussion
This study showed that there was no clear evidence of a relationship between disease 
severity as determined by the APACHE I I  scoring system and parameters of cosinor 
analysis of circadian rhythmicity. Nor were there any differences in APACHE II score 
between those patients with normal circadian rhythms and those with abnormal rhythms 
and those patients who died compared with those that survived
It may be that APACHE II is not the best measure of disease severity to use. APACHE  
scoring was developed to predict ICU  and hospital outcome and although often used as 
an index of severity of illness it was not developed or validated for this. Other scoring
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Figure 167. Graphs to show the change in a. mesor, b. amplitude and c. percentage rhythm for each ICU patient 
studied on two or more occasions
systems such as the therapeutic intervention scoring system (TISS), which scores one to 
four points for each of 70 nursing and medical procedures (Cullen, 1974), may provide 
further information.
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CHAPTER 9 GENERAL DISCUSSION
9.1. Circadian rhythms in critically ill patients
The main aim of this thesis was to determine whether circadian rhythms in critically ill 
patients are desynchronised from those observed in a healthy individuals using urinary 
aMT6 s excretion, plasma melatonin and core body temperature as markers of the 
endogenous clock.
A  retrospective study into the nature of the CBT rhythm was the starting point, using data 
taken from nursing charts at the Intensive Care Unit, Royal Free Hospital, London. In 
common with the study of Tweedie et al, 1989, statistically significant rhythms in a 
period of 24 hours were found but only in 49.5% of the patient days studied compared to 
80% of patients in the Tweedie study. The retrospective CBT data also picked up 
abnormalities in the position of acrophase both within individual subjects and between 
subjects. The lower incidence of significant CBT rhythms may be due to the patients 
being more ill and may be related to the fact that all the patients studied were febrile.
The use of CBT as a circadian rhythm marker in the ICU  environment has a drawback in 
that the true rhythm is probably masked. Many patients have infections associated with 
high CBT (>38.0°c) or low CBT (<35.0°c). ICU  patients also show major changes in 
metabolism. The metabolic response to injury is often associated with fever and 
characterised by 'ebb' and 'flow' phases (Cuthbertson, 1942). There is a rapid 
mobilisation of glycogen and triacylglycerol fuel stores as part of the 'fight or flight'
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response, an increased metabolic rate and breakdown of body tissues and in creased 
plasma concentrations of adrenaline and noradrenaline (Frayn, 1986). The true CBT is 
also manipulated through the use of drugs. Most patients had viral, bacterial or fungal 
infections and were treated with antiviral, antibiotics or antifungal drugs, which could 
influence CBT. Many patients were also given drugs such as paracetamol, which would 
also reduce the temperature. The use of air-fluidised beds and space blankets may also 
influence CBT.
Evidence to support the view that CBT is possibly masked in IC U  patients, came from 
the studies where CBT was measured prospectively with simultaneous measurements of 
urinary aMT6 s excretion rate and plasma melatonin. Cosinor analysis was able to fit 
significant cosine curves to CBT rhythms in 10 out of 14 volunteers that had significant 
rhythms in plasma melatonin and urinary aMT6 s excretion rate. A  total of seven ICU  
patients had significant CBT rhythms with cosinor analysis, but only one patient also had 
significant urinary aMT6s excretion rate and plasma melatonin rhythms (R30) and one 
patient had a significant urinary aMT6 s excretion rate but no corresponding significant fit 
to the plasma melatonin rhythm (R27). In addition, patients who demonstrated normal or 
phase shifted circadian rhythms for urinary aMT6s excretion rate or plasma melatonin 
had non-significant fits to a cosine curve for CBT.
Four patterns of variation in urinary aMT6 s excretion rate and plasma melatonin were 
defined: grossly abnormal patterns, arrhythmic patterns, phase shifted patterns and 
normal patterns. This data provided further evidence that the circadian rhythms of
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critically ill patients are disturbed and suggested that possible transitions in circadian 
rhythm patterns occur throughout an extended IC U  stay (i.e. greater than 3 days). This 
was supported by the studies in which urinary aMT6 s excretion rate was measured on 
more than one occasion at weekly intervals. Changes in the rhythms from grossly 
abnormal or suppressed patterns to phase shifted patterns or normal patterns were 
observed in 5 ICU  patients, whilst increases in amplitude were detected in two patients. 
An attempt to relate different rhythm patterns observed to changes in severity of illness 
using study day APACHE II scores was unsuccessful and no significant relationship was 
found. However a relationship maybe found using other scoring systems such as the 
newer APACHE I I I  system (Knaus et al, 1991) or Therapeutic Intervention Scoring 
System (U SS) (Cullen et al, 1974).
9.2. Problems associated with circadian rhythm studies in ICU
This study aimed to determine the nature of circadian rhythms in critically ill patients. 
However endeavours to do so have highlighted a number of issues that complicate such 
attempts and demand further investigation.
In healthy human subjects, it is generally agreed that normal 24h circadian rhythmicity is 
governed by an interaction between the endogenous pacemaker located in the SCN and 
environmental zeitgebers such as the light-dark cycle, social interaction and mealtimes. 
Core body temperature, urinary aMT6 s excretion rate and plasma melatonin are also 
generally accepted as being reliable markers of the endogenous rhythm in healthy 
individuals, although urinary aMT6 s and plasma melatonin rhythms have been shown to
425
be affected by drugs such as benzodiazepines and (3-blockers (Cowen et al, 1985; Arendt 
et al, 1985, Ralph and Menaker, 1986).
Most studies of circadian rhythmicity in clinical situations have looked at groups of 
individuals where one or two regulatory factors are disturbed or absent. In blind 
individuals with no conscious or unconscious light perception, the light-dark input is 
absent and therefore this aspect of circadian regulation is lost. In jet lag and shift work 
studies an abrupt change in exposure to the light-dark cycle is the main cause of 
disturbances in circadian rhythmicity. In critically ill patients the situation is more 
complex and disturbance in circadian rhythmicity is likely to be the result of a 
combination of factors.
In IC U ’s such as the Royal Free Hospital, patients are exposed to changes in light 
intensity. Light intensity is often low (<2001ux) for much of the day regardless of season. 
In unpublished work from this laboratory (Middleton, Stone and Arendt), a 200 lux: 8 lux 
12L: 12D cycle was insufficient to synchronise human circadian rhythms. Patients are 
also often exposed to bursts of bright light in the early morning, which would have the 
effect of phase advancing or phase delaying circadian rhythms depending on its timing 
in relation to the phase of the endogenous pacemaker. To add to the problem is the fact 
that patients are often sedated so that they do not perceive any changes in light intensity.
The nature of the disease from which the patient is suffering may affect the rhythmicity 
of melatonin and its metabolites, particularly if that disease is associated with poor renal
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or liver function. A  study investigating plasma melatonin rhythms in cirrhotic patients 
showed that daytime levels of plasma melatonin were raised, while the onset time and 
acrophase time were consistently and significantly phase delayed (Steindl et al, 1995). 
Patients in this study were not recruited if there was any evidence of liver failure in terms 
of abnormal liver function tests. However the liver’s ability to metabolise may have been 
impaired by some of the drugs used in the ICU. Cytochrome P450 is involved in the 
metabolism of a number of drugs and recently it has been shown that the CYP1A  
subfamily of cytochrome P450 is involved in melatonin metabolism (Yeleswaram et al, 
1999). Drugs such as the anaesthetic agent propofol have been shown to inhibit the 
cytochrome P450 isozymes CYP1A1, as well as CYP2B1 and CYP2E1 (Chen et al,
1995).
The stress response has a profound effect on endocrine function in critically ill patients. 
Pain, hypotension, hypoxia, acidosis initiate afferent nerve impulses that impinge on the 
hypothalamus and result in the release of adrenaline and noradrenaline from the adrenal 
glands (Chemow et al, 1984). Stress also results in the increased secretion of ACTH and 
therefore cortisol, increased antidiuretic hormone and prolactin secretion, together with a 
decrease in TSH. This is possibly why cosinor analysis produced few significant fits to 
cosine curves with the plasma cortisol, TSH  and prolactin rhythms in the ICU  patients 
studied.
Patients with renal failure were also omitted from the study but the ICU  patients studied 
had abnormal circadian rhythms of urine volume and creatinine clearance, suggesting
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impaired renal function. This could account for the abnormal urinary aMT6 s excretion 
rates observed in some patients. However raised levels of plasma cortisol associated 
with the stress response as demonstrated in chapter 6  and the use of nephrotoxic drugs 
such as amphotericin and aminoglycosides such as gentamicin, tobramycin and amikacin 
(Sonheimer and Migdal, 1987), could also impair renal function.
Drugs used in ICU  may affect the levels of plasma melatonin. A  recent study by Reber et 
al, showed that the anaesthetic agents isoflurane and propofol elevate plasma melatonin 
levels during surgery and these levels remain high in the recovery period with isoflurane 
but decrease when propofol is used (Reber et al, 1998).
Further complications arise from the problem of sleep disruption in ICU. In healthy 
individuals sleep is believed to be important for its restorative properties as it is 
associated with a period of increased protein synthesis and cell division for renewal of 
tissues such as the skin, bone marrow, gastric mucosa, bone and brain (Adam and 
Oswald, 1984). The quality of this sleep is more important than the quantity, with the 
most important stage of the sleep cycle being slow wave sleep (SWS). During SW S there 
is increased growth hormone secretion, which stimulates protein and RN A  synthesis, thus 
it promotes an anabolic response.
It follows therefore that in the critically ill, if an anabolic response is to be achieved, thus
aiding recovery, sleep is an important contributing factor. However a study investigating
the events most commonly remembered by patients cared for on IC U  revealed that sleep
disturbance was the most common problem recalled (Turner et al, 1990; Elpem et al,
1992). Polygraphic monitoring of sleep by Hilton showed that sleep time is greatly
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reduced in ICU  patients, sometimes to as little as 6 minutes in 24 hours in one patient 
(Hilton, 1976). The common causes of sleep disruption in ICU  are pain, anxiety (Redding 
et al, 1977), therapeutic interventions (Walker, 1972; Meyer et al, 1994) and noise (Kahn 
et al, 1998; Wallace et al, 1999). Noise in particular is a major problem as the ICU  is a 
busy environment with all monitoring and life support equipment fitted with warning 
alarms. Furthermore there are frequent ward rounds and people talking generate noise. 
Rao et al showed that increased noise levels of frequency 440 Hz shortened the period of 
SW S in healthy men, together with a decrease in plasma melatonin secretion (Rao et al,
1996). This would not be a major problem for patients who are cared for in ICU  for a 
short period for example 3 to 4 days. However, there are groups of patients who are 
'slow weaners' i.e. they take a long time, sometimes weeks, to be taken off artificial 
ventilation, and noise for such patients, could cause long-term sleep deprivation. Sleep 
disturbance and deprivation are problems that might be reflected in abnormal circadian 
rhythms of plasma melatonin. There is no evidence as yet to show whether short-term 
sleep deprivation in normal subjects in darkness, affects melatonin.
As already mentioned, the ICU  is a high technology environment and patients can often 
be surrounded within a small area by blood pumps, artificial ventilators, monitors, 
haemodiafiltration units and computers, all of which generate electromagnetic radiation. 
A  recent study reported that exposure to a 50Hz magnetic field possibly has a phase delay 
effect on the onset of the plasma melatonin nocturnal rise in healthy male subjects with 
some evidence for a reduction in the peak levels of melatonin (Wood et al, 1998). The 
present ICU  study did not monitor field strengths but it is likely that levels are high and 
possibly influence ICU  patient circadian rhythmicity.
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Plasma melatonin levels may also be influenced by the nutrition of the patients and in 
particular, the availability of tryptophan, the amino acid necessary for the production of 
serotonin and melatonin. Many normal foods have been shown to influence melatonin 
levels and this may not occur if patients are parenterally fed.
9.3. Future circadian rhythm studies in ICU patients
This study identifies the need for a number of further investigations into the nature of 
circadian rhythms in critically ill patients.
First, further investigation into the effect of drugs on the metabolism of melatonin is 
required. Studies could be carried out using common drugs such as the antibiotics, or 
more specialised drugs such anaesthetic agents, or drugs that are known to affect liver 
metabolism such as rifampicin. With the less dangerous drugs, studies could be carried 
out on healthy subjects whereby a dose of a drug is taken and urinary aMT6s excretion 
could be measured before and after the drug dose. Studies on the induction of enzymes 
could also be carried out using chronic dosing. For those drugs deemed unethical for use 
in healthy subjects, liver slices could be perfused with each drug of interest and the 
aMT6 s produced could be measured. A  PhD student from this laboratory is currently 
carrying out this work.
This study has demonstrated that the circadian rhythms of some critically ill patients are 
phase shifted, but whether these rhythms are phase advanced or delayed has not been 
shown and it is difficult to determine without continuous urine collection during a
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patient's’ stay in ICU. Further studies are required measuring plasma melatonin 
concentrations on ICU  patients on consecutive days in order to determine this. However 
problems may arise ethically in terms of the volumes of blood taken for such analyses, as 
current methods require lm l of plasma per duplicate. Development of a quick 
immunoassay for plasma melatonin estimation requiring small sample volumes, such as 
an E L ISA  is essential if further work is to be carried out, not only on ICU  patients but 
also on patients in other clinical situations. However the EL ISA  would have to produce 
results that are as precise and as sensitive as current methods.
The relationship between sleep and plasma melatonin in critically ill patients needs to be 
determined, preferably using electroencephalography (EEG) to characterise the sleep 
stages. The influence of electromagnetic fields on circadian rhythmicity in ICU  also 
requires quantification, but consistent results in healthy individuals will need to be 
carried out first.
Results from such studies will hopefully clarify and quantify the factors that influence 
circadian rhythmicity of critically ill patients and will highlight problem areas in terms of 
the IC U  environment that may be altered to help improve IC U  patients' circadian 
rhythms.
Bright light or exogenous melatonin may have a role to play in the resynchronisation of 
circadian rhythms in critically ill patients. Bright light treatment has been shown to be 
effective in producing corrective delays or advances in the sleep patterns and circadian
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rhythms of individuals with advanced or delayed sleep phase disorders (Lewy et al, 1985; 
Czeisler et al, 1988). Furthermore, exogenous melatonin has also been shown to help in 
the re-adaptation to new time zones in jet lag (Arendt et al, 1987) and working times in 
shift work (Deacon and Arendt, 1995). It has also had some beneficial effects on 
circadian rhythm disorders in blind subjects with disturbed sleep patterns (Aldhous and 
Arendt, 1991; Sack et al, 1990; Palm et al, 1991).
However use of bright light therapy or exogenous melatonin would require knowledge of 
the patients’ circadian phase so that bright light or exogenous melatonin administration 
could be timed appropriately to induce phase delays or advances as appropriate. Again 
this would require a quick and easy assay to determine plasma melatonin levels, so that 
'treatment' could be implemented quickly. Alternatively, a strong light-dark cycle could 
be maintained in the unit every day.
9.4. Conclusions
The present study has identified abnormal circadian rhythms in critically ill patients, 
using CBT, urinary aMT6 s excretion and plasma melatonin, which appeared in some 
cases to improve in terms of circadian phase and amplitude as the patients' health 
improved. Plasma melatonin appeared to be the most reliable circadian rhythm marker 
for IC U  patients as significant plasma melatonin rhythms were detected when no rhythm 
or a markedly abnormal rhythm was detected in the urinary aMT6 s excretion rate or 
CBT. Normal urinary aMT6 s excretion requires normal renal and liver function for 
metabolism and an absence of drugs influencing metabolism to be unaffected and normal
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CBT requires the patient to be afebrile. This is likely not to be the case in critically ill 
patients.
It is clear that rectification of abnormal circadian rhythms in ICU  patients either with 
bright light or exogenous melatonin would be of great benefit in ensuring that patients 
sleep well at the correct times, which could improve recovery time. It might also mean 
that there is a reduction in the incidence of common problems such as poor weaning from 
ventilation and ICU  psychosis, in which sleep deprivation has been implicated as a cause.
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APPENDIX I
D R U G D E T A IL S
Acyclovir Antiviral drug for 
herpes simplex and 
varicella zoster.
Amiodarone hydrochloride Anti arrhythmic ding
Aminophylline Bronchodilator
Amitryptilene Hydrochloride Tricyclic antidepressant 
with some sedation, 
serotonin in neurons.
Amphotericin Antifungal drug
Aspirin Non-opioid analgesic.
Atenolol 6 adrenoceptor blocker 
acting more on bj then b2
receptors - cardioselective.
Atracurium besylate Neuromuscular blocking drug
Benzylpenicillin Antibiotic.
Bismuth subgallate Antiseptic cream
Bumetanide Loop diuretic.
Calcium carbonate Used to compensate for calcium 
losses.
Carbamazepine Anti-epileptic drug
Cefotaxime Antibiotic (cephalosporin) 
against gram negative bacteria.
Ceftazidime Antibiotic (cephalosporin) 
against gram negative bacteria.
Chlormethiazole Hypnotic used in alcohol 
withdrawal, status epilepticus 
and sedation
Chlorpromazine Antipsychotic drug
Ciprofloxacin Antibiotic (4-quinolone) 
against gram positive and
Clotrimazole
Co-amilffuse
Codydramol tartrate. 
Co-trimoxazole
Cyclazine 
Cyclosporin A  
Diamorphine hydrochloride 
Digoxin
Dopamine Hydrochloride
Enalapril
Epoprostenol
Erythromycin
Fentanyl
Fluconazole
Flucloxacillin
Folic Acid
Frusemide 
Gamma Interferon 
Gancyclovir 
Gentamycin sulphate
Glycerine
Cisapride Gut motility stimulant 
for the gut wall.
Antifungal drug
Potassium sparing diuretic
Non opioid analgesic.
A  sulphonamide 
antibacterial drug.
Anti-emetic
Immunosuppressant.
Analgesic
Positive inotropic drug 
for heart failure and 
Supraventricular arrhythmias
Inotropic drug acting on
contractility with little 
doses produce an increase 
vasoconstriction.
ACE inhibitor.
Inhibits platelet aggregation
Antibacterial drug.
Opioid analgesic
Antifungal drug
Antibacterial drug
Treatment for iron / folic 
acid deficiency anaemia.
Loop diuretic for oedema
Adjunct to antibiotics
Antiviral drug
Aminoglycoside antibiotic 
used for the treatment of 
infections.
Rectal stimulant for
gram negative bacteria.
Heparin
Hydrocortisone
Hypromellose Eye Drops 
Insulin
Ipratropium Bromide
Isoniazid
Lactulose
Lignocaine
Lofepramine
Lorazepam
Magnesium glycophosphate
Meropenem
Methylprednisolone
Metoclopramide hydrochloride
Metronidazole
Midazolam
Morphine
Nifedipine
Nystatin
Omeprazole
Paracetamol
Pethidine hydrochloride
Potassium chloride
Propofol
Pyrazinamide
Anticoagulant.
A  mineralocorticoid for inflammatoiy 
and allergic disorders, and shock.
Eye preparation for tear production
Treatment for Type 1 or Type II 
Diabetes.
Antimuscarinic
Treatment of tuberculosis.
Osmotic laxative
Local anaesthetic
Tricyclic antidepressant
An intermediate - acting benzodiazepine 
Used as an anxiolytic.
Magnesium supplement.
Antibiotic.
Corticosteroid
Anti-emetic drug.
Antimicrobial drug
Water soluble benzodiazepine.
Opioid analgesic 
Calcium channel blocker 
Antifungal drug 
Proton pump inhibitor 
An analgesic.
An analgesic
Used to compensate for loss of potassium 
Intravenous general anaesthetic 
A nicotinic acid derivative
constipation.
Rifampicin
Selegiline hydrochloride
Senna
Simvistatin
Sodium chloride
Sodium valproate 
Sucralfate
Teicoplanin 
Temazepam 
Terbutaline sulphate
Theophylline
Thioridazine hydrochloride 
Thyroxine sodium
Tramadol hydrochloride 
Vecuronium bromide
Vigabitrim
Warfarin
Ranitidine H 2  receptor antagonist used
in the treatment of gastric and 
duodenal ulcers.
Antituberculosis drug.
Selective monoamine 
oxidase B inhibitor.
Laxative.
H M G  Co A  reductase 
inhibitor for hypercholesterolaemia
Used in cases of sodium 
depletion
Antiepileptic drug.
Selective antimuscarinic drug 
Used in the treatment of ulcers.
Glycopeptide antibiotic
Benzodiazepine
Selective short acting 62  - 
agonist used as a bronchodilator.
A  bronchodilator
An antipsychotic drug.
A  thyroid hormone used 
in the treatment of 
hypothyroidism.
Analgesic.
Non depolarising muscle 
relaxant.
Antiepileptic drug. 
Anticoagulant.
